i
ISBN: 0-8247-8121-X This book is printed on acid-free paper. Headquarters Marcel Dekker, Inc. 270 Madison Avenue, N...
161 downloads
2786 Views
3MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
i
ISBN: 0-8247-8121-X This book is printed on acid-free paper. Headquarters Marcel Dekker, Inc. 270 Madison Avenue, New York, NY 10016 tel: 212-696-9000; fax: 212-685-4540 Eastern Hemisphere Distribution Marcel Dekker AG Hutgasse 4, Postfach 812, CH-4001 Basel, Switzerland tel: 41-61-261-8482; fax: 41-61-261-8896 World Wide Web http://www.dekker.com The publisher offers discounts on this book when ordered in bulk quantities. For more information, write to Special Sales/Professional Marketing at the headquarters address above. Copyright © 2000 by Marcel Dekker, Inc. All Rights Reserved. Neither this book nor any part may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, microfilming, and recording, or by any information storage and retrieval system, without permission in writing from the publisher. Current printing (last digit): 10 9 8 7 6 5 4 3 2 1 PRINTED IN THE UNITED STATES OF AMERICA
DEDICATION
This book is dedicated to four individuals who were giants in our field and have passed away in the last few years. Their contributions to the scientific literature, program management, and global tuberculosis control are without parallel. Stefan Grzybowski, a native of Poland, graduated from the University of Edinburgh and did postgraduate work at Brompton Hospital. He came to Canada in 1954, first working in Ontario and then moving to the University of British Columbia in 1964, ultimately as Professor and Director of Pulmonary Disease. The size and body of his work would have been enough to earn him an honored place among his peers, but it will be as a unique person that this vital, remarkable man will be remembered. He approached his life’s work with unquenchable energy, human concern, and infectious humor. His passing leaves a large void in the field of tuberculosis and he will be greatly missed by his many friends and colleagues. Among the numerous qualities that made Karel Styblo an exceptional person were his passion for truth and integrity, his care for human beings, and his indefatigable courage. His passion for truth meant that he spared no effort to obtain proof. Once he obtained that proof, nothing would make him depart from it. He strove very hard to obtain the means and monies to provide proper short-course chemotherapy for patients in developing countries and is considered the father of the now pervasive directly observed therapy short course (DOTS) strategy of the World Health Organization (WHO) and the International Union Against Tuberculosis and Lung Disease (IUATLD). The IUALD and the Royal Netherlands Tuberculosis Association (KNCV) were extremely important to him as they supported him in the demonstration, implementation, and propagation of his concept of tuberculosis control throughout the world. Guan-qing Kan was well known in the tuberculosis community especially as Honorary Director of the Beijing Research Institute for Tuberculosis Control, Honorary President of the Chinese Anti-Tuberculosis Association, and Chief Editor of the Bulletin of the Chinese Anti-Tuberculosis Association. Based on his international experience and China’s situation, he put forward China’s guidelines on tuberculosis control. In 1978, Kan promoted finding the source of TB infection as a top priority and began fully utilizing the powerful weapon of DOTS. These strategies opened a new page in tuberculosis control in China and gave Beijing the lowest prevalence of smear-positive cases in all of China. This
iii
iv
Dedication
success attracted the attention of the WHO and the antituberculosis societies of many countries and paved the way for the successful World Bank loan to China. His death is a great loss to China’s medical community and tuberculosis physicians worldwide. Alexander G. Khomenko, who died in 1999 after a long illness, was a member of the Russian Academy of Medical Sciences, an honored scientist of the Russian Federation, and Director of the Central Tuberculosis Research Institute of the Russian Academy of Medical Sciences. A long-time member of the Executive Committee of the IUATLD, he was the leader in bringing new Western ideas, such as DOTS and evidence-based medicine, into the former Soviet Union and getting them widely accepted. It would be fair to state that he almost single-handedly prevented Russian Tuberculosis Care and Control from falling out of the mainstream of the world’s medical science. L. B. R. E. S. H. To the memory of my father, Dr. C. Sheppy Hershfield (1904–1989), whose concepts of social justice for all had a profound influence on my life. E. S. H.
INTRODUCTION
In her book A History of Medicine (1992), Lois N. Magner comments on the impact of Robert Koch’s announcement in 1882 that he had discovered the tubercle bacillus: “To understand the profound effect of Koch’s announcement requires an appreciation of the way in which this disease (tuberculosis) permeated the fabric of life in the nineteenth century.” In fact, in the 17th century, it was already “difficult to believe that anyone could reach adulthood without at least a touch of consumption.” Since 1950, biomedical research and public health concepts have considerably modified our perspective on tuberculosis. Indeed, no one should fail to recognize the remarkable progress that has benefited generations of people all over the world. However, as we enter a new millennium, it would appear that we are now complacent about tuberculosis, perhaps in great part because of our past successes. We are told that the prevalence of tuberculosis is increasing because, on the one hand, its incidence is going up, and, on the other hand, its treatments are not as effective as they were in the past. Indeed, regarding the latter, the theory and reality of drug resistance are now clearly established. In the United States, the government is responding by stimulating a renewed research focus on understanding drug resistance and also on developing new, effective therapeutic agents. With the tools and approaches in hand to address these research questions, we can be optimistic that answers will soon be found. The issue of complacency is greatly different because to successfully address it requires a “will” that is difficult to create. It is a sad state of affairs that public health matters have not improved as much as they could because the will, or the interest to do what could and should be done, is often lacking. This is not a problem specific to tuberculosis and to other communicable diseases. Indeed, the same problem exists in the control of chronic diseases. This book addresses a wide range of biological and clinical questions; it also discusses worldwide public health issues and what must be accomplished to address them. At the very least, we should make full use of what we know works. v
vi
Introduction
The editors, Lee B. Reichman and Earl S. Hershfield, are well-recognized experts in the study and control of tuberculosis. They, and a remarkable array of contributors, bring the reader up-to-date on the extent of the tuberculosis problem worldwide, and they propose solutions to combat its resurgence. The first edition, published in 1993, had a wide audience. This second edition is a tool for those who are concerned about tuberculosis and want to do something about it. The Lung Biology in Health and Disease series has included many unique volumes. This one is added to the list with the conviction that it will contribute to solving a problem that affects us all. As the executive editor of the series, I am grateful to Drs. Reichman and Hershfield for the opportunity to present this timely and most important contribution. Claude Lenfant, M.D. Bethesda, Maryland
PREFACE TO THE SECOND EDITION
This second edition of Tuberculosis: A Comprehensive International Approach appears only seven years after the debut of the first edition, which was the first textbook exclusively devoted to tuberculosis in over twenty years. In response, it exhausted three printings—unprecedented for a book devoted solely to tuberculosis. Because, since the publication of the first edition in 1993, so much more information has been forthcoming, the editors, executive editor, and publishers felt a revised and expanded edition was required. In 1993, concurrent with publication of the first edition, the World Health Organization publicly recognized, for the first time, that tuberculosis was a “global health emergency.” The year 1993 also marked the beginning of the reversal of the resurgence of tuberculosis in the United States, which was one of the greatest public health successes of the twentieth century. This reversal underscored the observation that political will is the most critical ingredient in tuberculosis control. Unfortunately, events since 1993 have demonstrated that without political will, tuberculosis will get worse and potentially become incurable. As we enter the new millennium, tuberculosis remains the leading killer among the infectious diseases. As this edition goes to press, one-third of the world’s population remains infected. A very ominous new problem is the vast increase in documented multiple drug resistant tuberculosis (MDRTB), which is always a man-made phenomenon. This book presents evidence that the inexpensive but effective directly observed therapy short course (DOTS), the World Health Organization/International Union Against Tuberculosis and Lung Disease standard of care, is not being utilized enough to prevent multidrug resistance. Furthermore, the increasing levels of MDRTB may jeopardize the worldwide use of DOTS, as DOTS may be ineffective in the presence of MDRTB and can actually compound drug resistance. This ominous scenario will increasingly require the use of expensive and more toxic drugs tailored to a patient’s individual drug susceptibility profile— known as DOTS-Plus—to control the epidemic. vii
viii
Preface to the Second Edition
This new edition is unique in that it is responsive to tuberculosis programs in both low- and high-prevalence countries. With the resurgence of tuberculosis and the recent huge amount of attention paid to this disease, this remains the only textbook that presents a comprehensive international approach. Once again we are proud to include contributions from many of the world’s leading authorities on tuberculosis. We are especially honored that the table of contents includes chapters from our mentors and teachers as well as our students. We would like to thank the contributors and their secretarial staffs for meeting our deadline. Jean Norwood and Janet Hayward were invaluable in organizing and coordinating the work. Our production editor, Moraima Suarez, was of great assistance in helping put the work together and carrying it through production. To Claude Lenfant, Executive Editor of the Lung Biology in Health and Disease series, we express our heartfelt thanks for his counsel, support, and encouragement. Finally, we acknowledge the support and patience of our wives, Rose Reichman and Betty Ann Hershfield, and our children, Daniel and Deborah Gar Reichman and Jeffrey, David, and Bryan Hershfield. Lee B. Reichman Earl S. Hershfield
PREFACE TO THE FIRST EDITION
Tuberculosis is an ancient disease. In the past it has been both feared and respected. Despite being glamorized in literature, drama, and opera, its effects have led to death, disfigurement, and disability. It has wiped out young people in the prime of their lives; it has devastated families. The history of tuberculosis parallels the socioeconomic ills of humankind. Endemic in many populations, it rose to epidemic proportions with the advent of overcrowding, undernutrition, lack of fresh water, and poor sewage disposal. When susceptible populations were exposed for the first time, the epidemic flourished. In the long fight against this disease, treatments often evolved from fear and ignorance. Individuals with tuberculosis were isolated, treated with various potions, and subjected to a variety of surgical interventions. The advent of the mass radiograph for early diagnosis and the development of potent antituberculous medications and highly effective treatment regimens raised the hope that eradication of this disease was possible. However, the inability of governments to develop appropriate national tuberculosis control programs has hindered the fight against this disease. The lack of patient adherence to prescribed regimens has led to the development of relapses, often with drug-resistant organisms. Finally, the appearance on the world scene of widespread human immunodeficiency virus infection has increased tuberculosis rates worldwide, in both developing and developed countries. It is against this background that we offer Tuberculosis: A Comprehensive International Approach. This book represents a complete consideration of this disease from the historical, theoretical, practical, and operational points of view. Hopefully the various chapters will provide the reader with valuable information so that appropriate treatment regimens and control programs can be developed to ensure that those infected fully benefit from the most recent advances. We are proud to include contributions from many of the world’s leading authorities on tuberculosis. Their combined knowledge forms the basis of the current principles and practices embodied in this volume. We are especially honored ix
x
Preface to the First Edition
that the List of Contributors includes many of our mentors and teachers as well as our colleagues. We would like to thank the contributors and their secretarial staffs for their assistance in meeting our deadline. Ms. Jean Norwood and Ms. Janet Haywood were invaluable in organizing and coordinating the work. Our Production Editor, Elaine Grohman, was of great assistance in helping us put the work together and carry it to production. To Dr. Claude Lenfant, Executive Editor of the Lung Biology in Health and Disease series, we wish to express our heartfelt thanks for his most cheerful counsel and encouragement. We acknowledge the support and patience of our wives, Rose Reichman and Betty Anne Hershfield, and our children, Daniel and Deborah Gar Reichman, and Jeffrey, David, and Bryan Hershfield. Lee B. Reichman Earl S. Hershfield
CONTRIBUTORS
Nils Eric Billo, M.D., M.P.H. Executive Director, International Union Against Tuberculosis and Lung Disease, Paris, France Nancy J. Binkin, M.D., M.P.H. Associate Director, International Activities, Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia Henry M. Blumberg, M.D. Associate Professor, Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, and Hospital Epidemiologist, Grady Memorial Hospital, Atlanta, Georgia Naomi N. Bock, M.D., M.S. Medical Officer, Research and Evaluation Branch, Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia W. Henry Boom, M.D. Associate Professor, Division of Infectious Diseases, Department of Medicine, Case Western Reserve University School of Medicine, and University Hospitals of Cleveland, Cleveland, Ohio Jaap F. Broekmans, M.D., M.P.H. Director, Royal Netherlands Tuberculosis Association (KNCV), The Hague, The Netherlands Emmanuelle Cambau, M.D. Assistant, Department of Bacteriology and Hygiene, Faculté de Médecine Pitié-Salpêtrière, Université Pierre et Marie Curie, Paris, France Antonino Catanzaro, M.D. Professor, Department of Medicine, University of California, San Diego, San Diego, California Richard E. Chaisson, M.D. Professor, Department of Medicine, Johns Hopkins University, Baltimore, Maryland xi
xii Pierre Chaulet, M.D.* Algiers, Algiers, Algeria
Contributors Professor, Faculty of Medicine, University of
Cynthia Bin-Eng Chee, M.D., F.R.C.P.(Edin) Consultant, Tuberculosis Control Unit, Department of Respiratory Medicine, Tan Tock Seng Hospital, Singapore Daniel Chemtob, M.D., M.P.H., D.E.A. Director, National Tuberculosis and AIDS Unit, Ministry of Health, Jerusalem, Israel David L. Cohn, M.D. Professor, Division of Infectious Diseases, Department of Medicine, University of Colorado Health Sciences Center, and Associate Director, Denver Public Health, Denver, Colorado George W. Comstock, M.D., Dr.P.H. Professor, Department of Epidemiology, School of Hygiene and Public Health, Johns Hopkins University, Baltimore, Maryland Nancy D. Connell, Ph.D. Assistant Professor, Department of Microbiology and Molecular Genetics, New Jersey Medical School National Tuberculosis Center, UMDMJ–New Jersey Medical School, and International Center for Public Health, Newark, New Jersey Thomas M. Daniel, M.D. Professor Emeritus, Department of Medicine, Center for International Health, Case Western Reserve University School of Medicine, and University Hospitals of Cleveland, Cleveland, Ohio Anne L. Davis, M.D. Associate Professor, Division of Pulmonary and Critical Care Medicine, Department of Medicine, New York University Medical School and Bellevue Hospital Chest Service, New York, New York Jerrold J. Ellner, M.D. Hunterdon Professor of Emerging and Reemerging Pathogens, and Director, Infectious Diseases Division, Department of Medicine, UMDNJ–New Jersey Medical School, Newark, New Jersey Wafaa M. El-Sadr, M.D., M.P.H. Professor, Department of Medicine, Columbia University College of Physicians and Surgeons, and Chief, Division of Infections Diseases, Harlem Hospital Center, New York, New York Donald A. Enarson, M.D., F.R.C.P.(C), F.R.C.P.(Edin) Professor, Department of Medicine, University of Alberta, Alberta, Canada, and Director of Scien* Retired.
Contributors
xiii
tific Activities, International Union Against Tuberculosis and Lung Disease, Paris, France Sue C. Etkind, R.N., M.S. Director, Division of Tuberculosis Prevention and Control, Massachusetts Department of Public Health, Boston, Massachusetts Paul E. Farmer, M.D., Ph.D. Director, Program in Infectious Disease and Social Change, Department of Social Medicine, Harvard Medical School, Boston, Massachusetts Paul E. M. Fine, V.M.D., Ph.D. Professor, Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, England Paula I. Fujiwara, M.D., M.P.H. Director and Assistant Commissioner of Health, Tuberculosis Control Program, New York City Department of Health, and Supervisory Medical Officer, Centers for Disease Control and Prevention, Atlanta, Georgia Karen E. Galanowsky, R.N., B.S.N., M.P.H. Nursing Consultant, Department of Tuberculosis Control, New Jersey Department of Health and Senior Services, Trenton, New Jersey Jacques Grosset, M.D. Professor, Department of Bacteriology and Hygiene, Faculté de Médicine Pitié-Salpêtrière, Université Pierre et Marie Curie, Paris, France Earl S. Hershfield, M.D., B.Sc., F.R.C.P.(C) Professor, Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada Philip C. Hopewell, M.D. Professor, Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of California, San Francisco, and Associate Dean, San Francisco General Hospital, San Francisco, California Jim Yong Kim, M.D., Ph.D. Director, Program in Infectious Disease and Social Change, Department of Social Medicine, Harvard Medical School, Boston, Massachusetts Kraig Klaudt Advocacy Campaign Coordinator, Program on Communicable Diseases, World Health Organization, Geneva, Switzerland
xiv
Contributors
Barry N. Kreiswirth, Ph.D. Director, Tuberculosis Center, Public Health Research Institute, New York, New York, and International Center for Public Health, Newark, New Jersey Adalbert Laszlo, Ph.D. Director, WHO Collaborating Center for Tuberculosis Bacteriology Research, Health Canada, Ottawa, and Consultant Tuberculosis Bacteriology, International Union Against Tuberculosis and Lung Disease, Nepean, Ontario, Canada Philip A. LoBue, M.D. Medical Epidemiologist, Division of Tuberculosis Elimination, Field Services Branch, Centers for Disease Control and Prevention, San Diego, California Bonita T. Mangura, M.D. Associate Professor, Department of Medicine, New Jersey Medical School National Tuberculosis Center and International Center for Public Health, UMDNJ–New Jersey Medical School, Newark, New Jersey Richard I. Menzies, M.D., M.Sc., F.R.C.P.(C) Associate Professor, Department of Medicine and Department of Epidemiology and Biostatistics, Montreal Chest Institute, McGill University, Montreal, Quebec, Canada Bess Miller, M.D., M.Sc. Associate Director for Science, Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia Carole D. Mitnick, Sc.M. Research Fellow, Program in Infectious Disease and Social Change, Department of Social Medicine, Harvard Medical School, Boston, Massachusetts Flor M. Muñoz, M.D. Assistant Professor, Department of Microbiology and Immunology and Department of Pediatrics, Baylor College of Medicine, Houston, Texas Sonal S. Munsiff, M.D. Director, Epidemiology and Surveillance, Tuberculosis Control Program, New York City Department of Health, New York, New York Eileen C. Napolitano, B.A. Deputy Director, New Jersey Medical School National Tuberculosis Center and International Center for Public Health, UMDNJ–New Jersey Medical School, Newark, New Jersey Edward A. Nardell, M.D. Associate Professor, Department of Medicine, Harvard Medical School, Chief, Department of Pulmonary Medicine, Cambridge
Contributors
xv
Hospital, and Tuberculosis Control Officer, Massachusetts Department of Public Health, Boston and Cambridge, Massachusetts Richard J. O’Brien, M.D. Chief, Research and Evaluation Branch, Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia Frances R. Ogasawara, M.S., C.H.E.S.† Associate Managing Director, American Lung Association, New York, New York Sharon Perry, Ph.D. Staff Research Associate, Department of Medicine, University of California, San Diego, San Diego, California Willy F. Piessens, M.D. Professor, Department of Immunology and Infectious Diseases, Harvard School of Public Health, Harvard Medical School, Boston, Massachusetts Mario C. Raviglione, M.D. Coordinator, Strategy Development and Monitoring of Endemic Bacterial and Viral Diseases, Communicable Disease Control, Prevention and Eradication, World Health Organization, Geneva, Switzerland Hans L. Rieder, M.D., M.P.H. Chief, Tuberculosis Division, International Union Against Tuberculosis and Lung Disease, Paris, France Camilo C. Roa, Jr., M.D. Professor, Department of Medicine, University of the Philippines College of Medicine, Manila, Philippines Rodrigo L. C. Romulo, M.D. Assistant Professor, Section of Infectious and Tropical Diseases, Department of Medicine, Faculty of Medicine and Surgery, University of Santo Tomas, Manila, Philippines Sara Rosenbaum, J.D. Harold and Jane Hirsh Professor, School of Public Health and Health Services, The George Washington University, Washington, D.C. Annik Rouillon, M.D., M.P.H. Honorary Executive Director, International Union Against Tuberculosis and Lung Disease, Paris, France Mona Saraiya, M.D., M.P.H. Medical Epidemiologist, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia
† Retired.
xvi
Contributors
Holger Sawert, M.D., M.P.H. Medical Officer, Ministry of Public Health, World Health Organization, Bangkok, Thailand Patricia M. Simone, M.D. Chief, Field Services Branch, Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia Jeffrey R. Starke, M.D. Associate Professor, Department of Pediatric Infectious Disease, Baylor College of Medicine, Houston, Texas Elizabeth J. Stoller, M.P.H.‡ Director, Francis J. Curry National Tuberculosis Center, San Francisco, California Elizabeth Tayler, M.B.B.S., M.R.C.P.(UK), M.F.P.H.M. Health Coordinator, Department of Health, Department for International Development (DFID), British High Commission, Abuja, Nigeria Ralph Timperi, M.P.H. Assistant Commissioner, Massachusetts State Laboratory Institute, Massachusetts Department of Public Health, Boston, Massachusetts Chantal Truffot-Pernot, D.Pharm. Assistant, Department of Bacteriology and Hygiene, Faculté de Médecine Pitié-Salpêtrière, Université Pierre et Marie Curie, Paris, France Jaap Veen, M.D., Ph.D., D.T.P.H. Senior Tuberculosis Consultant, Royal Netherlands Tuberculosis Association (KNCV), The Hague, The Netherlands Yee-Tang Wang, M.D., F.R.C.P.(Edin) Senior Physician and Head, Tuberculosis Control Unit, Department of Respiratory Medicine, Tan Tock Seng Hospital, Singapore Daniel Weiler-Ravell, M.D. Director, Division of Respiratory Physiology and Medicine, Carmel Medical Center, Haifa, Israel Sheri Weiser, M.A. National Tuberculosis and AIDS Unit, Ministry of Health, Jerusalem, Israel Israel Yitzhak, L.V.N. Health Educator, National Tuberculosis and AIDS Unit, Ministry of Health, Jerusalem, Israel
‡
Current affiliation: Institute for Global Health, San Francisco, California.
CONTENTS
Introduction Claude Lenfant Preface to the Second Edition Preface to the First Edition Contributors Part One
PROGRAMMATIC BACKGROUND
1. A Historical Perspective on Tuberculosis and Its Control Anne L. Davis I. Early Perceptions and Practices II. Concepts from the Renaissance Through the Eighteenth Century III. Nineteenth- and Twentieth-Century Developments and Concepts References 2. Tuberculosis Control in Low-Income Countries Donald A. Enarson I. II. III. IV. V. VI. VII. VIII.
v vii ix xi
Introduction Objectives of Tuberculosis Control The Scientific Basis of Intervention Prevention Through Treatment Basic Principles of Tuberculosis Control Adaptations for Low-Income Countries Achieving Success in Low-Income Countries Effective Strategies for the Management of Tuberculosis
3 5 7 10 43 55 55 55 56 57 58 60 62 65 xvii
xviii
Contents IX. Future Challenges References
3. Tuberculosis Control in Low-Prevalence Countries Jaap F. Broekmans I. The Prospect of Elimination II. Framework for Tuberculosis Control in Low-Prevalence Countries III. Surveillance IV. Program Monitoring References 4. Tuberculosis Laboratories: The Centerpiece of National Tuberculosis Control Programs Adalbert Laszlo I. II. III. IV. V. VI.
68 71 75 75 81 86 89 92
95
Introduction National Tuberculosis Programs Tuberculosis Diagnostic Services Tuberculosis Diagnostic Techniques The NTP National Tuberculosis Laboratory Network Structure and Function of the National Tuberculosis Laboratory Network VII. The National Tuberculosis Laboratory Network as a Source of Data VIII. The National Tuberculosis Laboratory Network as a Source of Operational and Epidemiological Information IX. Conclusion References
101
5. Evaluation of Applied Strategies of Tuberculosis Control in the Developing World Pierre Chaulet and Earl S. Hershfield
107
I. Introduction II. Prerequisites for Evaluating a Tuberculosis-Control Strategy III. Evaluation of the Strategies Applied in Tuberculosis Treatment IV. Evaluation of Strategies Applied in the Detection of Tuberculosis Cases V. Conclusion References
95 97 99 100 101
103 104 104 105
107 108 111 119 124 124
Contents Part Two
xix BASIC ASPECTS
6. Epidemiology of Tuberculosis George W. Comstock I. II. III. IV.
Introduction Etiological Epidemiology Administrative Epidemiology Conclusion References
7. Bacteriology of Tuberculosis Jacques Grosset, Chantal Truffot-Pernot, and Emmanuelle Cambau I. II. III. IV. V. VI. VII. VIII.
Introduction Biological Safety General Characteristics of Tubercle Bacilli Bacteriology for Diagnosis and Monitoring Treatment of Tuberculosis Strain Typing of M. tuberculosis Drug Activity Against M. tuberculosis Immunodiagnostic Tests for Tuberculosis Direct Detection of M. tuberculosis by Nucleic Acid Amplification References
8. Immunology of Tuberculosis Thomas M. Daniel, W. Henry Boom, and Jerrold J. Ellner I. Introduction II. Mycobacterial Protein Antigens III. The Mycobacterial Cell Wall: Mycobacterial Adjuvants and Mycobacterial Polysaccharides IV. Granuloma Formation V. Cell-Mediated Immunity VI. Humoral Immunity VII. Immune Spectrum and Immunoregulation VIII. HIV–M. tuberculosis Interactions IX. Conclusions References 9. Transmission of Tuberculosis Edward A. Nardell and Willy F. Piessens I. Aerobiology of Tuberculosis II. Epidemiology of Transmission
129 129 130 141 149 149 157 157 158 158 160 168 169 175 177 178 187 187 188 192 194 194 199 200 202 203 204 215 217 221
xx
Contents III. IV. V. VI. VII.
Infectious Dose for Humans Recent Outbreaks Preventing Transmission Governmental Recommendations: An Overview Preventing Transmission from Unsuspected Cases of Tuberculosis VIII. Engineering Approaches to Preventing Transmission References 10. Pathogenesis of Tuberculosis Willy F. Piessens and Edward A. Nardell I. Introduction II. Stage 1 (Week 1): Invasion III. Stage 2 (Weeks 2 and 3): Logarithmic Bacillary Growth and the Early Tuberculous Lesion IV. Stage 3 (After Week 3): Infection Control V. Stage 4 (Months to Years Later): Endogenous Reactivation and Transmission VI. Clinical Correlates of Immune Events in Human Tuberculosis VII. Conclusion References 11. Mycobacterial Strain Genotyping Nancy D. Connell and Barry N. Kreiswirth I. II. III. IV. V. VI.
Part Three
Introduction Methodologies Interpreting Genotypes International Applications of Molecular Fingerprinting Implications for Basic Research Clinical Applications of Molecular Fingerprinting References
225 227 228 229 230 231 236 241 241 242 248 249 252 254 255 255 261 261 262 265 267 269 270 270
CLINICAL ASPECTS
12. Tuberculin Skin Testing Richard I. Menzies
279
I. Introduction II. Technical Aspects
279 280
Contents
xxi
III. Simple Cognitive Aspects: False-Negative and False-Positive Reactions IV. Complicated Cognitive Aspects: Interpreting Tuberculin Tests V. Conclusions References 13. Case Finding in High- and Low-Prevalence Countries Hans L. Rieder I. II. III. IV. V. VI.
Introduction Sources of Transmission and Other Cases Identification of Sources of Transmission Factors Modifying the Choice of Case-Finding Methods The Role of Case Finding in Tuberculosis Control Conclusions References
14. Diagnosis of Tuberculosis Philip A. LoBue, Sharon Perry, and Antonino Catanzaro I. II. III. IV. V. VI. VII. VIII.
285 296 310 311 323 323 324 325 331 332 333 334 341
Introduction Medical History and Physical Examination Routine Laboratory Tests The Tuberculin Skin Test Diagnostic Tests: Pulmonary Disease Extrapulmonary Tuberculosis Pediatric Tuberculosis Developments in Rapid Diagnosis: Nucleic Acid Amplification Tests X. Summary References
341 341 343 343 343 351 356
15. Contact Follow-Up in High- and Low-Prevalence Countries Sue C. Etkind and Jaap Veen
377
I. II. III. IV. V. VI.
Introduction Definitions Need for Contact Tracing Contact Tracing in Low-Prevalence Countries Contact Tracing in High-Prevalence Countries New Technology: The Role of Restriction Fragment Length Polymorphism Testing
356 363 363
377 378 379 380 389 391
xxii
Contents VII. Challenges and Unanswered Questions VIII. Summary References
16. Treatment of Tuberculosis Paula I. Fujiwara, Patricia M. Simone, and Sonal S. Munsiff I. Introduction II. History of Tuberculosis Treatment in the Chemotherapeutic Era III. Antituberculosis Medications IV. Standard Antituberculosis Treatment Regimens in the United States V. Antituberculosis Treatment Regimens in Resource-Poor Countries VI. Methods Used to Diagnose Tuberculosis and Monitor Treatment VII. Special Clinical Situations VIII. Adherence to Treatment IX. The Future of Treatment References 17. Responding to Outbreaks of Multidrug-Resistant Tuberculosis: Introducing DOTS-Plus Paul E. Farmer, Jim Yong Kim, Carole D. Mitnick, and Ralph Timperi I. II. III. IV.
Introduction: Strengths and Limitations of DOTS What Is DOTS-Plus? Making DOTS-Plus Work: A Case Study Pitfalls in the Planning and Execution of DOTS-Plus Programs V. Conclusions: DOTS-Plus, We Can’t Afford Not to Try It References
18. Treatment of Latent Tuberculosis Infection David L. Cohn and Wafaa M. El-Sadr I. Introduction II. Treatment of Latent Tuberculosis Infection in Immunocompetent Hosts III. New Regimens for Treatment of Latent Tuberculosis Infection
394 395 396 401 401 402 405 415 418 420 423 432 435 436
447
447 453 455 462 466 466 471 471 472 481
Contents
xxiii
IV. Treatment of Latent Tuberculosis Infection in HIV-Infected Persons V. Treatment of Latent Tuberculosis Infection in Special Populations VI. Development of Disease Due to Resistant Organisms VII. Recommendations for Treatment of Latent Tuberculosis Infection VIII. Conclusions and Future Directions References 19. BCG Vaccines and Vaccination Paul E. M. Fine I. II. III. IV. V. VI. VII. VIII. IX. X.
Part Four
Introduction Historical Background BCG Vaccines Current BCG Policies The Protective Efficacy of BCG Protection Against Diseases Other Than Tuberculosis Adverse Reactions The Impact of BCG Vaccination Programs Improving Upon BCG Immediate Prospects for Vaccination Against Tuberculosis References
482 491 492 493 496 497 503 503 503 505 505 508 512 512 513 514 516 518
SPECIAL PROBLEMS
20. Tuberculosis and Human Immunodeficiency Virus Infection Philip C. Hopewell and Richard E. Chaisson
525
I. Risk of Tuberculosis in Persons with HIV Infection II. Prevalence of HIV Infection Among Patients with Tuberculosis III. Influence of HIV Infection on the Pathogenesis of Tuberculosis IV. Diagnosis of Tuberculosis Infection and Tuberculosis V. Treatment VI. Tuberculosis Caused by Multidrug-Resistant Organisms VII. Prevention VIII. Infection Control IX. Influence of Tuberculosis on the Course of HIV Infection
525 528 529 531 535 539 541 544 545
xxiv
Contents X. Necessary Changes in Approaches to Tuberculosis Control References
21. Tuberculosis in Children Flor M. Muñoz and Jeffrey R. Starke I. II. III. IV. V. VI.
Introduction Epidemiology Pathogenesis Clinical Forms of Tuberculosis Diagnosis of Tuberculosis in Children Treatment References
22. Case Management: The Key to a Successful Tuberculosis-Control Program Bonita T. Mangura and Karen E. Galanowsky I. II. III. IV. V. VI. VII. VIII. IX.
Part Five
Introduction Directly Observed Therapy Clinical Care and Public Health The Newark Experience The Nurse Case-Management Model Tuberculosis Therapy by Directly Observed Therapy Incremental Service Delivery Change and DOT The Interaction: Patient and Health Care Provider Impact on TB Control References
545 547 553 553 555 560 563 574 578 586
597 597 598 598 599 600 601 602 604 604 605
UNIQUE ASPECTS OF TUBERCULOSIS CONTROL
23. Tuberculosis Infection Control Henry M. Blumberg I. Introduction and Historical Overview II. Trends in Nosocomial Transmission of Tuberculosis III. Institutional Controls in the United States and Other Developed Countries IV. Hospital Discharge Planning and Standards V. OSHA Requirements for a Tuberculosis-Control Program VI. Institutional Controls in Developing Countries and Areas with Very Limited Resources References
609 609 610 617 630 631 631 636
Contents
xxv
24. Tuberculosis in Correctional Facilities Naomi N. Bock
645
I. II. III. IV.
Introduction Epidemiology of Tuberculosis in Correctional Facilities Transmission of Tuberculosis in Correctional Facilities Risk Factors for Tuberculosis Among Inmates in Correctional Facilities V. Correctional Facility Tuberculosis and the Community at Large VI. Controlling Tuberculosis in Correctional Facilities References 25. Tuberculosis Among Immigrants Mona Saraiya and Nancy J. Binkin I. II. III. IV. V. VI.
Introduction History of Migration of TB Definitions Epidemiology of TB Among Foreign-Born Persons Drug Resistance Contribution of Immigration to Transmission of TB in Low-Prevalence Countries VII. Approaches to TB in the Foreign-Born References 26. Coalition Building for Tuberculosis Control: The Philippine Experience Camilo C. Roa, Jr., and Rodrigo L. C. Romulo I. Coordinating Tuberculosis-Control Efforts: The Need for Coalitions II. TB Interest Groups III. Rallying Around a Common Goal IV. The Philippine Coalition Against Tuberculosis V. Formalizing and Expanding VI. Generating Resources VII. The Birth of PHILCAT VIII. Pushing Onwards IX. Developing a Unified Strategy: Identifying More Stakeholders X. National Consensus on Tuberculosis XI. Coalition Activities: Achieve Objectives and Maintain Member Enthusiasm
645 646 648 648 649 651 654 661 661 661 662 664 675 677 678 687
693
693 694 696 696 697 697 698 698 700 702 702
xxvi
Contents XII.
Summary References
27. Tuberculosis Education Eileen C. Napolitano and Elizabeth J. Stoller I. Introduction II. Evidence of the Need for Training and Education for Providers III. Current Training Initiatives IV. Health-Care Providers in Need of Education and Training V. Methods VI. Future Directions for Training VII. Topics for Further Discussion References 28. Political Will: The Singapore Tuberculosis Elimination Program Cynthia Bin-Eng Chee and Yee-Tang Wang I. Singapore: An Island City-State II. Tuberculosis in Singapore III. Rationale for the Singapore Tuberculosis Elimination Program IV. Organizational Structure of STEP V. Key Factors for the Success of STEP VI. Conclusion References 29. Medical Anthropology: An Important Adjunct to International TB Control Daniel Chemtob, Sheri Weiser, Israel Yitzhak, and Daniel Weiler-Ravell I. II. III. IV.
Introduction The Relevance of Social Science to Public Health Some Basic Concepts in Social Science Some Key Perspectives in the Social Science Literature on TB V. An Anthropological Study of TB Among Ethiopian Immigrants in Israel VI. The Contribution of Social Science to the New National Program for the Elimination of TB in Israel VII. Conclusion References
703 703 705 705 707 711 713 714 717 718 720
727 727 729 734 735 736 739 740
745
745 746 750 754 757 762 765 766
Contents
xxvii
30. The Role of Nongovernmental Organizations Annik Rouillon, Nils Eric Billo, and Frances R. Ogasawara I. Introduction II. National Tuberculosis Associations III. The International Union Against Tuberculosis and Lung Disease IV. Present Trends: Irreplaceable Partners V. Summary References 31. Economic Considerations for Tuberculosis Control Holger Sawert I. Political Commitment and Economic Arguments II. Economic Analysis: Basic Concepts III. Specific Points for the Analysis of Tuberculosis Control Interventions IV. Example: Improving Tuberculosis Control in Thailand References 32. The Impact of Managed Care on Tuberculosis Control in the United States Bess Miller and Sara Rosenbaum I. Introduction II. Tuberculosis Control in the United States: Current Organizational Structure III. The Advent of Managed Care and Its Impact on TB Control IV. Concerns of TB Health Officials About Managed Care V. Response of TB Health Officials to the Advent of Managed Care VI. Role of Contracts and Memoranda of Agreement VII. Conclusion References 33. The Impact of Health Sector Reform on Tuberculosis Control in Developing Nations Elizabeth Tayler I. II. III. IV.
Introduction Why Health Sector Reform Is Needed Impact of Health Sector Reform Upon TB Services Political Commitment
771 771 775 787 793 795 795 799 799 802 804 807 814
817 817 818 819 820 821 823 825 825
829 829 831 832 833
xxviii
Contents V. Case Finding and Diagnosis VI. Standardized Short-Course Regimen and Supervision of Therapy VII. Drug Supply VIII. Recording and Reporting IX. Conclusions References
34. Mobilizing Society Against Tuberculosis: Creating and Sustaining Demand for DOTS in High-Burden Countries Kraig Klaudt I. Assessment of the Current Response to the Global TB Epidemic II. The Role of Information, Education, and Communication, Advocacy, and Social Mobilization III. The C.A.U.S.E. Strategy for Mobilizing Society IV. The Main Components of Advocacy V. Potential Initiatives to Help Mobilize Society to Control TB VI. Conclusion References Part Six
Index
835 837 837 838 840
843
843 846 850 854 858 863 863
THE FUTURE
35. Tuberculosis in the Future Richard J. O’Brien and Mario C. Raviglione I. II. III. IV. V.
834
Tuberculosis in the 1990s: Reasons to Be Hopeful Problems Looming at the End of the Twentieth Century TB in the New Millennium: Clues from Modelers The Promise of New Technologies Tuberculosis Elimination: An Impossible Dream? References
867 867 871 874 877 878 881 885
Part One PROGRAMMATIC BACKGROUND
1 A Historical Perspective on Tuberculosis and Its Control
ANNE L. DAVIS New York University Medical School and Bellevue Hospital Chest Service New York, New York
Since the first appearance of tuberculosis in humans probably some 8000 years ago (1–3), its control has continued to elude the brightest minds and to challenge both the human and economic resources of countries around the world. One third of the world’s population is estimated to be infected. If the trends of the 1990s continue, the annual number of new cases could exceed 8 million, and 30 million deaths will have resulted from the disease between 1990 and 2000 (4). As an indolent wasting, debilitating condition, “the Captain of the Men of Death” (5), or a highly lethal epidemic, “The Great White Plague” (6,7), it is different from most infectious diseases in the worldwide magnitude of its effects. From a constellation of elusive illnesses of hypothetical etiologies to its final recognition as a single disease caused by a specific microorganism, it has challenged the imagination and intellect of people from prehistory to the present. It has stimulated as well as snuffed out the creative and intellectual endeavors of those who have encountered it. It has enchanted the imaginations of writers, artists, musicians, philosophers, scientists, and most recently news reporters. It has spawned a global public health movement, called attention to the deplorable effects of poverty, overcrowding, and ignorance and raised awareness of the vital role of the nursing and other health professions, as well as veterinary medicine, in its control. The continuing ability of the disease to elude control has prompted re3
4
Davis
strictive laws (8–11) and raised legal ethical issues as recently as the 1990s (12–16). Not only when but also how and where tuberculosis originated and spread is still the subject of debate. Some believe that it existed in animals long before it affected humans (1–3,17,18). When primitive agricultural practices permitted permanent settlements, cattle, swine, and sheep became domesticated and often shared the family’s dwelling space, making the spread between animals and humans possible but initially sporadic and endemic. Whether Mycobacterium tuberculosis evolved from Mycobacterium bovis is still unclear, but some believe that biological and historic evidence support such an evolution (1). The strong degree of DNA homology (19) and the immunological properties suggest that they are subspecies (20) and that M. tuberculosis evolved through genetic mutations from M. bovis in humans after the domestication of cattle (1). Concepts about where on the globe tuberculosis began and how it spread are also changing as new archeological discoveries and molecular technologies emerge (21–25). The distribution of infection and severity of the disease have varied with the time period and geographic location (3,26–31). The epidemiology has been imperfectly hypothesized from the spotty data available before the development of modern tools for more accurate identification of the disease and required reporting of cases. Even if one accepts that tuberculosis was endemically present in areas of Eurasia, Africa, India, China, Japan, and the Americas for perhaps several thousand or more years, the chronology of its devastating impact in the different populations of the world has yielded differing theories explaining the observed phenomena (1,32–34). In addition to exposure to infected cattle, their milk, and milk products (1,17,18,34–37), human “herd immunity” (38) and migration and immigration patterns, industrialization, poverty, poor nutrition, overcrowding, unhealthy lifestyle changes, and concomitant disease [e.g., human immunodeficiency virus (HIV) infection] have played a role. During the lengthy history of the disease there have been brief glimpses of enlightenment, but progress primarily had to await additional observations and discoveries beginning during the Renaissance but continuing with increasing acceleration to the present. The discovery and isolation of the etiological agent by Robert Koch in 1882 and subsequent developments in the first part of the twentieth century provided more accurate ways of detecting the disease, generated vigorous public health campaigns, introduced new treatment and prevention strategies, and renewed hope that tuberculosis could be prevented and even cured. Clinical and laboratory investigations burgeoned and have provided the background for the present application of sophisticated new tools to the persistent challenges retarding the conquest of tuberculosis into the next century. This chapter can only hint at the rich history of this ancient disease and highlight a few of the events and trends—particularly in the nineteenth and twentieth
History of Tuberculosis
5
centuries—that have led to current concepts of tuberculosis and strategies for its potential control.
I. Early Perceptions and Practices Prehistoric humans thought that supernatural powers were responsible for all that they did not understand, including sickness. Diagnosis was unimportant because the treatment was the same: appeasing the supernatural spirit or scaring away the evil demons, evoked by magic. Herbs and animal parts, their secretions and excretions, were used therapeutically. Sometimes certain stones or colors (red, especially) were considered beneficial. The sun, moon, and stars were also believed to influence health. Transference of disease to another object or animal was practiced (18). A child with scrofula was passed through the hole of a tree or a rock with the belief that the disease would thus be transferred (39). Some of these superstitions regarding disease and health, that existed when Egyptian, Babylonian, Greek, Roman, Hindu, Chinese, and Japanese civilizations began, still exist among some populations in parts of the world where traditional healers still practice (26,40–42). Awareness of such customs is important for the development of successful control programs (40,41). The observations of ancient societies, as detailed in their skeletons, artefacts, drawings and paintings, and later in writings are remarkably recognizable as the clinical features of tuberculosis as we know it today. The bony deformities found in skeletons, drawings, and sculptures in Egypt, Peru, and other countries are very suggestive of Pott’s disease (39,44–47). Data from written sources, although scarce, also tend to support the hypothesis that tuberculosis has existed for a very long time (18,39,48), but some scholars are skeptical because perceptions of the symptoms and course of what we now call tuberculosis varied widely until the last decades of the nineteenth century when the unity of the disease was established. It was known as phthisis (“wasting disease”) or consumption as well as scrofula (the cervical swellings resembling cow’s udders), lupus vulgaris, lung hemorrhage, chronic diarrhea, and hectic fever. The Hindus alluded to consumption. Some historians believe that descriptions of consumption passed orally from generation to generation long before the Vedas were written (26,39). Hindu drugs were known to the Egyptians, who derived cotton from India, long before Hippocrates. Many Greek drugs had Sanskrit names. Hindu remedies were also mentioned in the Old Testament. Antedating by centuries many of the remedies still believed to be beneficial for consumption as late as the nineteenth and first half of the twentieth centuries, the Hindus recommended milk, especially from a lactating woman, many meats and vegetables, and avoidance of fatigue. The Yajur Vedas advised that “to mount and be carried on
6
Davis
gentle horses makes an exercise which increases the flesh and blood and helps sleep. . . . A consumptive should go and live in high altitudes” (39). The Greeks apparently saw most forms of the disease and contributed detailed descriptions of the cardinal symptoms—age, incidence, and prognosis (18,43,49). The careful observations and interest in scientific inquiry by Hippocrates and his followers removed medicine from the realms of religion and philosophy and began to replace superstition with common sense. At the end of this era, Rome and subsequently Byzantium assumed importance, but little medical progress was made. When the Roman Empire eventually disintegrated about 600 A.D. and the Dark Ages ensued, the writings and teachings of Galen (130–200 A.D.), a Greek emigré to Rome, became authoritative in medicine for about the next 1400 years (43,50). The prior interest in keen observation and scientific inquiry exemplified by Hippocrates and others of the Greek Golden Age faded. Mystical explanations for natural phenomena again prevailed, and authority reigned as the source of knowledge. In summary, as these early civilizations developed, little progress was made in the understanding and control of phthisis. Diagnosis, at its best, was based almost solely on careful observations of the patient. Limited attempts at physical examination were made. References to râles and to succussion have been found in the Hippocratic Collection (18,43,49). Human dissection was not permitted, except transiently, in Alexandria around 332 B.C. (39). Sputum as a diagnostic or prognostic tool was barely mentioned, but Aretaeus did suggest that inspection of the sputum was of greater diagnostic value than testing it with fire or water (43). One Hippocratic aphorism stated that “in persons affected with phthisis, if the sputa which they cough up have a heavy smell when poured upon coals, and if the hairs of the head fall off, the case will prove fatal” (49). Without the benefit of pathological or microbiological studies, the causes and pathogenesis of these afflictions were highly speculative. An imbalance of the four humors, heredity, defluxions proceeding from the head, something exhaled in the patient’s breath. ulceration of the lung, which might be due to inflammation extending from the nose or throat, or even chilling of the lung or trauma were a few of the theories (43). The contagious nature of phthisis was not recognized (18). Although long before mycobacteria were identified, Aristotle had hinted at the possibility (39), and Galen (50) and Avicenna, the Arab physician, had suggested (43,51), it was not until the seventeenth century that measures were briefly put in place in Italy to quell the spread. Treatment continued to include many of the superstitious practices of earlier times as well as the old Hindu remedies. Bloodletting and cupping were also employed. Pliny the Elder (23–79 A.D.) commented that sea voyages were desirable especially for hemoptysis (39), and some specific therapeutic concoctions such as wolf’s liver boiled in wine or boiled crocodile for chronic cough were
History of Tuberculosis
7
mentioned. Later “the King’s Touch” for scrofula instituted by King Clovis in 494 A.D. was considered beneficial (39,43), although the idea of healing by royal touch may have originated with Pyrrhus (318–272 B.C.), who cured disease of the spleen by the touch of his right toe. The Christian practice of “laying on of hands” to heal derives from this early belief in the royal healing power. During the Dark Ages, the Christian church and Arab physicians (Syrians, Persians, and Spaniards by virtue of their common language) determined the course of medicine, primarily by collecting and preserving the texts of the Greek physicians. II. Concepts from the Renaissance Through the Eighteenth Century After the invention of printing and the translation of the great Greek texts into Latin and their publication by the middle of the sixteenth century, discussions about possible causes for tuberculosis and controversies over contagion were revived. At last anatomical and pathological studies began to provide a basis for understanding the clinical features and pathogenesis of tuberculosis as we know it today. A. Contagiousness and Early Attempts to Control
A notable achievement in this period was the advancement, at least temporarily, of the notion of contagiousness of tuberculosis. Heironymous D. Fracastorius’s description in his book, De Contagione, in 1546 of three methods of infection— direct contact, fomites, and air—and his postulation of the existence of “seminaria,” imperceptible particles which he believed could exist outside the body for several years and still infect, were the most articulate and original enunciations up to this time of the modern germ theory of contagion (1). In phthisis he postulated that the “seminaria” could come not only from outside, but could arise within the body as well, from “putrefaction of the humors” (39). He believed that “the original germs generate and propagate other germs precisely like themselves and these in turn propagate others until the whole mass and bulk of humors is infected by them” (1,52). He also suggested that contagion was selective: some organs are affected while others may be spared, and “some bodies catch infections very easily, others either not at all or with difficulty” (52). He even suggested the idea of sterilization, which went unheeded for the next 300 years. In the initial stage of treatment, “pay attention to the germs only, for if these could be destroyed, by caustic means no more effective remedy could be employed” (52). Similar conclusions regarding control of tuberculosis with emphasis on detection, isolation, and prompt treatment of infectious tuberculosis followed in the twentieth century, but experience both before (53) and since the chemotherapy era has shown that tu-
8
Davis
berculosis is more than a simple infectious disease and that its effective control requires combat on many fronts (27,54–57). During the seventeenth century the contagious nature of tuberculosis was accepted and dreaded throughout much of Europe, but by the latter half of the century those north of the Alps began touting hereditary or constitutional factors. In southern Europe the contagion notion persisted and resulted in strict measures to safeguard the public. In 1699 the The General Sanitary Council of the Republic of Lucca ordered that “the health of the human body shall not be harmed or imperiled by objects remaining after death of a person infected with the disease of phthisis” (58). Disinfection measures were promptly instituted, including replastering the entire house by the authorities, decontamination or burning of household goods, and removal of the poor sick to a hospital (59). Furthermore physicians had to report persons treated for or suspected of tuberculosis or they faced fines of 300 ducats or banishment for 10 years for a second offense (59). Although systematic recording of cases was not yet practiced, it is generally agreed that there was a sharp increase in cases of consumption in Britain and then throughout western Europe during the 1600s, especially in the overcrowded cities. Following Lucca’s attempts at record-keeping, compulsory notification was introduced by Ferdinand VI in Spain and in Naples. Parish registers from England quoted by Thomas Beddoes in his 1799 essay (60) indicate that over a 7- to 10-year period one in four deaths was ascribed to tuberculosis. Similar mortality statistics were available from New England in the United States (37). Both Florence (1754) and Naples (1782) subsequently passed edicts to control contagion, and for a while the latter’s rules were strictly enforced in Spain and tubercular patients were forbidden to emigrate (52). However, opposition finally prevailed, and the laws were removed or forgotten. Fears that the laws would evoke prejudice against the tubercular poor and create financial burden contributed to the demise of these early public health efforts (52,58,59). These arguments are reminisicent of those expressed against the pioneering public health laws in New York City at the turn of the twentieth century. B. Concepts of Etiology and Pathogenesis
Once Andreas Vesalius (1514–1564) had established the principal of dissecton and corrected Galen’s errors, correlation of post-mortem examination with clinical aspects began to demystify the puzzling constellation of symptoms and signs that we now call tuberculosis. It took more than 100 more years before the results of autopsies during the sixteenth and seventeenth centuries were published by Theophile Bonet in his Sepuchretum in 1679. Cavities (vomicae) were described in some of the lungs of cases from the leading Parisian physician, Jean Fernel
History of Tuberculosis
9
(1497–1558), who had stated that these occurred frequently in consumptive patients (39). Symptoms of consumption were connected with pathological findings by Richard Morton in 1689 in his systematic treatise, Phthisiologica (39). Francis de le Boe (Sylvius) (1614–1672), a professor at Leyden, observed that tubercles were identified with the symptoms of phthisis. He noted their tendency to grow and gradually to suppurate and even to lead to cavities (61), but he misinterpreted their origin as being tiny lymph nodes (39,43,61). Thomas Willis (1621–1675) of Oxford first proposed the heretical idea that phthisis was possible without ulceration (43,51,61). He also noted the variations in the pathology and clinical course in different individuals, which up to this time had not been fully appreciated (51). William Stark (1741–1770), a meticulous Scotland-trained pathologist, observed structural changes in phthisis, which led him to believe, unlike his predecessors, that observed changes reflected variations in the speed and evolution of the pathologic process rather than different diseases (43,51). Of particular note is Benjamin Martin’s amazing book A New Theory of Consumption, More Especially of Phthisis or Consumption of the Lungs, written in 1719, 26 years after Leeuwenhoek’s opening of a new world of microscopical vistas. It was remarkable in its anticipation of the germ theory proposed and validated more than 100 years later. He believed that consumption was not only contagious, but that this infection was possibly due to “some certain Species of Animacula or wonderful minute living creatures that, by their peculiar shape or disagreeable parts are inimicable to our nature” (43,62). He goes on to suggest “the possibility of very minute animals being not only the original and essential cause of many distempers hitherto inexplicable; but that they are, perhaps, the very malignity so much complained of in many distempers but so little understood” (51,52,62). Marten also commented on the liklihood of tuberculosis contagion: “by habitual lying in the same bed with a consumptive patient, consistently eating and drinking with him or by frequently conversing so nearly as to draw in part of the breath he emits from the lung, consumption may be caught by a sound person. . . . I imagine that slightly conversing with consumptive patients is seldom or never sufficient to catch the disease.” (51,52,62). Marten predicted that his ideas would be scorned, and indeed they were for two centuries, until Villeman and Koch appeared. By the end of the eighteenth century, tuberculosis was rampant: early attempts at control had failed, the cause(s) was still speculative, and the treatments ineffective. Although the gross pathology had been described and the tubercles were believed to be associated with the disease, their origin was unknown, as was the relationship of their occurrence in different parts of the body.
10
Davis III. Nineteenth- and Twentieth-Century Developments and Concepts
The observations and investigations of the next hundred years would establish the fact that the diverse clinical and pathological manifestations were indeed one disease, tuberculosis. They would revolutionize understanding of the cause, improve diagnostic accuracy, and lead to more rational attempts at therapy and control. The correlations of clinical symptoms and signs with specific pathology led to new interest in expanding techniques for eliciting physical signs of anatomical pathological changes. A. Percussion and Auscultation in Diagnosis
The use of percussion and of a new tool, the stethoscope, augmented information gained from symptoms alone, and this could be correlated with the history and pathological observations. Leopold Auenbrugger, an innkeeper’s son, had watched his father tapping wine casks to determine their full or empty state. He decided to apply the technique to his patients and to cadavers on which he experimented (43,51,52). Students of physical diagnosis today would be impressed with the scope of his work, as illustrated by his categorization of his observations in the book Inventum Novum ex Percussione Thoracis Humani, ut Sigmo Abstrusos Interni Pectoris Morvos Detegendi, published in 1761. It took another half century for medical clinicians to recognize the value of Auenbrugger’s approach to diagnosis. Only when Jean Nicholas Corvisart, Professor of Medicine at the College of France, discovered the work in 1797, translated and published the original text, and practiced the method did percussion begin to achieve acclaim (51). Laennec ( b. 1781) devised an indirect method of listening to the sounds generated in the chest. Direct auscultation and succussion, practiced by the ancient Greeks, was not practical in obese patients or women or when hospital vermin were common (39). He constructed a simple instrument to obviate these obstacles and first published his observations in 1819 in his Traite de l’Auscultation Mediate. The stethoscope was at first ridiculed as a mere mechanical toy, and critics considered it ludicrous that a “physician would proudly listen through a long tube applied to the patient’s thorax, as if the disease were a living being that could communicate its condition to the sense without” (39,63). Despite initial skepticism, auscultation and percussion remained the only methods of examination of the chest until Roentgen’s discovery of x-rays later in the century. Even with today’s more sophisticated tools, percussion and ausculation have not yet been discarded.
History of Tuberculosis
11
B. Tuberculosis as One Disease
Bayle had dispelled some of the prevalent misconceptions in his Recherches sur la Phthisie Pulmonaire, published in 1810. On the basis of 900 autopsies—many of them on patients he had known at the bedside—he described phthisis on the basis of pathological injury rather than differences in symptoms or possible causes or complications. He described miliary and extrapulmonary lesions, but he was unable to recognize the etiological unity of his findings or to differentiate cases of bronchiectasis or lung abscess (43). His work attracted Laennec, and they were good friends until Bayle’s death in 1816 at the age of 42 (43). Laennec, in a second edition of his book in 1826, noted that “whatever be the form under which the tuberculous matter is developed, it presents, at first, the appearance of a grey semitransparent substance, which gradually becomes yellow, opaque and very dense. Afterwards it softens, and gradually acquires a fluidity nearly equal to that of pus: it being then expelled through the bronchi, cavities are left, vulgarly known by the name of ulcers of the lungs, but which I shall designate tuberculous excavations” (43,51). Although Stark and Bayle had imperfect glimpses of tuberculosis as possibly a single disease, Laennec noticed that tubercles found in various organs and in various varieties and stages of development seemed uniformly to characterize the disease. He traced its evolution from the tiny gray tubercle through successive eruptions and all its pathological manifestations, thus claiming for the first time the unity of the disease. Laennec’s accomplishments were not without their toll. His work was cut short, when he died from tuberculosis in 1826 at age 45 (43). The concept of the unity of tuberculosis which Laennec had so meticulously expounded was disputed until the bacteriological era confirmed it. Such eminent professors as Broussais and Virchow led the dissension. In the meantime, Johann Lukas Schonlein, Professor of Medicine in Zurich, embraced the idea of the tubercle being the fundamental anatomical lesion and suggested in 1839 that the word “tuberculosis” be used for all manifestations of phthisis (58,61). Clinical pathological studies continued throughout the nineteenth and into the twentieth century, with radiological correlations being added. The work of Parrot, Kuss, and Ghon (64) elucidated the characteristic changes of primary infection in children (and subsequently recognized at any age) and supported the theory that most tuberculosis is acquired by inhalation. The pathogenesis of generalized tuberculosis was demonstrated by Carl Weigert in 1882, and the mechanisms of such complications as laryngeal and intestinal tuberculosis, so common before chemotherapy, and of bronchogenic spread were also demonstrated (65). Ranke in 1917 attempted further clarification of the relationship of the primary complex and the later manifestations of tuberculosis. He proposed three stages of the disease and provoked much discussion about “endogenous” exacerbation ver-
12
Davis
sus “exogenous” reinfection as the source of the third stage (43). In 1935 Opie summarized the then current views by noting that “there is no agreement concerning the relative frequency of endogenous and exogenous infection of adults” or whether or not first infection makes one more or less susceptible to a new infection (66). Discussion continues today as molecular techniques suggest that exogenous reinfection occurs more frequently than was previously believed (67–69), especially when prevalence in the community is high. C. Cause and Transmissibility in Animals and Humans
That tuberculosis is a specific infectious disease was not recognized until Jean Antoine Villeman’s astute observations. Working with military horses, he had observed that healthy young rural horses brought into crowded military depots often died of fulminating glanders (52,61). He also noted that military men stationed in barracks, not out in the field, and prisoners, industrial workers, and members of cloistered religious orders were more likely to have tuberculosis than the general population (52). Inocculation experiments had been performed by Kortum in 1789 and later by Cruveilhier, who considered tuberculosis not to be specific but to result from inoculation of a number of substances (39). In 1865 Villemin began his signal series of experiments. He inocculated products of the disease, such as sputum and gray and soft tubercles from the lung and other organs from humans to lower animals and from animal to animal and found that the disease developed in the inoculated animals (51,65). He concluded that tuberculosis is a specific disease the cause of which resides in an inoculable agent. He also went on to show that all forms of scrofula are really tuberculosis (70). Despite Villeman’s significant contribution, many in France and England continued to challenge it, claiming that he was just producing a foreign body reaction. His work, however, stimulated tuberculosis research elsewhere, especially in Italy and Germany, and by 1880 his conclusion was known and accepted (51,52). It was not until Robert Koch isolated the tubercle bacillus in 1882, however, that the unity and transmissibility of tuberculosis were finally confirmed. Experimenting within the new science of bacteriology, Koch developed a method of plate cultivation, which by permitting separation of colonies made possible isolation of individual strains (71). Koch demonstrated that the bacillus he had isolated inoculated into animals could reproduce the disease in them and that the organism could be recovered from those tissues and, when reinoculated into other animals, could again produce the disease (72). Koch’s postulates and his precise experiments to prove them have served as a model for infectious disease investigators ever since. Even though Koch’s demonstrations seem indisputable now, there were at the time still skeptics who clung to their preconceived notions or unproven hy-
History of Tuberculosis
13
potheses. At Koch’s momentous presentation before the Physiological Society in Berlin, the audience looked to Virchow for comment. His silence was cutting. Virchow persisted to the end of his life in claiming that scrofula and pulmonary phthisis were not the same disease. He lectured that certain aspects of the disease in cattle known as “pearl disease” (so named because of the appearance of the lesions on the serous membranes) looked like lymphosarcomas. The peculiar distribution of these grape-like or potato-like lesions in the peritoneum or internal genitalia led to speculation that they must be related to nymphomania and satyriasis (65). Koch himself did not appreciate that there was a distinction between human and bovine tuberculosis. Between 1896 and 1898 Theobold Smith in the United States demonstrated that these were separate strains (73), but even as late as 1908 at the International Conference on Tuberculosis in Washington, D.C., there was still controversy over whether the disease in humans and that in cattle were caused by two different tubercle bacilli (65,74). Ravenel (75) of the United States, however, presented incontrovertible evidence that the bovine bacillus is responsible for most tuberculosis in cattle, a vital step in the subsequent eradication of tuberculosis from bovine herds and consequently preventing many cases of tuberculosis in humans as well. Proving which species of the organism was responsible for bovine tuberculosis took ingenuity. Because cattle can develop cavitary pulmonary lesions, the organism could be recovered from pulmonary secretions. Nocard, a French veterinarian, did this by grasping a cow’s tongue and swabbing the throat—when the cow coughed, he tried to catch the secretions. Ravenel more cleverly constructed a hood, which he put over the cow’s nose and mouth. At the bottom was a wooden platform upon which the cow’s coughed-up secretions would fall. He then collected and examined them for the tubercle bacillus (65). Although contagiousness of tuberculosis had long been suspected, considerable skepticism remained as to whether tubercle bacilli were the cause or merely a by-product of tuberculosis (76). Even those accepting the fact of its transmissibility did not agree about how the infection was transmitted. D. Modes of Transmission: Implications for Control
It was still hypothesized that tuberculosis might be transmitted through the ovum even after Koch’s announcement. Osler temporarily perpetuated the idea using silkworm infestation as an example, saying that even the silkworm egg can be invaded by a parasite, thus providing hereditary transmission. This notion was gradually eroded and finally discounted in Cornet’s statement that the tubercle bacillus would have to be straddling a spermatozoa as it enters the ovum, a situation thought to be too absurd to be believed (65). Theories of how tuberculosis might be transmitted helped to determine certain control measures (Fig. 1). Cornet, among others, was a proponent of the dust
14
Davis
History of Tuberculosis
15
theory, namely that dust arising from expectorated sputum, which has dried and become pulverized, floats in the air and is inhaled (77). The belief that tuberculosis might also be transmitted by soiling hands or mouth helped to foster the idea that most tuberculosis started in childhood. That surfaces could be contaminated was demonstrated by strategically placing pans of water around to collect material emanating from the patient’s cough or by swabbing the floor. Inoculation of animals with such collected material produced tuberculosis (65). It was later confirmed that particles carrying M. tuberculosis can be transiently resuspended by an air current and become a possible reservoir for infectious respirable particles (78). This concept as a major mode of transmission was disputed by Flugge (77), who instead postulated that moist droplets produced by cough and sprayed into the air were the means. Considerable controversy prevailed during the 1880s and 1890s, but Cornet’s work was so persuasive that the environment was contaminated and the disease still so lethal that disinfection pervaded all of the early laws for tuberculosis prevention and control in the United States in the early 1890s and the first part of the twentieth century. Sulfur candles might be used, or, once a patient had died, the walls might be swept down with soft bread if they were whitewashed or papered or washed with carbolic acid or formalin solution if painted (65). It was not until the 1930s, extending into the 1960s, that the current understanding of transmission by droplet nuclei was demonstrated by Wells (79,80) and further elucidated by Richard Riley (81). Wells exposed animals to various concentrations of droplet particles and demonstrated that it is not the moist droplet particle that is the usual immediate means of transmission, but the particle that loses its content of moisture, leaving a single bacillus or small clump of bacilli to float freely in the air for considerable periods of time. Wells termed these lighter particles “droplet nuclei.” He noted that the heavier droplets, greater than several micrometers in diameter, generally fell to the floor and dried out and their organisms usually died off. Droplet nuclei produced by a single cough in Loudon’s and Robert’s experiments remained suspended in the air after 30 minutes (82). Such droplets could be readily inhaled and if they reached an alveolus could initiate primary infection (80,81). Riley and coworkers in Baltimore subsequently demonstrated how the dried nuclei may be airborne for some distances and still be capable of infecting animals (83). Such transmission was demonstrated in humans in the well-documented Figure 1. Antituberculosis campaign educational poster circa 1915. For some time transmission of tuberculosis was believed to be by fomites and dust particles. Disinfection was widely used until the work of Wells and Riley in the mid-twentieth century showed that airborne droplet nuclei were the means of transmission. (Courtesy of the American Lung Association, New York.)
16
Davis
Navy submarine epidemic reported during the 1960s (84) and more recently in hospital outbreaks of multidrug-resistant tuberculosis (85). The work of Wells, Riley, and their colleagues, as reflected in a National Tuberculosis Association Committee Report in 1967 (86), has been crucial to the modern strategies of environmental tuberculosis control aimed at preventing infected droplet nuclei from entering the air, diluting their numbers by adequate number of air exchanges, preventing dissemination by maintaining negative pressure in the contaminated space relative to the adjoining areas, using devices to filter or “sterilize” the air leaving the room, and preventing persons entering the infectious patient’s room from inhaling infected particles by using particulate respirators (87–89).
E. Evolution of Public Health Campaign
Other events important to the history of tuberculosis were occurring during the nineteenth century. The first international medical congress, held in 1867 in Paris, included presentations on tuberculosis, including Villeman’s work. Subsequent international congresses devoted specifically to tuberculosis were held regularly until the end of the century and still meet periodically even today. Toward the end of the nineteenth century, national organizations composed of medical, lay, and government persons evolved to combat tuberculosis in Austria, Denmark, and France, with other countries in Europe and Canada rapidly joining the movement (43). Lawrence Flick in Philadelphia in 1892 organized the first voluntary society in the United States to combat a specific disease, the Pennsylvania Society for Prevention of Tuberculosis (90). He wanted to disseminate the idea of the communicability of tuberculosis and to stop its spread using education, legislation, research, and better patient care. Other voluntary associations began to arise and competed for the honor of representing the United States at the International Tuberculosis Congress in Paris in 1904. Adolphus Knopf urged the organization of a strong national scientific and popular organization against the disease. The National Association for the Study and Prevention of Tuberculosis, later called the National Tuberculosis Association and now known as the American Lung Association, was thus born in 1904 (90,91). By 1914, with the collaboration of its many grass-root affiliates, it had become a powerful force in the crusade against the disease (90). Through the innovative idea of a Danish postal worker, Einar Holboell, and the philanthropic efforts of Emily Bissell, a Delaware Red Cross volunteer, the sale of Christmas seals provided remarkable financial support for an expanding antituberculosis campaign (92). In 1902 an International Central Bureau for the campaign against tuberculosis under the emblem of the double-barred cross was established, with an office in Berlin and then Geneva. After World War I, it became the International Union
History of Tuberculosis
17
Against Tuberculosis, now the International Union Against Tuberculosis and Lung Disease (IUATLD) (43). The antituberculosis campaign extended to other parts of the industrializing world: Asia, Africa, the Near East, and Latin America. In 1898 in Japan, Goto Shinpei petitioned the government to establish an office of sanitary police. Attention to epidemic control and water supplies would keep the population healthy and benefit Japanese imperialism (42). In China the YMCA organized city-wide health campaigns between 1915 and 1921, enlisting the cooperation of city officials, educators, churches, newspapermen, students, boy scouts, and the Chamber of Commerce, but tuberculosis was a low priority of the government despite the dismal statistics available in the early twentieth century. It was 1933 before the Chinese Medical Association held its first tuberculosis conference and an antituberculosis association was formed in Shanghai (42). In Korea the first tuberculosis sanatorium opened in 1928, the School of Hygiene was organized, and in 1932 the sanatorium became the seat of the new Korean Christmas Seal organization. Some historians feel that the campaign against tuberculosis has been driven primarily by “the need to protect the investment and profits of the owning class” (93). When labor was initially unskilled, cheap, and easily replaceable, employers had little concern for the health of individual workers. Only as the labor pool shrank and increased skills were required did employers realize the financial importance of not losing employees. Such motives may have hastened the institution of preventive measures in South Africa in the early twentieth century as the alarming rates of pneumococcal disease and tuberculosis in mine workers became known (94). The other catalyst in the campaign was the recognition by physicians that untreated, unsupervised poor people were a threat not only to themselves but to the larger public’s health as they came in contact with middle and upper class persons as their servants, repairmen, or in other capacities. During the recent resurgence of tuberculosis in New York City this threat resurfaced, caught the media’s attention and thus the public’s, and undoubtedly stimulated the rapid action of legislators and public health departments even beyond the United States. The time was also ripe for social activism. The belief in the importance of constitutional and hereditary factors in tuberculosis persisted throughout the nineteenth and even the twentieth century in North America and England, despite Koch’s isolation of the infectious agent. Toward the end of the nineteenth century vulnerability to tuberculosis was linked to immorality and lower social class. Adolphus Knopf in his 1907 prize-winning essay, “Tuberculosis as a Disease of the Masses and How to Combat It” (95), identified those most susceptible as the unfortunate poor, the ignorant or depraved, or the alcoholic. As large numbers of people moved from rural to urban areas and immigants flooded the larger cities, greedy landlords offered the worst of housing conditions: dark cramped quarters with inadequate water, sewage, or ventilation (Fig. 2).
18
Davis
Figure 2. Tenement visit by visiting nurse in 1924. The nurse/social worker was an essential link in the antituberculosis campaign, educating families about tuberculosis, expectoration, disinfectation, importance of ventilation, good hygiene, and nutrition. She was a liaison between the community, medical facilities, and the health department, identifying those at risk or ill, referring to appropriate medical facilities, and monitoring their subsequent follow-up. The poverty and inadequate housing reflected here, believed to contribute to prevalence of the disease, are still with us. (Photograph Courtesy of the Bellevue Hospital Chest Service Archives, New York.)
Death rates from tuberculosis in the 1890s soared to more than 776 per 100,000 (93) in some districts. Xenophobia augmented the difficulties of controlling the disease. Many Americans feared being overwhelmed by aliens with different cultures and beliefs. New waves of immigrants and refugees in the latter part of the twentieth century stimulated similar sentiments in some areas, and many immigrants do not seek health care for sociocultural, economic, or other reasons, including fear of the consequences if they are undocumented (96,97). As Koch had predicted at the conclusion of his scholarly thesis in 1882, “when the conviction that tuberculosis is an exquisite infectious disease has become firmly established among physicians, the question of an adequate campaign
History of Tuberculosis
19
against tuberculosis will certainly come under discussion, and it will develop by itself” (72). He was correct in predicting that such a campaign would evolve. In Edinburgh Sir Robert W. Phillip was a prime mover in establishing an organized system for the control of tuberculosis. In 1887, just 5 years after Koch’s announcement, Phillip opened the first tuberculosis dispensary in the world. It became the nucleus of the Edinburgh Anti-tuberculosis Scheme (37,43). Phillip’s dispensary was unique in its organization not only for the treatment of tuberculosis, but also in its prevention, case finding, record filing, sputum examinations, home visits by physicians, and specially trained nurses. Social service in the home, classification, triage, and aftercare of discharged patients was practiced, and education was freely dispensed (98). In the United States, Canada, and Germany the sanatorium movement preceded any generally organized antituberculosis effort (98). Phillip’s pioneering efforts led to the development of city chest clinics throughout the world, often integrating case finding and referral within a sanatorium or hospital system in collaboration with developing municipal antituberculosis structures (99,100) (Fig. 3). In the United States state health departments began to broaden their mandates from primarily sanitary water supplies, safe sewage, and garbage disposal to the control of transmissible diseases. Public health physicians began to replace sanitary engineers. In 1888 Commissioner of Health in New York City, Joseph D. Bryant, asked a group of consultants, including Herman Biggs, an 1883 graduate of the Bellevue Medical College, to issue a position paper on tuberculosis for the Board. The document asserted the validity of Koch’s findings and recommended the inspection of cattle to prevent consumption of infected meat and milk, public education regarding the dangers of pulmonary discharges from tuberculous individuals, and disinfection of rooms occupied or previously occupied by tubercular individuals. Since the report was not embraced by most of the medical community, a political campaign to educate the public was launched, with flyers distributed in several languages (93). By 1893 the Board of Health requested updated recommendations and accepted the first six of the following measures recommended by Biggs (101): 1. Educate the public via circulars and publications. 2. Require public institutions to notify the Department within 7 days of all persons suffering from pulmonary tuberculosis. 3. Appoint inspectors to ensure effective disinfection of contaminated premises. 4. In hospitals, separate tuberculosis patients from other patients. 5. Establish a hospital exclusively for tuberculosis patients. 6. Require the Board of Health to do diagnostic bacteriological sputum examination in every case of pulmonary disease of doubtful character, at the physician’s request.
20
Davis
Figure 3. Tuberculosis clinic, Bellevue Hospital, early 1900s. The dispensary or TB clinic became an increasingly integral part of the tuberculosis-control effort. Because case rates were not declining as rapidly as mortality, more attention was directed to earlier identification of cases and prevention of transmission. The dispensary served as a diagnostic and triage center and provided social services, case management, and follow-up after hospital or sanatorium care in cooperation with the health department. James Alexander Miller established in New York this model organization, similar to that initiated by Dr. Phillip of Edinburg in 1888. Note the “No Spitting on the Floor” sign on the wall. (Photograph Courtesy of the Bellevue Hospital Chest Service Archives, New York.)
7. Insist that all physicians practicing in New York City notify the Board of all patients with pulmonary tuberculosis coming under their care. Just as in Naples in the 1700s, physicians resisted the “punitive” reporting laws. Physicians in New York and as far away as Philadelphia fought this suggestion on the basis that it would stigmatize such patients and make them outcasts of society and physicians would lose both medical control and a source of their income. Gradual enforcement of compulsory notification finally succeeded because of the political astuteness and sensitivity of the Board of Health and its advisors.
History of Tuberculosis
21
Between 1898 and 1910 the numbers of reported cases increased from 8,559 to 32,065 and sputum examinations from 1,920 to 40,000 (93). In Britain, although Sir Robert Phillip advocated compulsory notification as early as 1890, 20 more years elapsed before it was finally enacted into law (43). In 1901 Robert Koch commended Biggs for the willingness of the American people to accept the limitation of their liberties in the interest of public health, and he recommended the New York model for the “study and imitation of all municipal sanitary authorities” (102). Biggs, writing on administrative measures for the control of tuberculosis in New York City, noted that Edinburgh and New York had more comprehensive plans than any other cities, and he gave great credit to Sir Robert Phillip for his innovative initiative in addressing tuberculosis control (98). The New York City Health Department became a model in the United States in the 1890s. A century later, in the recent upsurge of the disease, it again reacted aggressively to squelch the epidemic and serve as a resource for others, including a delegation from the World Health Organization, in anticipation of similar increases in cases and problems with drug resistance in other parts of the world. The reasons for the upsurge even in developed countries are multiple (12,55,56, 96,97,103,104), but complacency and diversion of resources to other priorities contributed (27,56,103,104). The sudden need to relearn and reinstitute the lessons of the past has been painful and costly. The importance of continuous monitoring of control strategies and provision of adequate resources to implement necessary measures has been illustrated repeatedly by the necessity for task forces and conferences to address the continuing problem of control (37,56,105,106). F. Treatment and Control: The Sanatorium Era from the Mid-1800s to the Mid-1900s
The increasing emphasis on fresh air, diet, rest, and exercise as a means of preventing miasmas, the rise of the Public Health Movement stimulated by the atrocious sanitary conditions related to increasing urbanization, and the socioeconomic effects of the Industrial Revolution all intertwined with the development of the sanatorium era of treatment beginning around the mid-1800s and reaching its prime during the first half of the twentieth century (107). Diseased people may have been segregated in ancient times, but the “modern” sanatorium movement began slowly with the efforts of a few widely separated pioneers, then spread at an accelerating pace throughout the world. The originator of the movement was George Bodington, a Warwickshire physician, who in 1840 rebelled against the popular “antiphlogistic” therapy and advocated fresh air, sensible diet, and gradually increasing exercise. He felt that a structured program under close supervision was superior to the benefits of just go-
22
Davis
ing to a boarding house for the climate or change of scene. He instituted such a program in a house near his own (43). The Brompton Hospital in London in 1841 and the Channing Home in Boston in 1857 (43,108) took in consumptive patients out of humane concern, but it was Hermann Brehmer, his ex-patient Peter Dettweiler, and then Otto Walther who led the “more therapeutic” European sanatorium movement, which spread to the riverside and coastal areas of Great Britain, to the mountains of Switzerland, and after 1882 to America and other continents as well. Brehmer was aware of Rokitansky’s finding that 90% of those who died from other causes had healed tuberculous lesions within normal lung tissue, and he was curious about the reasons for such spontaneous cures. He thought that the pulmonary disease was due to deficient circulation of the blood to the lung, as manifested by the disproportion between the size of the phthisic lung and the small heart and aorta, and he strongly believed that tuberculosis was curable with exercise at high altitude and abundant food to stimulate the circulation and metabolism. Having experienced good results in his own case by application of his theory, by 1859 he managed to build a 40-room Kurhaus with entertainment rooms and a kitchen in Gobersdorf, a mountain valley 1715 feet above sea level in Silesia. By 1869 he had treated 958 patients (109). The later recognition that tuberculosis was infectious almost closed this first real sanatorium as patients were reluctant to congregate in an institution where they would be continuously exposed, but Brehmer developed a successful disinfection system to allay their fears. In addition he added chemistry and bacteriology laboratories and an observatory to monitor the meteorological conditions believed so important to the patients. The sanatorium flourished. By the time of Brehmer’s death in 1899 there were more than 300 sanatoria in Germany alone (110). In 1904 it was the largest in the world, able to accommodate about 300 patients (112). Brehmer’s ex-patient and assistant, Peter Dettweiler, later established his own sanatorium in Falkenstein, which became a mecca for visitors interested in sanatorium treatment. He advocated much closer medical supervision, patient education, rest with graduated exercise only as tolerated without fatigue, and openair treatment in all seasons. He introduced the reclining chair (Liegekur), which subsequently became a hallmark of “taking the cure,” and invented an “ingenious little cuspidor” to prevent spread of the disease. It was made of blue glass and could be hidden in the folds of a handkerchief and manipulated with one hand (111). Walther similarly opened a successful sanatorium in the Black Forest at Nordrach. His strict discipline and therapeutic regimen became popular in Britain and a prototype for many sanatoria that included Nordrach in their name (113). Carl Spengler’s establishment of a sanatorium in Davos (114) initiated a multiplicity of institutions—including Rollier’s for heliotherapy—hotels, and
History of Tuberculosis
23
boarding houses, which transformed Switzerland into a major health resort and inspired Thomas Mann’s novel The Magic Mountain (107). In the United States the perception of beneficial effects of altitude and climate were evident in the mid- to late 1800s, but it was Edward L. Trudeau who led the American sanatorium movement with the establishment of the Adirondack Cottage Sanitarium in 1885 near the village of Saranac Lake, New York. Having tirelessly cared for his brother during his rapidly fatal tuberculosis, Trudeau himself developed a cold abscess during medical school, but the true nature of his illness was recognized only shortly after he entered practice in New York City. The diagnosis was essentially a death sentence to him. As his health deteriorated, friends urged him to go to the mountains. He reluctantly left his wife and two young children for an exhausting trip to Paul Smith’s hunting lodge in the Adirondack Mountains. He wrote that “the change, the stimulus of renewed hope, and the constant open air life had a wonderful effect on my health” (115). The value of rest in the treatment of tuberculosis was not yet appreciated in the United States, but Trudeau noticed that his health improved as he was reclining on balsam boughs and blankets much of the day while he was being rowed by a guide from place to place on one of the beautiful Saranac lakes looking for fish or wildlife. When Trudeau first went to the Adirondacks in 1873, tuberculosis was still considered largely hereditary. Only the seriously symptomatic wealthy had access to climatic treatment. Trudeau’s awareness of the European sanatoriums and his own personal experience stimulated him, with the financial help of his influential friends and donations from devoted guides, to purchase some land and begin construction of first one and then a number of cottages in order to test the principles of a structured supervised regimen. A cottage system would permit expansion as monies became available, and after Koch’s work became known separate cottages seemed plausible as a strategy to minimize transmission. When Trudeau first obtained an English translation of Koch’s remarkable findings, he was inspired to set up his own little laboratory in a room of his house to study the tubercle bacillus and other aspects of the disease. With the guidance of Koch’s paper, a few lessons from Dr. Prudden in New York, and his own ingenuity, Trudeau managed to grow the tubercle bacillus despite the inclemently cold Saranac nights (107). He was only the second person in America to grow pure cultures, and throughout his life he supplied cultures without charge to other scientists (115). He repeated Koch’s experiments and was then able to test for the bacillus in patient’s secretions and perform his own experiments to determine factors related to progression of the disease and the effects of different treatments. Trudeau spent parts of almost every day in the laboratory, hoping to find some “magic bullet” against tuberculosis. The Saranac laboratory was the first in the United States devoted to original investigations into tuberculosis. When the sanatorium finally closed almost 40 years after Trudeau’s death from tuberculosis, the new Trudeau Institute for Re-
24
Davis
search was created in 1964 with financial help from the sale of the property, the fund-raising efforts of his only remaining son, Francis P. Trudeau, and his grandson, Francis B. Trudeau, Jr., and many devoted friends. Its contributions to the understanding of immunology and the interaction of dust diseases and tuberculosis and more recently the immune system in relation to other infectious diseases and cancer have extended far beyond the little village of Saranac Lake (107). Trudeau’s sanatorium treatment gained momentum only slowly, but when he reported the results of his first 165 patients at the opening of the Henry Phipps Institute in Philadelphia in 1903 (116) and noted that he had succeeded in educating the public as to the safety and value of sanatorium treatment (“phthisiophobia” was prevalent in some communities) (117), his influence began to spread. He participated in the medical and public health activities going on and evolving around him in 1904, became the first president of the newly organized National Association for the Study and Prevention of Tuberculosis (now the American Lung Association), and later president of the Congress of American Physicians and Surgeons (107). His protegés included Dr. Edward Baldwin, who was awarded the Trudeau Medal (the highest award of the National Tuberculosis Association) in 1927 for his research into immunological mechanisms; Dr. Lawrason Brown, who devised a system that set standards so that different centers could compare success rates and who founded the Journal of Outdoor Life in 1903 to disseminate information about the prevention and cure of tuberculosis to those seeking health through an outdoor life; Allen K. Krausse, a pathologist who went to Johns Hopkins as the first full-time teacher in the field of tuberculosis and subsequently was the first managing editor of the American Review of Tuberculosis (now the American Journal of Respiratory and Critical Care Medicine), first published in 1917 for promotion of clinical investigation, laboratory research, and discussion of scientific and philosophical issues; Esmond R. Long, a pathologist who later headed the Henry Phipps Institute in Philadelphia and contributed in collaboration with Florence Siebert to the additional understanding of immunological aspects of tuberculin; and James Alexander Miller, founder of the prestigious Bellevue Hospital Tuberculosis Service in New York City (now the Chest Service) (107). Trudeau’s epitaph—Guerir quelquefois, soulanger souvent, consoler toujours—is not only a tribute to the man, but exemplifies the caring spirit of Trudeau’s treatment center. From its simple beginning, it developed into a “tuberculosis university” (118), which included not only the Saranac laboratory for the study of tuberculosis, but a nurses’s training school, which opened in 1912 for ex-patient nursing students, and the internationally renowned Trudeau School for Tuberculosis, established in 1916 to provide postgraduate education in tuberculosis (107). Sanatoria proliferated throughout the United States and Canada. By 1904 there were 115 sanatoria in the United States with less than 8000 beds for tuber-
History of Tuberculosis
25
culosis. By 1923 there were 656 such facilities with 66,000 beds, about half being under state, county, or municipal auspices (119). The number of institutions and beds continued to increase steadily, despite declining mortality (with morbidity only slowly following suit), so that by 1953 there were 839 facilities in the United States and its territories with 130,322 beds set aside for tuberculosis patients. Federal hospital and mental institutions as well as state penal institutions accounted for some of these (120). As sanatoria sprouted around the world, so did controversies about the components of good sanatorium treatment, the benefits of treatment in a sanatorium versus alternative care at home, and finally whether the era of sanatorium care contributed positively or negatively to overall progress against the recalcitrant disease tuberculosis (107). The structured, sheltered environment provided by sanatoria represented to some patients a haven from the stigma and realities of their previous situations. It provided a structure for education and psychological support. To others, it represented a time of imprisonment, isolation, and diversion from their responsibilities and achievement of their ambitions. The sanatorium system enabled physicians to observe closely the effects of tuberculosis at different stages and with different manifestations in vast numbers of demographically diverse individuals. During this era the natural history of the disease, its pathogenesis, and its pathology were further elucidated. The closed environment permitted a valuable reference base and population for the study of emerging diagnostic and therapeutic technologies. From the public health standpoint, the effect of sequestering thousands of infectious persons for several months to whole lifetimes is still uncertain. Mortality had already been declining (37,121,122), and improved living conditions, nutrition, and economics may have played a role (121,122). The lagging decline in new case rates, however, despite growing availability of sanatorium beds and declining mortality, implies that isolation was not sufficient to eradicate the disease (53). Alternatives to sanatorium care during this period were often innovative and ranged from tents on tenement roof tops (Fig. 4), or window tents within a room, to old streetcars and even ferry boats (Fig. 5). Provisions for children included a unique foster care system in France (123) and preventoria in the United States [the first opened in 1909 and became the only one in the country to have cribs for the isolation of infants from tuberculous parents (124)]. Special camps and fresh air schools were organized for children with tuberculosis believed to be at risk because of anemia and malnutrition. Although the prevalence of tuberculosis was particularly devastating to blacks and American Indians, it was not until the 1930s that the enormity of the problem was recognized by the Tuberculosis Movement in America and facilities became more available to such patients (90,124).
26
Davis
Figure 4. Roof-top “cure” of tuberculosis, an alternative to sanatorium care. Beginning in the mid-1800s, before effective chemotherapy for tuberculosis, a structured, often strict regimen of fresh air, rest with specifically prescribed exercise, and abundant nourishment were the sole mainstays of treatment until adjunctive collapse therapies were introduced in the early twentieth century. (Photograph circa 1920. Courtesy of the Bellevue Hospital Chest Service Archives, New York.)
Initial enthusiasm during the period of sanatoria was supplanted by reality as statistics began to be examined around 1914–1920. Among nine sanatoria from which statistics were available for periods of up to 15 years, 51% of the discharged patients were dead at 5 years (125). Early data from Saranac Lake indicated that among those discharged as “cured” the death rate was still triple that of the general population (90,110). Relapse and reentry rates to sanatoria were as high as 50% in some cases (126), but not all (127,128). These discouraging results caused more attention to be paid to after-care and rehabilitation (129) (Fig. 6). Some sanatoria provided opportunities for learning new skills or for regaining lost ones, and abroad, model colonies were developed
History of Tuberculosis
27
where patients could live and work with supervision and encouragement (130). In the United States state vocational rehabilitation services increased 176% between 1936 and 1940 (131). Clinic practice was surveyed and standards recommended (99). More organized efforts at case finding, isolation of active cases, and emphasis on follow-up were initiated, and collapse therapies and surgical procedures were added to sanatorium regimens in the 1920s and 1930s. Mortality, which had steadily declined in Western Europe and the United States during the nineteenth century, decreased even further (37,122).
Figure 5. Children receiving eggs and milk on Southfield ferry boat in New York City. Children at risk of tuberculosis because of poor nutrition, living in crowded tenements, or household exposure to tuberculosis often received nutritional supplements and attended fresh air schools, or day camps. Children might be sent to “preventoria,” or in France they were placed in foster care in the countryside to remove them from exposure and to improve their resistance. (Photograph 1909, Courtesy of Bellevue Hospital Chest Service Archives, New York.)
28
Davis
Figure 6. Men enjoying occupational therapy or vocational rehabilitation. These activities, an integral part of improving compliance and better treatment outcomes before chemotherapy, helped break the monotony of “the cure,” which often lasted for months or even years. Retraining for physically less demanding work or providing work in a medically supervised sheltered environment might reduce relapses. Also, unfortunately, even after effective drugs many patients were left with crippling respiratory insufficiency from the extensive lung damage already sustained or from the collapse therapy and its sequellae. (Photograph circa 1930, Courtesy of the Bellevue Hospital Chest Service Archives, New York.)
G. Developments in Diagnosis: Laboratory Tests and X-Rays
After the causative agent of tuberculosis was known, more precise diagnosis was an early interest. Prudden and Trudeau applied examination of the sputum to clinical problems before the turn of the century, but Grancher and Gerhardt in 1890 each cautioned about the late appearance of the bacilli in the sputum in comparison to the physical signs (132). Relevant even today in the AIDS era is Riviere’s comment: “Disastrous is it to wait for the advent of tubercle bacilli to establish a diagnosis; still more disastrous to regard a negative sputum examination as evi-
History of Tuberculosis
29
dence that the patients’ disease is not tuberculous.” Riviere advocated repeated deep cough specimens (132). Other mycobacteria were known to exist before 1900, and with continuing advances in microbiological and molecular techniques and clinical experience it is now known that some are pathogenic and others not and that tuberculosis disease can be caused by M. tuberculosis complex, which presently includes not only M. tuberculosis and M. bovis, but also M. microti and M. africanum. By the early 1900s culture techniques and biochemical tests began to permit separation of these mycobacterial species by their growth rate, colonial and microscopic morphology, biochemical characteristics and behavior in experimental animals (73,75,133). By the 1940s and 1950s nontuberculous mycobacteria were being increasingly identified around the world (134). Rosenberger in 1908 was the first to describe acid-fast rods in blood, but their significance was disputed because animal tests did not confirm their pathogenicity. Riviere wrote: “So far as the early diagnosis of tubercle is concerned, the detection of bacilli in the blood offers as yet no practical assistance; we await with interest the appearance of further developments in this direction” (132). Riviere’s conclusion is of interest in view of the current availability of the peripheral blood-based PCR assay (135) and recovery of mycobacteria from blood with the use of the isolator tube (Wampole) (136). Experiments with other diagnostic tests such as the tuberculo-opsonic index initiated by Wright in 1905 and complement fixation methods in the early 1900s were abandoned. Throughout the twentieth century other immunological assays using various antigens from the tubercle bacillus were attempted (137,138). The recent upsurge of tuberculosis begining in the late 1980s has hastened the development of modifications and innovative culture techniques to improve the rapidity of diagnosis and detection of resistant organisms, such as the Bactec system, the Septi-chek AFB (BBL), and the Mycobacteria Growth Indicator Tube (MGIT,BBL), which are described elsewhere (136). Most exciting and promising, however, has been the recent application of nucleic acid probes to the earlier identification of mycobacterial species (139,140), and DNA fingerprinting, which has helped to identify clusters of disease and outbreak patterns and aided in the understanding of transmission and spread of resistant organisms in the community (21,68) and laboratory cross-contamination (141). Their usefulness and validity in the management of patients, however, is still being debated and evaluated (141–143). New technologies such as fiberoptic bronchoscopy and bronchoalveolar lavage have, in the last quarter of the twentieth century, enhanced diagnosis and improved understanding of pathogenesis and host immunological responses at different stages of tuberculosis (143a). They are discussed elsewhere. Even after Koch’s discovery, detection of disease continued to depend primarily on symptoms or physical findings and only seldom on radiographic tech-
30
Davis
niques. When Konrad Roentgen discovered x-rays in 1895, their value in diagnosis was, like many previous innovations, received with caution or ridicule. A London firm allegedly advertised the sale of x-ray–proof underclothing (43). The use of x-rays in the diagnosis and management of tuberculosis was apparently ignored except for a brief note in 1896 in Lancet (43). In Boston, Francis H. Williams, without knowledge of their physical findings, performed fluoroscopic examinations on more than 100 patients with pulmonary tuberculosis and reported correspondence between physical signs and xray examination in a considerable number, but in some the disease was more extensive than the physical examination indicated. In others, x-ray detected increased density before it could be discerned clinically (43). Valuable investigations were also going on in France and Britain. The Trudeau and Loomis Sanatoria were the first in the United States to apply this technique routinely (43). Even in the 1930s some senior and influential physicians, for fear of jeopardizing their reputations, which had been built on their physical diagnostic prowess, were reluctant to admit the value of the tool. By the 1930s x-ray examination of patients with pulmonary tuberculosis was routine, and in the middle of the twentieth century mass x-ray screening became a major thrust in the control of tuberculosis (Fig. 7). Agreement on the meaning of findings discovered on x-ray was certainly not uniform, just as it is not today. Additional pathological investigations were necessary to clarify the pathogenesis of the disease and facilitate roentgenological interpretation. Around the 1920s there was interest in the “early pulmonary infiltrate,” frequently recognized by roentgenological examination in adults who presented with tuberculosis but with few or no symptoms or typical apical “crackles” (65). Worldwide interest in the significance of this early infitrate stimulated many investigations through the 1940s. Medlar (144) and other eminent pathologists studied postmortem material from accident victims and those dying unexpectedly of unknown causes. The early lesions were shown to be small areas of exudative bronchopneumonic tuberculosis. They were typically found in the upper posterior part of the lung near the pleural surface. By the time they were visible radiologically, they were usually necrotic at the center, and with repeated culturing of gastric contents they were found frequently to be discharging tubercle bacilli. Communication with a small bronchus was usually demonstrated, but discharge of tubercle bacilli could be intermittent if the bronchiole became plugged with the semisolid caseous material. Hope of discovering this early infiltrate in order to detect the disease at its earliest stages to prevent spread prompted the mass x-ray surveys so popular in the mid–twentieth century (65). Even when x-ray screening was abandoned in the 1970s as case rates dropped, radiological examination of patients admitted to hospitals or clinics or doctors’ offices was considered productive (145). Developments in computed tomography and magnetic resonance imaging and the use of contrast material and nuclear medicine techniques have improved differential diagnosis and detection and helped guide management. With the re-
History of Tuberculosis
31
Figure 7. Mass x-ray screening mid-twentieth century. Once x-ray was accepted as a valuable diagnostic tool and more was learned about pathogenesis of tuberculosis from clinical, pathological, and radiological studies, mass screening was instituted in the 1940s in hope of detecting and treating cases earlier but was later abandoned as the drop in new cases made it less cost-effective. In many developing countries such surveys were not feasible. In such cases sputum smear has been used to detect disease, and when possible tuberculin testing has been used to detect distribution and prevalence of infection and to identify candidates for BCG vaccination. (Photograph Courtesy of the American Lung Association, New York.)
cent changes in the epidemiology of tuberculosis, the prevalence of impaired immune response, and more widespread mycobacterial drug resistance, the role of radiological tools has expanded rather than diminished. H. Adjunctive Therapies: Collapse Procedures and Surgical Resection
Better understanding of the pathology of tuberculosis and the ability through Roentgen’s discovery to see cavities during life spurred interest in mechanical methods of treating tuberculosis. Traction on the walls of cavities from elastic re-
32
Davis
coil augmented with respiration, and reduced blood and lymph flow to the upper zones from upright posture were thought to impair healing. The idea of collapsing the lung to “rest” the lung and promote healing was first suggested by Edmund Bourru in Paris as early as 1770. The history of collapse therapy has been described elsewhere (43,146,147). Carlo Forlanini of Pavia in 1894 was the first to induce pneumothorax successfully through the chest wall. John B. Murphy in Chicago independently applied pneumothorax in tuberculosis in 1897; he was the first to do it under x-ray control (146,147). Trudeau was treated with therapeutic pneumothorax before he died in 1915 (107). It became a major adjunct to bedrest during the latter part of the sanatorium era, sometimes used in conjunction with other surgical procedures (148). Hans Christian Jacobeus’s invention of the thorascope in 1911 and his thorascopic cauterization of adhesions (intrapleural pneumonolysis), which often prevented effective collapse, enhanced the usefulness of therapeutic pneumothorax (149). Experience after 1912 and particularly in the 1920s and 1930s indicated that artificial pneumothorax was effective in about one third of patients in whom it was attempted (150–152) and was best in patients with unilateral disease not responding to rest alone, although there were heated debates about the indications. Complications included mild serofibrinous pleurisy in about 80–90% of patients, chronic pleural changes leading to “trapped lung” in some, empyema occasionally, bronchopleural fistula rarely, and air embolism very rarely (152). Other procedures to aid cavity closure included avulsion or crushing of the phrenic nerve to induce hemidiaphragmatic paralysis. Pneumoperitoneum was occasionally used in intestinal and peritoneal tuberculosis, and in 1933 Vadja reported possible benefit in patients with pulmonary tuberculosis. About 50% of patients showed radiological cavity closure, and sputum conversion occurred in slightly fewer. It was used in patients with bilateral, far-advanced cavitary disease to elevate the diaphragm (107). Thoracic surgery began to flourish during this period. In Europe during the 1880s ribs were removed to bring the chest wall down to the lung. Estandler first used the term “thoracoplasty” in 1879, and de Cerenville in 1885 first applied the procedure to collapse a tuberculous cavity. John Alexander refined the technique and wrote the first of his famous textbooks at Trudeau’s sanatorium while curing his own vertebral tuberculosis (148,153). A number of variations on the procedure subsequently were developed, and collapse of the lung was occasionally achieved by introduction of oil, paraffin, or plastic spheres into an extraperiosteal pocket (plombage thoracoplasy) in an attempt to minimize deformity and pulmonary function impairment. Thoracoplasy could achieve cavity closure and sputum conversion in as many as 80% of selected patients. With collapse therapy mortality rates ranged from 14 to 27% after 1–20 years, but without collapse therapy patients with cavitary disease had an average survival time of less than 2 years. On the other hand, such therapy sometimes led to longer
History of Tuberculosis
33
sanatorium stays, serious impairment of pulmonary function, and increased mortality (107). Resection of diseased lung was first performed by Block in 1883 with fatal consequences (148). Even though Tuffier in 1891 successfully resected an apical tuberculous nodule, resection was considered so dangerous that it was not until 1934 that the first lobectomy and pneumonectomy were accomplished successfully for tuberculosis. However, before effective drugs against the disease and the technological developments that have markedly improved surgical outcomes, spread of disease, fistula formation, and empyema were common. In 1943 morbidity from such procedures was 50% or more and mortality 20–40% (153). In the 1950s with chemotherapy, resection for localized disease was rather common until the results of drug therapy proved it to be unnecessary in most cases. However, in selected multidrug-resistant patients resection is still occasionally performed. I. Tuberculin as Therapy, Method of Detection of Infection and Window to Understanding Immunity and Host Defenses
Koch followed many leads from the immunological studies of Jenner and Pasteur before him. He observed in guinea pigs that prior experience with tubercle bacilli, living or dead, altered the animal’s response to the new innoculation of tubercle bacilli and allowed the animal to survive. Much of what has become the science of cellular immunology has derived from Koch’s work (71,154). Koch later prepared a sterile filtrate of cultured organisms, subsequently termed “old tuberculin” (OT), and found that the same “Koch phenomenon” occurred. Koch’s great mistake was that he prematurely reported the use of this preparation as a remedy. It became widely used until it was soon recognized that it killed more patients than it helped (154,155). Koch’s observation of the delayed reaction to this material, however, spawned the term “delayed hypersensitivity,” and his observations of the difference in the effects of OT in patients infected with the tubercle bacillus versus noninfected patients formed the basis for the use of tuberculin as a diagnostic agent (156). Veterinarians were the first to recognize and demonstrate the potential diagnostic use of tuberculin. Tuberculosis was common in cattle, but symptoms, physical examination, and recovery of tubercle bacilli usually detected advanced disease. Professor Eber of Berlin and Leonard Pearson, an American who had worked in Koch’s laboratory in 1890, tested tuberculin in cattle as early as 1891 (157,158). It became evident early from clinical pathological correlations that the test could identify clinically inapparent infections. To control the spread of disease to other cattle and to humans, tuberculin-positive animals were slaughtered in large numbers (17,18). In the United States in 1917 the economic loss to the cattle industry and the serious threat of bovine tuberculosis to the public’s health prompted establishment of a national program to eliminate tuberculosis in cattle.
34
Davis
The positive tuberculin reaction rate in cattle approached 5% in 1918. Systematic testing was instituted, along with prompt disposal of infected cattle, adequate disinfection, and regulations governing movement of animals. Pasturization of milk assured further protection for humans (17,36,37). By 1974 tuberculin reactor rates were 0–0.03% in the United States (18). Various control measures have been used in other countries, where infection rates have been as high as 70–90%, with 30–40% having disease on slaughter (18). Eradication of bovine tuberculosis worldwide requires continued vigilence, public and legislative support, and adequate availability of veterinarians. Von Pirquet first demonstrated that reactions to OT in humans could be induced by cutaneous injection and that a response was indicative of prior tuberculous infection (156). His observations were published in 1907 and 1908. In the early 1900s a patch test, percutaneous test, conjunctival test, and subcutaneous test had been tried, but the intracutaneous test of Charles Mantoux introduced in 1908 persisted as the preferred method because the dose could be most precisely controlled and the reaction, measured in millimeters of induration, could be more readily quantitated (158). Tuberculin is still used as a major method of detecting tuberculosis infection, but experience during much of this century has prompted a variety of changes in its preparation, its method of administration, and its interpretation. As testing was extended beyond herds suspected of the disease, doubts began to occur regarding the specificity of the test because some cattle reacted to tuberculin but had no signs of tuberculosis infection at post-mortem examination. Although variations in administering or reading the test or overlooking a small lesion might have accounted for the reactions, E. G. Hastings believed by 1924 that sensitization by some other organism or organisms was the cause of these false-positive reactions (158). By the mid-1920s nontuberculous mycobacteria were recognized to be widespread, and by the 1930s veterinarians had concluded that false-positive tuberculin reactions were due to nontuberculous mycobacteria (158). As tuberculin testing was extended to apparently healthy humans, the need for a standardized tuberculin more reliable than Koch’s OT became apparent. The development of a purified protein derivative (PPD), which was a potent stable tuberculin without sensitizing properties, was prepared by Florence Siebert of the Henry Phipps Institute in Philadelphia in 1934, and in 1941 Siebert and Glenn made a single large lot of ammonium sulfate–precipitated PPD (lot 349608) from a single strain of human tubercle bacilli, which was deposited as the International Standard of mammalian tuberculin (PPD-S) (159). Even with PPD-S, problems with specificity and sensitivity have continued. Pulmonary calcification had been considered diagnostic of tuberculosis, but the presence of calcification in tuberculin nonresponders noted in the 1930s raised questions about its specificity. Studies by Carol Palmer beginning in 1943 (160) and subsequent studies confirmed the likelihood of a fungal (histoplasmosis) origin (161,162).
History of Tuberculosis
35
Concerns then arose about the sensitivity of the test. Quantitative studies showed that if sufficiently high doses of tuberculin were used, almost everyone would respond, while most patients with tuberculosis and known contacts reacted to a relatively low dose. Without a history of tuberculosis or known contact, only higher doses would elicit a response, so the author concluded that reactions to higher doses were probably not due to M. tuberculosis (163). Palmer, using what appeared to be the ideal dose of 0.0001 mg (5 TU), based on Furcolow’s studies, and 0.005 mg (250 TU) in student nurses found that with 5 TU the percentage of reactors correlated with the degree of exposure to tuberculosis and not place of residence, while with 250 TU the frequency of reactions correlated with geographical area of residence and not contact history. He concluded, like the veterinarians, that tuberculin sensitivity was not dependent on a single source but that antigenically related organisms prevalent in certain geographic environments could elicit a response to higher doses (158). Further Mantoux testing of general populations around the world indicated that sensitivity to 5 TU of PPD is quite uniform among tuberculous individuals, but in certain areas a bimodal distribution of reactions was apparent, with positive reactors having 6–26 mm induration (peak 14–15 mm), and those with reactions 5 mm were considered to be uninfected (164). In still other areas no clear-cut separation existed. The probability that these small reactions represented cross-reactions to tuberculin because of sensitization to other microorganisms was considered in the 1940s and 1950s (164,165). Between 1958 and 1970 further studies with some tuberculous mycobacterial antigens in Navy recruits demonstrated that reactions of 4–12 mm of induration and false-positive reactions to PPD-S appear to be related to prevalence of certain nontuberculous mycobacteria in the environment (166–169). In the 1960s false-negative results in bacteriologically proven cases of tuberculosis began to be reported (170,171). Adsorption of tuberculo-protein onto glass and plastic surfaces was believed to be a factor, and Tween R 80 detergent was subsequently added to help stabilize the material. Other recommendations coming from the advisory panel called by the NIH in 1972 related to timing of preparation in relation to infection and demonstration of bioequavalency of PPD tuberculin to 5 TU of PPD-S in phosphate buffer without polysorbate (158). Another problem affecting tuberculin test diagnostic reliability and interpretation was the “booster phenomenon,” an increase in the size of the reaction to a second tuberculin test compared to the reaction to the first test, first described by Steele and Willis (172). Two-step testing was then recommended for those undergoing serial testing to minimize errors in interpretation (173,174). Von Pirquet in 1908 had observed that the tuberculin test was almost always positive in patients moderately sick with tuberculosis but often negative in those with more severe or rapidly progressive disease (154). He used the terms “allergy” and “anergy” to describe the type of response elicited. For many years tuberculin reactivity was considered an indicator of protective immunity until Rich and Mc-
36
Davis
Cordick in 1929 (175) challenged this view and Wilson later showed that animals could be made tuberculin negative without losing their immunity (176). Koch’s initial investigations of tuberculin have spawned numerous questions and further studies. Tuberculin testing has enhanced knowledge about distribution and other epidemiological aspects of mycobacterial, nonmycobacterial, and fungal diseases and the role of environmental antigens, but more specific tests for tuberculosis based on more specific mycobacterial components are still being pursued. Demonstration of cellular transfer of cutaneous hypersensitivity to tuberculin by Merrill Chase in 1945 (177) and others led to the recognition of the pivotal role of the lymphocyte in cellular hypersensitivity, and Mackaness’s work at the Saranac Laboratory began to elucidate the interaction between cellmediated immune response and macrophage activation (178). Host and mycobacterial factors in delayed hypersensitivity and protective immunity and their relationship are still the subject of ongoing research, as is the meaning of skin test anergy. Several editorials in the 1970s addressed these issues and reflect the understanding at that time (179,180,181). Since the AIDS epidemic the meaning of a negative tuberculin skin test and its relationship to protective immunity and to anergy are still disputed (182,183) as the complex interplay of many factors in tuberculin skin test sensitivity and host immune responses continues to be explored (184). J. Vaccine Development
Ever since Koch’s discovery of the microbial etiology, there has been interest in developing an effective vaccine to prevent tuberculosis. After 1882 many attempts using killed or chemically treated tubercle bacilli generally failed. In 1891 Trudeau found that a strain of M. tuberculosis became attenuated for the guinea pig after repeated subcultures on a serum glycol medium. The RI strain elicited protective immune responses in the animal, but it was not tried in humans. His studies established that living attenuated tubercle bacilli gave greater protection than killed bacill. A live vaccine appeared then to be needed (59). Albert Calmette, a scientist at the Pasteur Institute in Lille, and Camille Guérin, a veterinary school graduate and associate of Calmette, were working with a virulent bovine type tubercle bacillus previously isolated from a heifer’s udder by Nocard in 1902. Serendipitously they found that adding ox bile to the medium to prevent clumping, and subculturing of the microorganism lowered its virulence. Between 1906 and 1919 after 231 3-weekly transfers, they had a microorganism that failed to produce progressive tuberculosis when injected into guinea pigs, rabbits, cattle, or horses. In 1921 it was first given to a human, a newborn child whose mother had died of tuberculosis a few hours after the birth (185). In 1924 oral vaccinations had been given to 664 infants and an additional 114,000 were vaccinated by 1928 without serious consequences. It began to be used in
History of Tuberculosis
37
Spain, Germany, and Scandinavia, but some British and U.S. authorities were skeptical about it. In 1928 the League of Nations announced the safety of the bacille CalmetteGuérin (BCG) for vaccination of humans and animals, but the deaths of 72 and infection of 135 of 250 children orally vaccinated in Lübeck, Germany, in 1929–1930 halted general acceptance of the vaccine until after World War II. It turned out that the children had inadvertently received a virulent strain. After 20 months of criminal proceedings the Lübeck doctors were imprisoned and BCG was exonerated (185). Even after most countries embraced the use of the vaccine, the United States and the Netherlands were not proponents of its use, and only in the late 1940s did England and Australia begin widespread use (186). In 1948 the first International BCG Congress in Paris stated that BCG was effective in preventing tuberculosis and that the BCG strain stably maintained its residual virulence (187). The Danish Red Cross had begun vaccination campaigns in war-ravaged Europe because of the serious tuberculosis situation, and in 1948 a joint enterprise with three Scandanavian voluntary organizations and UNICEF was initiated (188). In 3 years this International Tuberculosis Campaign had effected testing of almost 30 million persons and vaccination of 14 million. After mid-1951 this work was continued and expanded under joint WHO/UNICEF auspices. By the end of 1956 an additional 160 million people had been tuberculin tested and 60 million had been vaccinated (188). The preparation of the vaccines, the details of the animal experiments, the immunological aspects, the variable results from 0 to 80% effectiveness, and possible reasons for the differences have been discussed by others (189–193). The methodological aspects have also been evaluated (188,194–196). BCG vaccine trials have provided some of the best and most complete information on tuberculosis in human populations and have been invaluable in the development of vaccine trial methodology. The past failures of BCG in terms of variable and unpredictable efficacy and yet its remarkable success in terms of the magnitude of its worldwide use can point the way to future success with new vaccines. The 1949 international campaign was the first large-scale centralized public health campaign conducted with the WHO structure and was a forerunner and model for subsequent campaigns, including the eradication of smallpox (188). BCG has evoked endless discussions about the relationship between cellmediated immunity and delayed hypersensitivity. It has stimulated research into host immune mechanisms in mycobacterial infection. It has served as a vehicle for the introduction of other antigens in the hope of creating a single multiantigenic vaccine for use in developing countries (197). It has also led to a number of investigations of immunostimulation in neoplasia, especially in the therapy of bladder cancer. Attempts to develop better vaccines with novel molecular genetic approaches are accelerating and will be discussed elsewhere.
38
Davis K. Drug-Therapy Trials
A search for an effective therapy began almost immediately after the causative bacillus was identified. Koch’s tuberculin had failed, but Ehrlich’s magic bullet for syphilis stimulated interest in other chemical agents for tuberculosis. A number of these had been tried in animals and some in selected human patients. Amberson’s clinical trial of gold in 1931 is historically important in that randomization was utilized for the first time. Randomization was between a group of patients and a group of controls matched “as close as possible” (198). The study represents a transition from the matched to modern randomized clinical trials. The paper is also notable for Amberson’s meticulously detailed critique of previously reported clinical studies. A number of trials of sulfanilamide and other related compounds were performed in the late 1930s and early 1940s in experimental animals and humans with some favorable results, but often with significant associated toxicity (199). Waksman’s Nobel Prize–winning isolation of streptomycin in 1944 together with Schatz’s crucial astute laboratory observations (200) and Feldman’s and Hinshaw’s first clinical application ushered in the momentous era of modern chemotherapy of tuberculosis (43,201). Within 12 months of its announced isolation, William Feldman, professor of comparative pathology at the Mayo Foundation of Experimental Medicine, and H. Corwin Hinshaw, a bacteriologist and subsequent consultant physician at the Mayo Clinic, together demonstrated unequivocably streptomycin’s antituberculosis action in vitro and in vivo (43,201). A number of clinical trials ensued, including cooperative investigations by the Army and Navy and U.S. Veterans Administration (202–204) with liasons with the American Trudeau Society, the Mayo Clinic group, and Walsh McDermott’s group studying toxicity at Cornell University Medical College. Details are summarized elsewhere (199). It was apparent by 1947 not only that streptomycin was the most effective therapeutic agent so far against experimental tuberculosis in guinea pigs, but also that it produced promising results in certain types of pulmonary and extrapulmonary tuberculosis in humans. Rapid development of drug resistance and some toxicity became early concerns, however. Although Max Pinner had commented, in relation to evaluation of chemotherapy that “the therapeutic effects of a truly efficacious chemotherapeutic agent are not likely to depend for proof on elaborate control series” (205), the British Medical Research Council decided that studies using their precious allocation of streptomycin should be rigorously planned and use concurrent controls. Their trial, begun in 1947 (206), was a model for subsequent trials not only in the United Kingdom, but overseas as well, and was the first to incorporate all of the elements of the modern, randomized clinical trial (207). Many attempts to prevent or delay bacterial resistance by varying dosage, duration, or frequency of medication were, however, to no avail.
History of Tuberculosis
39
The second important landmark in understanding chemotherapy of tuberculosis was the recognition that a two-drug regimen could prevent the emergence of resistance. Jorgen Lehman, following up on earlier studies indicating that benzoic acid and salicylic acids stimulated oxygen uptake by pathogenic strains of M. tuberculosis, was searching for competitive inhibitors of these acids. He discovered that para-aminosalicylic acid (PAS) had demonstrable bacteriostatic activity in vitro against M. tuberculosis. Animal experiments and a small clinical trial were begun in 1944. His favorable report in 1946 (208) paved the way for subsequent trials. The Medical Research Council study of three concurrent regimens—PAS alone, streptomycin alone, and the combination of streptomycin and PAS—reported in 1949 and 1950 (209) demonstrated unequivocably the reduction in risk of developing streptomycin resistance when both were used and broadened the potential application of such treatment. Nevertheless, chemotherapy was not yet accepted as definitive therapy except in tuberculous meningitis and miliary tuberculosis. The drugs at first tended to be used adjunctively with bedrest, collapse therapy, or surgical resection (210). Until the appearance of isonicotinic acid hydrazide (isoniazid) in 1951 and subsequent laboratory and clinical experience with this new “miracle drug” (211), it was not appreciated that chemotherapy alone might cure tuberculosis. Many additional clinical trials were carried out with various combinations, dosages, frequencies of administration, and durations of these initial three drugs and others as they became available in the 1950s and 1960s. By the 1970’s experience had dictated that ethambutol, rifampin, and pyrazinamide be added to the list of first-line drugs against tuberculosis (201). The large clinical trials conducted by the U.S. Public Health Service and by the VA–Armed Forces Study Units in the United States, the collaborative studies in East Africa, Hong Kong, Singapore, and Madras under the joint auspices of the British Medical Research Council and WHO (199), together with others such as the International Union Against Tuberculosis (IUAT) (212), have provided invaluable information to guide therapy today. Information gained from these trials revolutionized the treatment of tuberculosis around the world. It led to abandonment of sanatoriums and emphasis on ambulatory therapy, discontinuation of collapse therapy, and sparing use of surgery for very selected patients. It changed the careers of sanatorium doctors and led to an emphasis on other aspects of pulmonary medicine and the neglect of tuberculosis in the medical curriculum. The trials taught that relapse rates tend to be a better endpoint in evaluating therapy than radiological findings and that failure of cavities to close did not always mean drug failure (199). Bed rest and sanatorium care did not add to the benefits produced by chemotherapy (203,213,214,). The eradication of tuberculosis was now deemed possible if drug therapy was applied vigorously to persons with disease and preventive therapy was given to those who were already infected but
40
Davis
without disease, as recommended by an expert group convened at Arden House by the American Lung Association (105). Ambulatory domiciliary care was feasible, as shown in Hong Kong and Madras (213,214) (Fig. 8). Short-course and intermittent regimens (204), stimulated by the problems of noncompliance with older standard regimens, drug costs, and availability of medical services in their countries of origin, were also effective elsewhere (199). Nine-month regimens were effective with inclusion of rifampin, and pyrazinamide permitted further shortening to 6 months. The importance of supervised and especially directly observed therapy (DOT) had long been appreciated from trials in other countries (215) but except for isolated instances was slow to be widely promoted in the United States until the problems of high noncompletion rates and multidrug resistance became alarmingly apparent in the late 1980s and early 1990s. L. Chemoprophylaxis
Once isoniazid, an effective, inexpensive oral medication with relatively low toxicity, was available, its usefulness in preventing tuberculosis was considered, especially in preventing the sequellae of infection (i.e., tuberculosis disease, which fosters transmission and stalls eradication). Controlled trials of chemoprophylaxis were carried out in a number of groups with various risk factors for developing disease; these are reviewed by Ferebee (216). In the United States isoniazid was shown to be effective, inexpensive, and relatively non-toxic in appropriately selected populations and was therefore preferred over BCG vaccination as a preventive strategy. BCG was not consistently shown to be effective except in preventing serious complications such as miliary tuberculosis and meningitis in children, and it has not been widely embraced in the United States, to the consternation of some (57). Because of the relatively low risk of acquiring infection in the United States, the diagnostic value of the tuberculin test has been considered important, and BCG would negate its reliability. Farer has also reviewed some of the personal and public health issues and the epidemiological and scientific background related to the use of chemoprophylaxis (217). In view of the competing risks of tuberculosis and isoniazid-associated hepatitis (218), lack of recent data from controlled trials, the possibility of drug-resistant infection, and the problems of distinguishing initial infection, exogenous superinfection, long-standing infection, and in some cases latent versus active disease, the recommendations regarding indications and choice of prophylactic therapeutic regimen continually change (219–223). While during the sanatorium era and beyond much attention was focused on practical therapies for tuberculosis, fortunately basic research was carried out simultaneously in a number of institutions around the world. In 1954 investigators from research institutes and medical school departments from the United States, the United Kingdom, France, Switzerland, and Denmark participated in a sympo-
History of Tuberculosis
41
Figure 8. Patient in Madras receiving ambulatory directly observed therapy. The British Medical Research Council clinical trials of antituberculosis chemotherapeutic agents proved that sanatorium or hospital care was not necessary and that domiciliary or ambulatory treatment could be successful. This finding had important implications for TB control not only for the developing world, but for all countries. Directly observed therapy in an outpatient setting is now a major control strategy of WHO. (Photograph Courtesy of the American Lung Association, New York.)
42
Davis
sium on the nature of the tubercle bacillus and the reactions of the host tissues. Arnold Rich’s prophetic remarks regarding the importance of fundamental research for long-range victory are as relevant now as they were almost 50 years ago (224): “In other spheres we know that superior weapons do not guarantee a permanent end of hostilities, and that for the surest preservation of security it is, in addition, essential to understand thoroughly the nature, designs and potentialities of the enemy and our own reaction toward, and human capacity to resist that type of nature; for new and superior defensive weapons can alone rarely if ever be relied upon to ensure enduring safety. Too often they are neutralized or surpassed by the development of new countermeasures by the enemy.” M. The Latter Half of the Twentieth Century
New tools and major technological developments have greatly accelerated knowledge about many aspects of tuberculosis. Max Lurie developed strains of animals that were genetically resistant or susceptible to M. tuberculosis and then studied the role of hereditary factors in the immunological responses in tuberculosis. Since then other animal models, including “knockout” mice and transgenic animals, improved cell culture techniques, development of specific monoclonal antibodies, and methods of isolating and identifying genes and gene products are among many tools facilitating research into the fundamental aspects of tuberculosis. The recent elucidation of the M. tuberculosis genome (225) opens up a whole array of prophylactic and therapeutic possibilities and may at last be another strategic milestone in humanity’s long struggle against this “captain of the men of death.” Despite the many advances in our understanding and ability to detect, diagnose, treat, and prevent tuberculosis and despite repeated admonitions of tuberculosis experts and lung association and other task forces, external societal factors persisting or resurfacing from the past, such as poverty, inadequate housing, poor nutrition, and ignorance, together with overpopulation, new waves of immigrants from countries of high prevalence of tuberculosis, drug abuse, emergence of the HIV epidemic, and increased problems with drug resistance have all combined to obstruct or delay tuberculosis control in the twentieth century. The unexpected (apparently transient in the United States) increase in tuberculosis in the late 1980s and early 1990s led to a revamping of the public health infrastructure so carefully constructed in the past. Case finding, isolation of infectious persons, and prompt appropriate treatment to completion under directly observed therapy—even in locked facilities, if necessary—became important issues. Education of a whole new generation of medical students, faculty, hospital and public health staff, and governmental officials as well as the public became imperative. Screening of high-risk populations and new guidelines for prophylactic treatment were issued. The race for faster methods of diagnosis, a more reliable
History of Tuberculosis
43
method of detecting infection, and for new effective therapies and vaccines based on new knowledge of host and mycobacterial responses became more compelling. After thousands of years the twenty-first century may bring eradication closer to fruition. References 1. Haas F, Haas SS. The origins of Mycobacterium tuberculosis and the notion of its contagiousness. In: Rom WR, Garay S, eds. Tuberculosis. Boston: Little, Brown and Company, 1996:3–19. 2. Ayvazian LF. History of tuberculosis. In: Reichman LB, Hershfield E, eds. Tuberculosis. A Comprehensive International Approach, 1st ed. New York: Marcel Dekker, 1993:1–20. 3. Bates JH, Stead WW. The history of tuberculosis as a global epidemic. Med Clin North Am 1993; 77:1205–1217. 4. Report on the tuberculosis epidemic, 1997. Global TB Programme. Geneva: World Health Organization, 1997. 5. Dubos R, Dubos J. The White Plague: Tuberculosis, Man and Society. Boston: Little, Brown, 1952:8. 6. Weisse AB. Tuberculosis: why “the white plague”? Perspect Biol Med 1995; 39:132–138. 7. Holmes OW. Medical Essays, 1842–1882. 2d ed. Boston: Random House, 1892:353. 8. Lerner BH. Public health then and now. Temporarily detained: tuberculous alcoholics in Seattle, 1949–1960. Am J Pub Health 1996; 86:257–265. 9. Gostin LO. Controlling the resurgent tuberculosis epidemic: a 50-state survey of TB status and proposals for reform. JAMA 1993; 269:255–261. 10. Centers for Disease Control and Prevention. Tuberculosis control laws—United States, 1993. MMWR 1993; 42(suppl RR-15):1–28. 11. Oscherwitz T, Tulsky JP, Roger S, Sciortino S, Alpers A, Royce S, Lo B. Detention of persistently non-adherent patients with tuberculosis. JAMA 1997; 278(10): 843–846. 12. Singleton L, Turner M, Haskal R, Etkind S, Tricarico M, Nardell E. Long-term hospitalization for tuberculosis control. Experience with a medical-psychosocial inpatient unit. JAMA 1997; 278:838–842. 13. Dubler NN, Bayer R, Landesman S, White A. The Tuberculosis Revival: Individual Rights and Societal Obligations in a Time of AIDS. A Special Report. New York: United Hospital Fund of New York, 1992. 14. The dual epidemics of tuberculosis and AIDS: health care policy, professional practice, law and ethics. A Conference for World AIDS Day, New York, American Society of Law, Medicine and Ethics, Columbia University School of Public Health, Albert Einstein School of Medicine and Montefiore Medical Center, New York City Department of Health, and United Hospital Fund, Dec. 4–5, 1992. 15. Annas GJ. Control of tuberculosis—the law and the public’s health. N Engl J Med 1993; 328:585–588.
44
Davis
16. Bayer R, Dupuis L. Tuberculosis, public health, and civil liberties. Annu Rev Pub Health 1995; 16:307–326. 17. Steele JH, Ranney AF. Animal tuberculosis. Am Rev Tuberc Pulm Dis 1958; 77:908–922. 18. Myers JA. Captain of All These Men of Death. St. Louis: Warren H. Green, Inc., 1977. 19. Baes I. Deoxyribonucleic acid relatedness among species of slowly-growing mycobacteria. Acta Pathol Microbiol Scand Sec B 1979; 87:221–226. 20. Wayne LG, Diaz GA. Reciprocal immunological distances of catalase derived from strains of mycobacterium avium, mycobacterium tuberculosis, and closely related species. Int J Syst Bacteriol 1979; 29:19–24. 21. Small PM, van Embden JDA. Molecular epidemiology of tuberculosis. In: Bloom BR, ed. Tuberculosis: Pathogenesis, Protection and Control. Washington, DC: American Society for Microbiology, 1994. 22. Salo WL, Aufderheide AC, Buikstra J, Holcomb TA. Identification of Mycobacterium tuberculosis DNA in a pre-Columbian Peruvian mummy. Proc Natl Acad Sci USA 1994; 91:2091–2094. 23. Hermans PWM, Messadi F, Guebrexabber H, van Soolingen D, de Haas PEW, de Neeling H, Ayoub A, Portaels F, Frommel D, Zribi M, van Embden JDA. Analysis of the population structure of Mycobacterium tuberculosis in Ethiopia, Tunisia, and the Netherlands: usefulness of DNA typing for global tuberculosis epidemiology. J Infect Dis 1995; 171:1504–1513. 24. Rigout SL, Maregeya B, Travore H, Collart JP, Fisette K, Portaels F. Use of DNA restriction fragment typing in the differentiation of Mycobacterium tuberculosis complex isolates from animals and humans in Burundi. Tubercle and Lung Dis 1996; 77:264–268. 25. Cohn DL, O’Brien RJ. The use of restriction fragment length polymorphisim (RFLP) analysis for epidemiological studies of tuberculosis in developing countries. Int J Tuberc Lung Dis 1998; 2(1):16–26. 26. Kiple KF, ed. The Cambridge World History of Human Disease. Cambridge: Cambridge University Press, 1993. 27. Kochi A. Tuberculosis: distribution, risk factors, mortality. Symposium to Commemorate the 150th birthday of Robert Koch, Berlin, June 20, 1994. Immunobiology 1994; 191:325–336. 28. Williams HE, Phelan PD. The epidemiology, mortality and morbidity of tuberculosis in Australia: 1850–94. J Paediatr Child Health 1995; 31:495–498. 29. Gryzybowski S, Styblo K, Dorken E. Tuberculosis in Eskimos. Tubercle 1976; 57(suppl):S1–S44. 30. Wartski SA. Epidemiology and control of tuberculosis in Israel. Public Health Rev 1995; 23:297–341. 31. Daniel TM, Bates JH, Downes KA. History of Tuberculosis. In: BR Bloom, ed. Tuberculosis: Pathogenesis, Protection, and Control. Washington, DC: American Society for Microbiology, 1994:13–24. 32. Paulsen HJ. Tuberculosis in the Native American: indigenous or introduced? Rev Infect Dis 1987; 9:1180–1186. 33. Clark GA, Kelley MA, Grange JM, Hill CM. The evolution of mycobacterial disease in human populations: a reevaluation. Curr Anthropol 1987; 28:45–62.
History of Tuberculosis
45
34. Manchester K. Tuberculosis and leprosy in antiquity: an interpretation. Med Hist 1984; 28:162–173. 35. Sigurdsson J. Studies on the risk of infection with bovine tuberculosis to the rural population. In: ACTA Tuberculosea Scand. Copenhagen: Einar Munksgaard, 1945; suppl 15. 36. Sjogren I, Sutherland I. Studies of tuberculosis in man in relation to infection in cattle. Tubercle 1974; 56:113–127. 37. Lowell AM, Edwards LB, Palmer CE. Tuberculosis. Cambridge, MA: Harvard University Press, 1969. 38. Stead WW. Genetics and resistance to tuberculosis. Ann Intern Med 1992; 116:937–994. 39. Webb GB. Tuberculosis. Clio Medica. New York: Paul B. Hoeber Inc., Medical Book Department of Harper & Brothers, 1936. 40. Brouwer JA, Boeree, Kager P, Varkevisser CM, Harries AD. Traditional healers and pulmonary tuberculosis in Malawi. Int J Tuberc Lung Dis 1998; 2:231–234. 41. Hewson MG. Traditional healers in Southern Africa. Ann Intern Med 1998; 128:1029–1034. 42. Andrews BJ. Tuberculosis and the Assimilation of Germ Theory in China 1895–1937. Vol. 52. Oxford: Oxford University Press, 1997:114–157. 43. Keers RY. Pulmonary Tuberculosis: A Journey Down the Centuries. London: Bailliere-Tindall, 1978. 44. Morse D, Brothwell D, Ucko PJ. Tuberculosis in ancient Egypt. Am Rev Respir Dis 1964; 90:524–541. 45. Perzigan AJ, Widmer J. Evidence for tuberculosis in a prehistoric population. JAMA 1979; 242:2643–2646. 46. Allison MJ, Mendoza D, Pezzia A. Documentation of a case of tuberculosis in preColumbian America. Am Rev Respir Dis 1973; 107:985–991. 47. Zimmerman MR. Pulmonary and osseous tuberculosis in an Egyptian mummy. Bull NY Acad Med 1979; 55:604–608. 48. Kinnier JV, Wilson MA. Diseases of Babylon: an examination of selected texts. J R Soc Med 1996; 89:135–140. 49. Adams LB. The Genuine Works of Hippocrates (English translation). Birmingham, AL: Classics of Medicine Library, Division of Gryphon Editions Ltd., 1985:739. 50. Walsh J. Galen’s treatment of pulmonary tuberculosis. Am Rev Tuberc 1931; 24: 1–41. 51. Cummins SL Tuberculosis in History from the 17th Century to Our Times. London: Bailliere, Tindall and Cox, 1949. 52. Haas F, Haas SS. The history of pulmonary medicine: tuberculosis from the Renaissance to 1900. In: Baum G, Wolinsky J, eds. Textbook of Pulmonary Diseases. 5th ed. Boston: Little, Brown, 1993:xix–xliii. 53. Frost WH. The outlook for the eradication of tuberculosis. Am Rev Tuberc 1935; 32:644–650. 54. Styblo, K, Salomao MA. National tuberculosis control programs. In: Reichman LB, Hershfield EH, eds. Tuberculosis: A Comprehensive International Approach, 1st ed. New York: Marcel Dekker, Inc., 1993:573–600.
46
Davis
55. Cantwell, MF, McKenna MT, McCray E, Onorato IM. Tuberculosis and race /ethnicity in the United States: impact of socioeconomic status. Am J Respir Crit Care Med 1997; 157:1016–1020. 56. The American Lung Association Conference on Re-establishing Control of Tuberculosis in the United States. March 11–13, 1994, Washington D.C. Am J Respir Crit Care Med 1996; 154:251–262. 57. Feldberg GD. Disease and Class. Tuberculosis and the Shaping of Modern North American Society. New Brunswick, NJ: Rutgers University Press, 1995. 58. Castiglione A. History of Tuberculosis. New York: Medical Life Press, 1933. 59. Dubos R, Dubos J. The White Plague. New Brunswick, NJ: Rutgers University Press, 1992. 60. Beddoes T. Essay on the Causes, Early Signs and Prevention of Pulmonary Consumption. London: Longman & Rees, 1799:4. 61. Burke RM. An Historical Chronology of Tuberculosis. 2d ed. Springfield, IL: Charles C Thomas, 1955. 62. Marten B. A New Theory of Consumption, More Especially of a Phthisis or Consumption of the Lungs. London: Knaplock, 1720:50–51. 63. Laennec RTH. A Treatise on Diseases of the Chest and on Mediate Auscultation. New York Academy of Medicine History of Medicine Series No. 17. New York: Hafner Publishing Company, 1962:5. 64. Ghon A. The Primary Lung Focus of Tuberculosis in Children (English translation by D. B. King). New York: Paul B. Hoeber, 1916. 65. Amberson JB. A retrospect of tuberculosis: 1865–1965. Am Rev Respir Dis 1966; 93:343–351. 66. Opie EL. Present concepts of tuberculosis infection and disease. Am Rev Tuberc 1935; 32:617–630. 67. Small PM, Shafer RW, Hopewell PC, Singh BP, Murphy MJ, Desmond E, Sierra MF, Schoolnick GK. Exogenous reinfection with multidrug resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med 1993; 328:1137–1144. 68. Alland D, Kalkut GE, Moss AR, McAdam RA, Hahn JA, Bosworth W, Drucker E, Bloom BR. Transmission of tuberculosis in New York City: an analysis by DNA fingerprinting and conventional epidemioloogic methods. N Engl J Med 1994; 330:1710–1716. 69. Shafer RW, Singh SP, Larkin C, Small PM. Exogenous reinfection with multidrugresistant Mycobacterium tuberculosis in an immunocompetent patient. Tubercle and Lung Dis 1995; 76:575–577. 70. Villeman JA. Etudes sur la Tuberculose: Preuves Rationales et Experimentales de la Specifite et de son Inoculabilite. Paris: Baillieres, 1868. 71. Daniel TM. Robert Koch. Tuberculosis and the subsquent history of medicine (editorial). Am Rev Respir Dis 1982 (Part 2); 125(3):1–3. 72. Koch R. The etiology of tuberculosis. Am Rev Tuberc 1932; 25:284–323. 73. Smith T. A comparative study of bovine tubercle bacilli and of human bacilli from sputum. J Exp Med 1898; 3:451–511. 74. Smith T. The relation between human and animal tuberculosis with special reference to the transformation of human and other types of the tubercle bacillus. Boston Med Surg J 1908; 159:707–711.
History of Tuberculosis 75. 76. 77. 78.
79. 80. 81. 82. 83. 84. 85.
86.
87.
88. 89. 90. 91.
92. 93.
47
Ravenel MP. The intercommunicability of human and bovine tuberculosis. Medicine 1902; 8:529–546. The bacillus tuberculosis and the contagiousness of phthisis. Boston Med Surg J 1883; 108:235–236. Chapin CV. Sources and Modes of Infection. New York: John Wiley and Sons, 1910:252–255. Smith PG, Moss AR. Epidemiology of tuberculosis. In: Bloom BR, ed. Tuberculosis: Pathogenesis, Protection, and Control. Washington, DC: American Society for Microbiology, 1994:47–59. Wells WF. On air-borne infection: II. Droplets and droplet nuclei. Am J Hyg 1934; 20:611–618. Wells WF. Airborne Contagion and Air Hygiene. Cambridge, MA: Harvard University Press, 1955. Riley RL, O’Grady F. Airborne Infection: Transmission and Control. New York: Macmillan, 1961. Loudon RG, Roberts RM. Droplet expulsion from the respiratory tract. Am Rev Respir Dis 1967; 95:435–442. Riley RL, Mills CC, O’Grady F, Sultan LU, Wittstadt F, Shivpuri DN. Infectiousness of air from a tuberculosis ward. Am Rev Respir Dis 1962; 85:511–525. Houk VN, Baker JH, Sorensen K, and Kent DC. The epidemiology of tuberculosis infection in a closed environment. Arch Environ Health 1968; 16:26–35. Edlin BR, Tokars JI, Grieco MH, Crawford JT, Williams J, Sordillo EM, Ong KR, Kilburn JO, Dooley SW, Castro KG, Jarvis WR, Holmberg SD. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med. 1992; 326:1514–1521. Infectiousness of tuberculosis: a report of the National Tuberculosis Association ad hoc Committee on Treatment of Tuberculosis in general hospitals. Am Rev Respir Dis 1967; 96:836–837. Nardell E, Keegan J, Cheney SA, Etkind SC. Airborne infection. Theoretical limits of protection achievable by building ventilation. Am Rev Respir Dis 1991; 144:302–306. Riley RL, Nardell EA. State of the art. Clearing the air. The theory and application of ultraviolet air disinfection. Am Rev Respir Dis 1989; 139:1286–1294. Guidelines for preventing the transmission of tuberculosis in health-care settings, with special focus on HIV-related issues. MMWR 1990; 39:RR-17. Shyrock RH. The National Tuberculosis Association 1904–1954. New York: National Tuberculosis Association, 1957. Knopf SA. A History of the National Tuberculosis Association. The Anti-Tuberculosis Movement in the United States. New York: National Tuberculosis Association, 1922. Hodges LM. The People Against Tuberculosis: The Story of the Christmas Seal. New York: National Tuberculosis Association, 1942. Haas F, Haas. S. The sociopolitical response to the discovery of mycobacterium tuberculosis. In: Baum GL, Crapo JD, Celli BR, Karlinsky JB, eds. Textbook of Pulmonary Diseases. 6th ed. Philadelphia: Lippincott-Raven Publishers, 1998: 3–21.
48 94.
95. 96. 97. 98. 99. 100. 101. 102. 103. 104.
105. 106.
107. 108.
109. 110. 111. 112.
113.
Davis Tuberculosis in South African Natives with Special Reference to the Disease Amongst the Mine Labourers on the Witwatersrand. Report of the Tuberculosis Research Committee. Johannesburg: South African Institute for Medical Research, 1932. Knopf SA. Tuberculosis as a Disease of the Masses and How to Combat It. New York: Fred P. Flori, 1907. Asch S, Leake B, Anderson R, Gelberg L. Why do symptomatic patients delay obtaining care for tuberculosis? Am J Respir Crit Care Med 1998; 157:1244–1248. Rubel AJ, Garro LC. Social and cultural factors in the control of tuberculosis. Public Health Rep 1992; 107:626–636. Elliott J. The evolution of dispensary control of tuberculosis. Am Rev Tuberc 1937; 36:577–591. Edwards H. Clinic standards and clinic practice. Am Rev Tuberc 1937; 36:592–601. Long ER. A half century of medical progress in the control of tuberculosis. Am Rev Tuberc 1954; 70:383–390. Winslow CEA. The Life of Hermann M. Biggs. Philadelphia: Lea and Febiger, 1929:132–133. Fox DM Social policy and city politics: tuberculosis reporting in New York, 1889–1900. Bull Hist Med 1974; 49:169–195. Brudney K, Dobkin J. Resurgent tuberculosis in New York City. Am Rev Respir Dis 1991; 144:745–749. Raviglione MC, Dye C, Schmidt S, Kochi A, for the WHO Global Surveillance and Monitoring Project. Assessment of worldwide tuberculosis control. Lancet 1997; 350:624–629. Long ER. Recommendations of the Arden House Conference on Tuberculosis. Am Rev Respir Dis 1960; 81:481–484. Centers for Disease Control. National action plan to combat multidrug-resistant tuberculosis: meeting the challenge of multidrug-resistant tuberculosis. MMWR 1992; 41(No. RR-11):1–57. Davis AL. History of the sanatorium movement. In: Rom W, Garay S, eds. Tuberculosis. Boston: Little, Brown, 1996:35–54. Knopf SA. The anti tuberculosis movement in the United States prior to and since the formation of the National Tuberculosis Association. Med Rec 1920; 97: 1071–1074. Kinghorn HM. Brehmer and Dettweiler. A review of their methods of treatment of pulmonary tuberculosis. Am Rev Tuberc 1922; V(12):950–972. Huber JB. Consumption. Its Relation to Man and His Civilization. Its Prevention and Cure. Philadelphia: Lippincott, 1906. Knopf SA. Geheimrath Dr. Dettweiler. Med Rec 1905; LXVII:136–137. Knopf SA. Herman Brehmer and the semi-centennial celebration of Brehmer’s sanatorium for the treatment of consumptives: the first institution of its kind. NY Med J Phila Med J 1904; LXXX(1):3–6. Bowditch VY. The English sanatorium. Three leading institutions as seen through American eyes—the newly completed King’s sanatorium in Sussex. J Outdoor Life 1906; III:461–464.
History of Tuberculosis 114. 115. 116. 117. 118. 119. 120. 121. 122. 123.
124. 125. 126. 127.
128. 129.
130. 131. 132. 133.
134. 135.
49
Long ER. A History of the Therapy of Tuberculosis and the Case of Frederic Chopin. Lawrence: University of Kansas Press, 1956:54. Trudeau EL. An Autobiography. National Tuberculosis Association. New York: Doubleday, 1944. Trudeau EL, The history of the tuberculosis work at Saranac Lake, New York. Med News NY 1903; October 24:1–12. Knoph SA. Are sanatoriums for consumptives a danger to the neighborhood? Med Rec 1896; 1(4):82–83. Skavlem JH. The closing of the Trudeau sanatorium (editorial). Am Rev Tuberc Pulm Dis 1955; 71:163–164. Growth of the sanatorium movement. J Outdoor Life 1923; 20:255. Tuberculosis Hospital and Sanatorium Directory. New York: National Tuberculosis Association, 1954:184–185, 188–189. Frost WH. The age selection of mortality from tuberculosis in successive decades. Am J Epidemiol 1995; 141:4–9. McKeown T. The Role of Medicine: Dream, Mirage or Nemesis? London: The Nuffield Provincial Hospitals Trust, 1976. Armand Delille P. The campaign against infantile tuberculosis in France and the preservation of childhood against its ravages by the system of the “Oeuvre Grancher.” Am Rev Tuberc 1918–1819; II(7):435–448. Teller ME. The Tuberculosis Movement: A Public Health Campaign in the Progressive Era. Westport, CT: Greenwood Press, 1988. Weisner DE. Sanatorium follow up studies. Am Rev Tuberc 1922; VI:320–326. Goldstein SE. After the sanatorium what? J Outdoor Life 1914; 11:266–268. Mitchell RS. Mortality and relapse of uncomplicated advanced pulmonary tuberculosis before chemotherapy: 1,504 consecutive admissions followed for fifteen to twenty five years (parts I and II). Am Rev Tuberc 1955; 72:487–501, 502–512. Stephens MG. Follow-up of 1,041 tuberculosis patients. Am Rev Tuberc 1941; 44: 451–462. Siltzbach LE. Medical aspects of the rehabilitation of the tuberculous. The experience of a quarter century with 964 patients at Altro Work Shops. Am Rev Tuberc 1942; 46:489–504. Woodhead GS, Varrier-Jones PC. Experiences in colony treatment and after-care. Lancet 1917; 2:779–785. Willis S. Perspectives and treatment in tuberculosis. Am Rev Tuberc 1944; 50: 251–256. Riviere C. The Early Diagnosis of Tubercle. 3rd ed. London: Oxford Medical Publications, 1921:197, 222. Grange JM. The mycobacteria. In: Topley & Wilson’s Principles of Bacteriology, Virology and Immunity. Parker MT, Duerden BI, eds. 8th ed. Vol. 2. Philadelphia: BC Decker, Inc., 1990:73–101. Runyon EH. Anonymous Mycobacteria in pulmonary disease. Med Clin North Am 1959; 43:273–290. Condos R, McCune A, Rom WN, Schluger NW. Identification of patients with active tuberculosis using a peripheral blood-based polymerase chain reaction assay. Lancet 1996; 347:1082–1085.
50 136. 137.
138. 139.
140.
141. 142. 143.
143a.
144. 145. 146. 147. 148. 149. 150. 151.
152.
Davis Hanna BA. Diagnosis of tuberculosis by microbiologic techniques. In: Rom W, Garay S, eds. Tuberculosis. Boston: Little, Brown, 1996:149–159. Daniel TM, Debanne SM. The serodiagnosis of tuberculosis and other mycobacterial diseases by enzyme-linked immunosorbent assay. State of the art. Am Rev Respir Dis 1987; 135:1137–1151. Daniel TM. Rapid diagnosis of tuberculosis: laboratory techniques applicable in developing countries. Rev Infect Dis 1989; 11(suppl. 2):S471–S478. Dalovisio JR, Montenegro-James S, Kemmerly SA, Genre CF, Chambers R, Greer D, Pankey GA, Failla DM, Haydel KG, Hutchinson L, Lindley MF, Nunez BM, Praba A, Eisenach KD, Cooper ES. Comparison of the amplified mycobacterium tuberculosis (MTB) direct test, amplicor MTB PCR, and IS6110-PCR for detection of MTB in respiratory specimens. Clin Infect Dis 1996; 23: 1099–1106. Editorial response: comparison of the amplified mycobacterium tuberculosis (MTB) direct test, amplicor MTB PCR, and IS6110-PCR for detection of MTB in respiratory specimens. Clin Infect Dis 1996; 23:1107–1108. Roth A, Schaberg T, Mauch H. Molecular diagnosis of tuberculosis: current clinical validity and future perspectives. Eur Respir J 1997; 10:1877–1891. ATS Workshop Report. Rapid diagnostic tests for tuberculosis. Am J Respir Crit Care Med 1997; 155:1804–1814. Goldberger MJ, Matthews WC, Rose DN, Fujiwara PI, Sbabaro J, Bozzette SA, Chaisson RE, Davidson BL, Geiter LJ, Jordan TJ, Moser KS, Reichman LB. Rapid diagnostic tests for tuberculosis: What is the appropriate use? Am J Respir Crit Care Med 1997; 155:1804–1814. Condos R, Rom WN, Liu YM, Schluger NW. Local immune responses correlate with presentation and outcome in tuberculosis. Am J Respir Crit Care Med 1998; 157:729–735. Medlar EM. The behavior of pulmonary tuberculous lesions. A pathological study. Am Rev Tuberc Pulm Dis 1955; 71(pt 2 of 2):1–244. Steinberg I, Barnard MW. Tuberculosis case-finding in a consultation chest service for private physicians. Am Rev Tuberc 1937; 36:602–612. Sakula A. Caarlo Forlanini, inventor of artificial pneumothorax for treatment of pulmonary tuberculosis. Thorax 1983; 38:326–332. Brown L. The Story of Clinical Pulmonary Tuberculosis. Baltimore: Williams & Wilkins, 1941. Gaensler EA. The surgery for pulmonary tuberculosis. Am Rev Respir Dis 1982; 125(pt II):73–84. Thompson SA, Greenberg M. Jacobaeus operation. Am Rev Tuberc 1941; 44: 183–190. Peters A. Artificial pneumothorax at the Loomis sanatorium over fourteen years. Am Rev Tuberc 1928; 18:348–374. Mitchell RS. Artificial pneumothorax: a statistical analysis of 557 cases initiated in 1930–39 and followed in 1949 (parts I-VI). Am Rev Tuberc 1951; 64:1–40, 127–158. Amberson JB, Jr. Tuberculosis. In: Cecil RL, ed. A Textbook of Medicine. 5th ed. Philadelphia: Saunders, 1940:313–370.
History of Tuberculosis 153. 154. 155. 156. 157. 158. 159. 160. 161. 162. 163.
164. 165. 166. 167. 168.
169.
170. 171.
172.
173.
51
Gibbon JH, Jr, Sabiston DC, Jr, Spencer FC, eds. Surgery of the Chest. 2d ed. Philadelphia: Saunders, 1969:420–439. Bothamley GH. The Koch phenomenon and delayed hypersensitivity: 1891–1991. Tubercle 1991; 72:7–11. Burke DS. Of postulates and peccadilloes: Robert Koch and vaccine (tuberculin) therapy for tuberculosis. Vaccine 1993; 8(11):795–804. Pottenger FM. Clinical Tuberculosis. Vol. 1. Pathological Physiology, Diagnosis and Prognosis. 2d ed. St. Louis: CV Mosby Co. 1922:502–515. Pearson L. Tuberculosis in cattle. Tuberculin as a diagnostic agent. Med News 1892; 60:358–359. Snider DE. The tuberculin skin test. Am Rev Respir Dis 1982 (Part 2); 125(3): 108–118. Seibert FB, Glenn JT. Tuberculin purified protein derivative: preparation and analyses of a large quantity for standard. Am Rev Tuberc 1941; 44:9–25. Palmer CE. Nontuberculosis pulmonary calification and sensitivity to histoplasmin. Public Health Rep 1945; 60:513–520. Christie A, Petersen JC. Pulmonary calification in negative reactors to tuberculin. Am J Public Health 1945; 35:1131–1147. Furcolow M.L. Development of calification in pulmonary diseases associated with sensitivity to histoplasmis. Public Health Rep 1949; 64:1363–1365. Furcolow ML, Hewell B, Nelson we, Palmer CE. Quantitative studies of the tuberculin reaction: I. Titration of tuberculin sensitivity and its relation to tuberculous infection. Public Health Rep 1941; 56:1082–1100. WHO Tuberculosis Research Office. Further studies of geographic variation in naturally acquired tuberculin sensitivity. Bull WHO 1955; 12:63–83. Edwards PQ, Edwards LB. Story of the tuberculin test. Am Rev Respir Dis (Part 2) 1960; 81:1–47. Palmer CE, Edwards LB. Tuberculin test in retrospect and prospect. Arch Environ Health 1967; 15:792–808. Edwards LB, Acquaviva FA, Livesay VT. Identification of tuberculous infected. Am Rev Respir Dis 1973; 108:1334–1339. Edwards LB, Acquaviva FA, Livesay VT, Cross FW, Palmer CE. An atlas of sensitivity to tuberculin, PPD-B, and histoplasmin in the United States. Am Rev Respir Dis 1969; 99:1–132. Falkinham JO, Parker BC, Gruft H. Epidemiology of infection by non-tuberculosis mycobacteria. I. Geographical distribution in the United States. Am Rev Respir Dis 1980; 121:931–937. Kent DC, Schwartz R. Active pulmonary tuberculosis with negative tuberculin skin reaction. Am Rev Respir Dis 1967; 95:411–418. Holden M, Dubin MR, Diamond PH. Frequency of negative intermediate strength tuberculin sensitivity in patients with active tuberculosis. N Engl J Med. 1971; 285:1506–1509. Steele AH, Willis HS. A study of the increase in sensitiveness in normal children produced by repeated injections of tuberculin. Transactions of the 30th Annual Meeting of the National Tuberculosis Association, New York, 1934 p. 1. Atkinson ML, Farer LS. TB testing for hospital employees: new recommendations. Hosp Med Staff 1979:16–20.
52
Davis
174. Thompson NJ, Glassroth JL, Snider DE, Jr, Farer LS. The booster phenomenon in serial tuberculin testing. Am Rev Respir Dis 1979; 119:587–597. 175. Rich AR, McCordock HA. An enquiry concerning the role of allergy, immunity, and other factors of importance in the pathogenesis of human tuberculosis. Bull Johns Hopkins Hosp 1929; 44:273–422. 176. Wilson GS, Schwabacher H, Maier I. The effect of desensitization of tuberculous guinea pigs. J Path Bact 1940; 50:89–109. 177. Chase MW. The cellular transfer of cutaneous hypersensitivity to tuberculin. Proc Soc Exp Biol Med 1945; 59:134–135. 178. Mackaness GB. The immunology of antituberculous immunity. Am Rev Respir Dis 1967; 97:337–344. 179. Youmans GP. Relation between delayed hypersensitivity and immunity in tuberculosis. Am Rev Respir Dis 1975; 11:109–118. 180. Lefford MJ. Delayed hypersensitivity and immunity in tuberculosis. Am Rev Respir Dis 1975; 111:243–246. 181. Salvin SB, Neta R. A possible relationship between delayed hypersensitivity and cell-mediated immunity. Am Rev Respir Dis 1975; 111:373–377. 182. Markowitz N, Hansen NI, Wilcosky TC, Hopewell PC, Glassroth J, Kvale PA, Mangura BT, Osmond D, Wallace JM, Rosen MJ, Reichman LB. Tuberculin and anergy testing in HIV-seropositive and HIV-seronegative persons. Ann Intern Med 1993; 119:185–193. 183. Tuberculin reactions in apparently healthy HIV-seropositive and HIV sero-negative women—Uganda. MMWR 1990; 39(37):638–639, 645–646. 184. Schluger NW, Rom WN. The host response to tuberculosis. State of the Art. Am J Respir Crit Care Med 1998; 157:679–691. 185. Sakula A. BCG: Who were Calmette and Guérin? Thorax 1983; 38:806–812. 186. Smith FB. Tuberculosis and bureaucracy—Bacille Calmette et Guérin: its troubled path to acceptance in Britain and Australia. Med J Aust 1993; 159:408–411. 187. Lugosi L. Theoretical and methodological aspects of BCG vaccine from the discovery of Calmette and Guérin to molecular biology. A review. Tubercle and Lung Dis 1992; 73:252–261. 188. Comstock GW. The international tuberculosis campaign: a pioneering venture in mass vaccination and research. Clin Infect Dis 1994; 19:528–540. 189. Ten Dam HG, Toman K, Hitze KL, Guld J. Present knowledge of immunization against tuberculosis. Bull WHO 1976; 54:255–269. 190. Fine PEM. The BCG story: lessons from the past and implications for the future. Rev Infect Dis 1989; 11(suppl 2):S353–S359. 191. Houston S, Fanning A, Soskolne CL, Fraser N. The effectiveness of bacillus Calmette-Guérin (BCG) vaccination against tuberculosis: a case-control study in Treaty Indians, Alberta, Canada. Am J Epidemiol 1990; 131:340–348. 192. ten Dam HG. Research on BCG vaccination. Adv Tuberc Res 1984; 21:79–106. 193. Rodrigues LC, Smith PG. Tuberculosis in developing countries and methods for its control. Trans R Soc Trop Med Hyg 1990; 84:739–744. 194. Clemens JD, Chuong JJH, Feinstein AR. The BCG controversy: a methodological and statistical reappraisal. JAMA 1983; 249:2362–2369.
History of Tuberculosis 195. 196. 197.
198. 199. 200.
201. 202. 203. 204. 205. 206. 207. 208. 209. 210.
211.
212.
213.
53
Smith PG. Epidemiological methods to evaluate vaccine efficacy. Br Med Bull 1988; 44(3):679–690. Comstock GW. Vaccine evaluation by case-control or prospective studies (editorial). Am J Epidemiol 1990; 131:205–207. Stover CK, de la Cruz VF, Fuerst TR, Burlein JE, Benson LA, Bennett LT, Bansal GP, Young JF, Lee MH, Hatfull GF, Snapper SB, Barletta RG, Jacobs WR, Jr., Bloom BR. New use of BCG for recombinant vaccines. Nature 1991; 351: 456–460. Amberson Jr. JB, McMahon BT, Pinner M. A clinical trial of sanocrysin in pulmonary tuberculosis. Am Rev Tuberc 1931; 24:401–435. D’Esopo ND. Clinical trials in pulmonary tuberculosis. Am Rev Respir Dis 1982 (Part 2); 125(3):85–93. Schatz A, Bugie E, Waksman SA. Streptomycin, a substance exhibiting antibiotic activity against gram positive and gram negative bacteria. Proc Soc Exp Biol 1944; 55:66–99. Ryan F. The Forgotten Plague: How the Battle Against Tuberculosis Was Won and Lost. Boston: Little, Brown, 1992. Barnwell JB. Veterans Administration Tuberculosis Division 1945–1947. Progress Report. Am Rev Tuberc 1948; 58:64–76. Snider GL. Tuberculosis then and now: a personal perspective on the last 50 years. Ann Intern Med 1997; 126:237–243. Fox W, Mitchison DA. State of the art: a short-course chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 1975; 111:325–353. Pinner M. Evaluation of chemotherapy. Editorial. Am Rev Tuberc 1944; 50: 257–259. Medical Research Council Investigation. Streptomycin treatment of pulmonary tuberculosis. Br Med J 1948; 2:769–782. Lillenfeld AH. The Fielding H. Garrison Lecture. Ceterus paribus: the evolution of the clinical trial. Bull Hist Med 1982; 56:1–18. Lehman J. Para-amino salicylic acid in the treatment of tuberculosis. Lancet 1946; 1: 15–16. Medical Research Council Investigation. Treatment of pulmonary tuberculosis with streptomycin and para-amino salicylic acid. Br Med J 1950; 2:1073–1085. Yeager RL, Goodwin RA, Parker EF, Muschenheim C, Chapman PT, Thomas MC, Mitchell R, Corpe RF, Ebert RH. Bed rest in the treatment of tuberculosis: a statement by the Committee on Therapy. Am Rev Tuberc 1954; 69:1069–1070. Robitzek EH, Selikoff IJ. Hydrazine derivatives of isonicotinic acid (Rimifon, Marsalid) in the treatment of progressive caseous-pneumonic tuberculosis. A preliminary report. Am Rev Tuberc 1952; 65:402–428. Bignall JR, Rist N. An international investigation of the efficacy of chemotherapy in previously untreated patients with pulmonary tuberculosis. A trial directed by the Committee on Treatment and the Committee on Bacteriology and Immunology of the International Union Against Tuberculosis. Bull Int Un Tuberc 1964; 34:79–191. Moodie AS. Ambulatory treatment of tuberculosis in Hong Kong. Tubercle 1956; 37:451–454.
54
Davis
214. Tuberculosis Chemotherapy Center Madras. A concurrent comparison of home and sanatorium treatment of pulmonary tuberculosis in South India. Bull WHO 1959; 21:51–144. 215. Bayers R, Wilkensin D. Directly observed therapy: history of an idea. Lancet 1995; 345(8964):1545–1548. 216. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Adv Tuberc Res 1970; 17:28–106. 217. Farer L. Chemoprophylaxis. Am Rev Respir Dis 1982; 125(Part 2 of 2):102–107. 218. Comstock GW, Edwards PQ. The competing risks of tuberculosis and hepatitis for adult tuberculin reactors (editorial). Am Rev Respir Dis 1975; 111:573–577. 219. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull WHO 1982; 60:555–564. 220. Snider DE, Cares GJ, Koplan JP. Preventive therapy with isoniazid: cost-effectiveness of different durations of therapy. JAMA 1986; 255:1579–1583. 221. Screening for tuberculosis and tuberculosis infection in high-risk populations, and the use of preventive therapy for tuberculosis infection in the United States: recommendations of the Advisory Committee for Elimination of Tuberculosis. MMWR 1990; 39(RR-8):1–12. 222. Mc Anulty JM, Fleming DW, Hawley MA, Baron RC. Missed opportunities for tuberculosis prevention. Arch Intern Med 1995; 155:713–716. 223. Villarino ME, Dooley SW, Geiter LT, Castro KG, Snider DE, Jr. Management of persons exposed to multidrug-resistant tuberculosis. MMWR 1992; 41(RR11):59–71. 224. Ciba Foundation Symposium on Experimental Tuberculosis. Wolstenholme GEW, Cameron MP, eds. Boston: Little, Brown and Co., 1955:2. 225. Williams N. Genome of TB culprit deciphered. Science 1998; 279:25.
2 Tuberculosis Control in Low-Income Countries
DONALD A. ENARSON University of Alberta Alberta, Canada, and International Union Against Tuberculosis and Lung Disease Paris, France
I. Introduction The importance of tuberculosis to public health can hardly be questioned. In the first meeting of specialists in internal medicine held in Paris in 1867, it was noted that tuberculosis was the most frequent condition with which the specialists had to deal, and for this reason a series of scientific meetings was initiated that led to the establishment of the International Union Against Tuberculosis and Lung Disease. More than a century later, in 1993, tuberculosis was reported as the most frequent cause of death from a single agent among persons aged 15–49 years (1) and has been declared a global emergency. Anyone today may become infected with tuberculosis simply by breathing the air in a space through which a tuberculosis patient has passed. Because of its frequency, its potential effects, and the fact that it can be spread to the general public, tuberculosis has a significance to public health greater than most other disease conditions. II. Objectives of Tuberculosis Control Because tuberculosis is caused by a microorganism whose principal reservoir is the human population and because it represents such a danger to public health, the 55
56
Enarson
objective of activities directed against this disease should be nothing short of its elimination from the human population. Some would argue that this is an unrealistic objective. Nevertheless, it may be a reasonable one because of the inefficiency of the dynamics of tuberculosis (2). Beyond this are the strategic implications of aiming at elimination; this objective clarifies the obstacles in the way of achieving it and an agenda for action. The folly of thinking that tuberculosis can be reduced to a level beyond which it is no longer a concern to the public without eliminating it has been dramatically illustrated by the resurgence of this contagious disease where it was previously thought to be controlled (3). III. The Scientific Basis of Intervention A. The Dynamics of Transmission
Tuberculosis involves a dynamic process (4). Understanding this process is essential to interventions for its control; transmission of the causative microorganism from one person to another is the key component. To become infected with tuberculosis, a biologically effective dose of the microorganism is required; this is achieved primarily by inhalation. The microorganism enters the environment as an aerosol, a susceptible individual is exposed, becomes infected, and may subsequently develop disease, which may be contagious, thus passing the organism to others. The individual remains contagious for a limited period of time, during which transmission may occur. This period is limited either by the death of the individual or the suppression of growth of the microorganism in the body (as when the patient is cured). The key transitions in maintaining the cycle are (1) from exposure to infection, (2) from infection to disease, (3) from disease to exposure. B. Determinants
Key determinants in the transition from exposure to infection are the concentration of microorganisms in the environment, the degree of susceptibility of the exposed, and the duration of exposure (5). The key determinant in the transition from infection to disease is the state of the immune system of the individual infected. Key determinants in the transition from disease to being contagious are the numbers of bacteria in the lung and their access to the airways. The stages in the transmission cycle increase its inefficiency. C. Probabilities
In enhancing or retarding transmission, the probability of transition from one state to another must be modified. An understanding of the “base” probabilities (the
Tuberculosis Control in Low-Income Countries
57
probabilities of transition in the absence of the intervention) is essential to evaluate the impact of any intervention. Base probabilities can be derived from studies of individuals in contact with those with active tuberculosis (5). The probability of transition from exposure to infection varies, on average, from slightly more than 25% in a person living in the same household as a case with sputum smear positive tuberculosis to about 12% for someone who is a friend or colleague of such a case. The probability of transition from infection to disease in this setting is less than 15%. Finally, the probability of a case of tuberculosis being highly contagious, if the case is an adult, is approximately 50%. Thus, the combined probability (if a susceptible person lives in the same household with a highly contagious case of tuberculosis) is 0.25 times 0.12 times 0.50, which is 1.5%. This is clearly an inefficient cycle of transmission, which makes it theoretically possible to consider elimination a reasonable objective. A strategy for elimination needs to take account of the fact that Mycobacterium tuberculosis remains dormant in a high proportion of those infected; the low probability and long latent period between infection and disease means that most of those infected do not have the disease but retain the possibility of developing the disease throughout their lifetime. Thus, an elimination strategy focused on the sources of infection must be sustained over a long period of time. IV. Prevention Through Treatment A. Failure of a Vaccine Strategy
The most promising strategy for elimination of a disease is vaccination, as with smallpox. A vaccine was one of the earliest tools developed for the control of tuberculosis following the identification of the causative organism (6). This vaccine is capable only of limiting the dissemination of the microorganism within the body after infection (7) and does not prevent infection. In addition, the most frequent schedule of administration (shortly after birth) prevents those forms of tuberculosis that are not highly contagious (8) and so has limited impact on the transmission cycle. B. Preventive Therapy as a Secondary Prevention Strategy
Shortly after the development of effective chemotherapy for treatment, it was used to treat latent bacteria in those who had been infected but who had not yet developed disease (9). It was clearly effective in reducing the probability of developing subsequent tuberculosis. However, the number of persons who needed treatment to prevent a contagious case, and the duration of such treatment made this strategy cumbersome to apply at a population level.
58
Enarson C. Evidence for Case Management as an Effective Preventive Tool
The possibility that chemotherapy could permanently cure a patient with tuberculosis was convincingly demonstrated in the early 1960s in Edinburgh (10). Prior to that time, many did not believe that tuberculosis could be cured, only that it could be suppressed, to reactivate at a later time in life. Evidence that chemotherapy could curtail infectiousness of a patient was provided by a study in India of the contacts of patients whose treatment was domiciliary as compared with those who received wholly ambulatory treatment (11); the proportion infected by exposure to the case was not different in the two groups. The ability of chemotherapy of tuberculosis cases to arrest infection of succeeding generations of children in the community has been more difficult to demonstrate. The evidence for its impact has been summarized (12). Supportive evidence includes the demonstration that the rate of decline in prevalence of infection in military recruits in the Netherlands was hastened after the introduction of chemotherapy (13), but it had been declining for some time prior to this period and was already at a relatively low level prior to the initiation of this treatment. More compelling evidence has been provided from intensive intervention in Inuit communities where the rate of tuberculosis was extremely high (14). The rates were very rapidly reduced primarily through the rapid identification and treatment of cases of tuberculosis in the community, but this was accompanied by an extensive application of preventive chemotherapy. V. Basic Principles of Tuberculosis Control A. Results of Chemotherapy
Chemotherapy of tuberculosis was associated with an immediate and dramatic effect on fatality: patients who would have clearly died of their disease remained alive. The trend in tuberculosis mortality after introduction of chemotherapy was illustrated in Norway (Fig. 1); the greatest reduction occurred immediately following the introduction of drugs before modern, multidrug chemotherapy was used. Subsequently it was conclusively shown that patients did not relapse if they had diligently completed the multidrug treatment prescribed (15). Chemotherapy, while saving the lives of patients, reduced the period of time of being contagious and prevented patients from again becoming contagious, removing them from the cycle of transmission. B. Effective Means of Case-Finding
Following the second world war, periodic radiographic examination of large proportions of the general population was performed in the belief that such active
Tuberculosis Control in Low-Income Countries
59
Figure 1. Trend in mortality from tuberculosis in Norway, 1925–1970, in relation to the introduction of chemotherapy. (Adapted from Ref. 59.)
measures would remove the infectious cases from the community and prevent further spread of tuberculosis. In an extensive field trial evaluating the components of the emerging strategy for tuberculosis control, Styblo and colleagues (16) in the Kolin district of Czechoslovakia showed convincingly that where routine services are regularly provided, periodic examinations are not efficient in identifying further cases of tuberculosis in the community, especially the most contagious cases. Studies in Kenya (17) indicated that patients identified on screening examinations had most likely attended the health service (in many instances on numerous occasions) where they had not been diagnosed. An international, multicenter evaluation of the ability of tuberculosis specialists to correctly identify active cases of tuberculosis using chest radiographs (18) demonstrated a striking degree of nonconcordance in the examination results. The most appropriate means of case detection was bacteriological examination of those presenting with compatible symptoms in routine health services.
C. Impact of Chemotherapy on Tuberculosis Control
In addition to saving the lives of tuberculosis patients, adequate multidrug chemotherapy rapidly reduced the numbers of tuberculosis patients in the community by quickly curing the long-term ( prevalence) cases, leaving primarily new, previously undiagnosed cases as the only patients in the community, and even these could be quickly rendered bacteriologically negative (Fig. 2).
60
Enarson
Figure 2. Impact of chemotherapy on prevalence of infectious cases, incidence of infectious cases, and prevalence of resistant cases of tuberculosis in Edinburgh in relation to the introduction of chemotherapy. (Adapted from Ref. 10.)
D. Rationalization of Tuberculosis Services
From the elements outlined above, a model was proposed for tuberculosis services as a full-scale public health program (19). It included government responsibility for tuberculosis control activities, ambulatory chemotherapy of tuberculosis patients using a standardized multidrug regimen under the supervision of a specialist, case detection based on examination of individuals presenting themselves to the general health services with symptoms compatible with tuberculosis, bacteriological monitoring of the course and outcome of treatment, periodic evaluation of activities, and the use of BCG vaccination. Application of this approach in many industrialized countries was followed by rapid reduction in the number of tuberculosis cases. VI. Adaptations for Low-Income Countries A. Constraints in Providing Tuberculosis Services
Attempts to reproduce the results achieved in industrialized countries using the same methods were successful in a few other countries, such as Cuba, Libya, Al-
Tuberculosis Control in Low-Income Countries
61
geria, Uruguay, and Chile. The poorest countries, where the majority of the cases lived, faced marked constraints. Infrastructure for providing services was in most instances nonexistent, financial resources were inadequate to deal with the disease burden, populations were scattered, and communication was insufficient to ensure accessibility to such services as did exist. Only few of the elements of the model developed in industrialized countries could be implemented promptly in the poorest countries. Vaccination was the easiest and was extensively applied; other elements were incompletely implemented due to the constraints encountered. B. The Need to Focus Interventions
The need to set priorities was evident. In addition to the experimental work supported by the World Health Organization (WHO) undertaken in the Kolin district of Czechoslovakia, a broad program of research was undertaken, primarily in India (20), which provided a scientific basis for discussion. A number of modifications were proposed. One of the earliest modifications was the use of isoniazid alone in the treatment of tuberculosis. This approach had been evaluated at the initiation of chemotherapy (21) and was shown to be effective in increasing the proportion of patients who could be cured, and the long-term outlook for those cured was not different from that for those whose disease was arrested using multidrug chemotherapy. It was clearly cheap and easy to apply and received enthusiastic support from many experts, including Johannes Holm, the executive director of the International Union Against Tuberculosis, an action praised by Halfdan Mahler, Director General of the World Health Organization (22). This policy led to the proliferation of resistance to isoniazid and ultimately to the present problem of multidrug resistance. Another recommendation was based on mathematical models applied to the transmission cycle for tuberculosis (23). The importance of case finding was stressed by the models because it was noted that if one could achieve a relatively modest level of success of treatment in a large number of cases, it would be much more effective in reducing the burden of disease in the community than if a high level of success of treatment was achieved in a limited number of cases. From this came a focus on case finding as the key activity of tuberculosis services. A formal recommendation was developed by WHO in 1964 for the development and implementation of national tuberculosis programs (24) and reiterated in a revision 10 years later (25). The report identified the need for a program that is countrywide, permanent, responsive to the felt needs of the population, integrated within the existing health services, and within the reach of the resources available. As a consequence of these recommendations, most governments instituted a national tuberculosis program.
62
Enarson VII. Achieving Success in Low-Income Countries A. Impact of Applied Interventions
Within a few years of the recommendation of this strategy, millions of cases of tuberculosis were reported to WHO (26). The number of notified cases of tuberculosis declined in successive reports, which was interpreted as indicating success of the strategy. A more critical evaluation of the evidence, however, suggested that the number of cases of tuberculosis reported to WHO seriously underestimated the real number of cases that existed and that, instead of declining, the number of cases may actually have been increasing (27). Far from being successful, the interventions were shown to have been contributing to a worsening of the tuberculosis situation (28), an analysis initially presented to the annual meeting of the International Union Against Tuberculosis in 1973. Subsequent information from the national prevalence surveys periodically carried out in East Asia [particularly in Korea (29) and China (30)] indicated that more than half the sources of transmission of tuberculosis were cases known to the health services that had received treatment but had not been cured. Moreover, the majority of these cases harbored drug-resistant microorganisms. Instead of bringing the problem under some semblance of control, the ineffective treatment of the cases was actually making the epidemiological situation far worse than if the patients had never been treated. The conclusion of this evaluation was that it was far better to do nothing at all than to treat the cases badly! This information had already been available from the first years of chemotherapy in Edinburgh (Fig. 2) as well as from community studies in India (31), but the message had not been heeded. The immediate consequence of the lack of success was a decline in priority given to tuberculosis and an emphasis on improving general health services through a focus on “primary health care” and mobilization of the general population for health following the successful examples of services in China and of specific projects in India and Indonesia. It was felt that, when such services were established, it might be possible to revisit the focused intervention against tuberculosis (32). B. Redefining the Strategy
The failure of attempts to successfully address the tuberculosis problem in low-income countries was very much evident in Beijing in 1978, when Kan and Zhang (33) set out to introduce a revised strategy for management of tuberculosis in that municipality of 10 million inhabitants. Their program emphasized diagnosis based on bacteriological examination, treatment employing direct observation of a regimen of 12 months of chemotherapy including streptomycin, isoniazid, and para-aminosalicylic acid for one month, followed by twice-weekly streptomycin
Tuberculosis Control in Low-Income Countries
63
and isoniazid for 11 months, with an emphasis on the successful treatment of newly diagnosed cases, a separate treatment regimen for patients failing to respond to initial treatment, and BCG vaccination of newborns. Over the subsequent decade, the program was expanded from several model areas, where it had proved successful, to cover the entire population of the municipality. Childhood tuberculous meningitis virtually disappeared, and subsequent evaluation of tuberculin reactivity in a cohort of unvaccinated children showed that transmission of tuberculosis has been dramatically reduced. The reduction in transmission paralleled the decline in prevalence of tuberculosis cases in adults whose numbers were rapidly reduced through the implementation of directly observed chemotherapy, even though rifampicin-containing regimens were not used. The success in the model areas at the outset of the program was sufficient to convince the authorities of the municipality to provide full funding as the program was expanded to the whole population, and this treatment has been provided to the entire population free of charge through the resources of the local government. The constraints on implementing successful tuberculosis services were equally in mind in 1977 when the government of Tanzania invited representatives of the International Union Against Tuberculosis, WHO, and the Tanzania Anti-tuberculosis Association to a Meeting on the National Tuberculosis Control Program, financed by the Swiss Association against Tuberculosis, in an attempt to consolidate the sporadic successes achieved in certain parts of the country over the preceding years (34). After this meeting a process was commenced that included the establishment of a panel of national and international participants and a workshop, from which resulted a plan and the establishment of a national committee. The proposal was approved by the Ministry of Health in May 1977 (35). The principles of this program followed those of the Ninth Report of the WHO Expert Committee. Other key components were: A defined structure, with implementation in district health services, a designated health worker responsible to ensure that policies are followed, with support from both an intermediate and central level in order to ensure a regular supply of necessary materials, liaison with other relevant bodies, planning, monitoring, and evaluating services. Standardization of technical policies, including ambulatory treatment with different treatment regimens for new and previously treated patients, procedures for bacteriological monitoring of the results of treatment, case finding focusing on microscopic examination of sputum specimens from patients presenting with symptoms to the routine health services, and vaccination with BCG as part of the expanded program on immunization.
64
Enarson Routine evaluation, monitoring activities, and their results using standardized instruments for recording and reporting as an integral part of the routine activities of the program. An in-built program of research as an essential component of the activities and included in the routine budget of the program.
This program was introduced after intensive training of existing health service personnel and with a concentrated effort of supportive visits to the district medical officers who had responsibility for its implementation. At the outset, treatment of cases never previously given chemotherapy involved a daily regimen lasting 12 months: 2 months of isoniazid, streptomycin, and thioacetazone, followed by 10 months with isoniazid and thioacetazone. Early results of the program were disappointing: success in treatment, at the outset just over 30% of sputum smear–positive cases, rose to 56% within the first several years but stabilized at that level. The failure to achieve a higher level of success was primarily caused by a high proportion of patients who failed to complete their treatment. By 1982, it was clear that the results achieved by the program would not be satisfactory if the current strategy was not revised. At this point, it was decided to introduce a rifampicin-containing chemotherapy regimen for the treatment of new cases who were sputum smear positive, consisting of 8 months of treatment: 2 months of isoniazid, rifampicin, pyrazinamide, and streptomycin followed by 6 months of isoniazid and thioacetazone daily. This was administered under very careful supervision, requiring patients to be admitted to the hospital for direct observation of swallowing of medications in the initial intensive phase of treatment while rifampicin was being given. Results in the first groups of patients were very encouraging, with 89% the patients successfully treated. With the progressive extension of this policy, the overall success rate for the whole country in the treatment of new sputum smear–positive cases approached 80% within several years and has remained at this level ever since. The most important component of success in treatment was a reduction in the proportion of patients failing to complete the full course of their treatment. The proportion of patients dying while taking treatment was already very low (6%) even when the success rate of treatment was low, and this changed very little as the success of treatment improved. There was a decline in the proportion of patients in whom the sputum remained or became again smear positive while taking treatment, but this proportion was relatively small (5%) even at the outset. The decline in proportion of cases failing to complete the full course of treatment was the determining factor in the improvement in treatment results. No systematic evaluation was made of the reasons for the decline in failing to complete treatment. The decline did not begin immediately but lagged 18–24 months after introduction of the revised strategy (36). Patients treated in the pro-
Tuberculosis Control in Low-Income Countries
65
gram pointed out that the community, at the outset, did not believe that tuberculosis was a curable disease, but that it could be controlled only to a certain extent and the moment of death merely delayed. The interaction of groups of patients at various stages in their treatment course at the time that they were in hospital or came together to the ambulatory clinic for the directly observed treatment demonstrated to the patients, their families, and the community that individuals were improving and being permanently cured. This factor was determinative in the increasing proportion of patients who followed their treatment to completion. The health education provided by patient-to-patient interaction was much more powerful than the same health education given by a health worker. Moreover, the daily interaction of patients for directly observed medications provided the opportunity for this interchange. Periodic evaluation of drug susceptibility in a representative sample of patients was undertaken (37). Among patients never previously treated, the proportion of cases resistant to isoniazid was low (10%) and did not change over the three decades evaluated; resistance to both isoniazid and rifampicin (multidrug resistance) was essentially nonexistent and had not appeared in the community by 1988. The most important factor in preventing the emergence of drug resistance, even while using the medications throughout the country, was undoubtedly the policy to ensure that rifampicin was used only in the initial intensive phase of treatment, along with at least three other medications, and to use thioacetazone, along with isoniazid, in the continuation phase. This minimized the period of directly observed treatment and ensured that rifampicin was never used alone with isoniazid in patients in whom initial resistance to isoniazid was not rare. VIII. Effective Strategies for the Management of Tuberculosis A. Generalization of the Strategy
The success achieved in Tanzania was received with some skepticism; the commitment of the government to health care as a priority, the centralized organization of the health service, and the general accessibility of the health service were thought to be reasons for the success. Clearly, the generalizability of the strategy was not accepted. In consequence, and in collaboration with a number of partners, the strategy was extended during the following 5 years to a number of other lowincome countries: Malawi, Senegal, Mozambique, Benin, Nicaragua, Yemen, Mali, and parts of Kenya (areas with nomadic populations). Similar results were obtained in Malawi (38), Mozambique (39), Kenya (40), Benin (41), and Nicaragua (42). The other countries failed to achieve satisfactory results: in Mali, the failure to extend the services into the periphery compromised accessibility; in Senegal, simple failure to follow the principles (in particular, directly observed
66
Enarson
treatment) compromised the results of treatment; in Yemen, both of these errors resulted in equally inadequate results in spite of strong financial inputs. A critical evaluation of the results, particularly those in Tanzania, as part of a larger project termed the “health sector priorities review” undertaken by the World Bank and published in 1989 (43) demonstrated the success of these programs and pointed out their cost-effectiveness. Based on information obtained from Tanzania for patients commencing treatment in 1986, the estimated costs of this treatment were: per case treated, $123 using the 12-month regimen not containing rifampicin and $168 for the 8-month regimen containing rifampicin; $368 and $314 per case cured; $569 and $514 per death averted. The detailed analysis was extended to include Malawi and Mozambique (44). Average costs per case treated using 8-month chemotherapy were $160–217 with hospitalization and $139–196 for ambulatory treatment. The conclusion of this evaluation was that chemotherapy for sputum smear–positive tuberculosis patients is cheaper than other cost-effective health interventions such as immunization against measles and oral rehydration therapy. Further comparison was made and published in the annual report of the World Bank in 1993 (1). In this report, 47 health interventions were compared for cost and effectiveness: chemotherapy for smear-positive tuberculosis was estimated to cost $1–3 per disability-adjusted life-year saved as compared with a cost of more than $10 for measles vaccination; it was estimated to be among the three most cost-effective of the 47 interventions. B. The “Policy Package”
At the time of the retirement of Dr. Styblo as director of scientific activities, a review of the experience of the International Union Against Tuberculosis and Lung Disease (IUATLD) in the collaborative tuberculosis programs was made (45). Up to that point (1988), a total of 109,691 cases of sputum smear-positive tuberculosis who had never previously received chemotherapy had been evaluated in collaborative programs in Tanzania, Malawi, Mozambique, Nicaragua, and Benin. Among these, 52,840 had been given treatment with the 8-month daily regimen containing streptomycin, isoniazid, rifampicin, and pyrazinamide in the initial 2 months of treatment followed by 6 months of daily isoniazid and thioacetazone. The rifampicin was always directly observed to be swallowed (given combined with isoniazid in the same tablet), and the isoniazid and thioacetazone was also provided as a combined preparation. Of these patients, 80% were successfully treated compared with only 56% of those given the 12-month regimen not containing rifampicin. The conditions necessary for achieving success in these programs were: 1.
Political commitment on the part of government, reflected by the establishment of an adequate structure. This included a designated manager within the district (serving, on average, 100,000 population), an in-
Tuberculosis Control in Low-Income Countries
2.
3.
4.
67
termediate-level manager to support the district manager and a central unit for supervision, materials management and training, consisting of a full-time coordinator, as well as logistical support for administration and transport. A secure supply of drugs and materials, including the amount of medications and diagnostic supplies required for regular use as well as a stock (6 months equivalent at central, 3 months equivalent at region, and 3 months equivalent at district levels) to ensure that the supply was never interrupted. A network of microscopy centers with a system of quality control consisting of a binocular microscope and a trained microscopist who, among other duties, carried out sputum smear examinations. Each center was located at the same site as the district manager. Proper recording and reporting of cases, using a standard set of forms and registers: the numbers of cases newly diagnosed and the results of their treatment were recorded and reported on a quarterly basis, based on the “cohort” of patients registered within the same calendar quarter.
In addition, requirements for the introduction of rifampicin-containing treatment regimens were outlined: 1.
2.
3.
Adequate supervision of drug taking during the initial intensive phase, consisting of observing the swallowing of every dose of medication during the period in which rifampicin was being administered. Proper training and supervision of health workers: initial training in the technical policies of the national tuberculosis program was followed by quarterly supportive visits from officers of the program, focusing on the records of patients and interviews with selected individual patients. Step-wise introduction of rifampicin-containing regimens, not at a single point in time. The sites selected for initial introduction were those most likely to achieve success (showing the best results using the 12-month regimen) and gradually but progressively expanded to other sites are thus the majority of patients in the country. Patients unable to participate in direct observation of the swallowing of medications were not given a rifampicin-containing treatment regimen.
This experience was reviewed once again in 1995 (46). From 55,561 cases in 1990 at a total cost of $3.5 million ($63 per case) of donor support, the collaboration increased to include 129,889 cases in 1994 in 26 low-income countries at a cost of $3.0 million ($23 per case). The reduction in cost was primarily due to a reduction in the price of medications obtained through centralized drug procurement with international tender and competitive bidding.
68
Enarson C. The Importance of Action Beyond Medication
While these results were encouraging, they were not sufficient to stimulate an adequate response to address the global problem. The most important achievement was the recognition of tuberculosis as a priority among decision makers and their commitment to providing resources to address it. Three important developments helped to promote this recognition and commitment. The first, and probably most important, was the recognition in the popular press, particularly in the United States, of the threat posed by tuberculosis (47). This recognition had an impact far beyond the borders of the United States and extended to decision makers in low-income countries. The second important development was the evaluation by the World Bank of tuberculosis as a high priority, the management of which was among the most cost-effective of any health intervention in low-income countries. The third was the designation by WHO of tuberculosis as a “global emergency.” Recognition of the cost-effectiveness of interventions in tuberculosis led the World Bank to provide loans to a number of countries, many of which, such as China, India, and Bangladesh, have large numbers of tuberculosis cases. These loans have set in motion revised programs based on the experience of the IUATLD collaborative programs and have reported a high degree of success (48). The priority given by WHO has led to a series of actions that have been indispensible to the extension of tuberculosis services in low-income countries. The declaration of a global emergency raised the visibility of tuberculosis in the various regions where the disease is particularly frequent. The acceptance of the thesis that a great deal can be achieved using existing technology (49) has stressed immediate action. The adoption of the principles of the IUATLD collaborative programs, first in the form of the framework for effective tuberculosis control (50), prepared under the leadership of Dr. Petra Graf, and subsequently, under the user-friendly brand name DOTS, has advanced the awareness of the strategy. Subsequently, the Global Tuberculosis Program of the World Health Organization has been markedly expanded in personnel, budget, and activities and has provided the credibility and leadership that had previously been lacking and that can only be provided by an official, governmental organization if it is to gain the attention of political leaders and other decision-makers. IX. Future Challenges A. Feasibility of Elimination
The objective of tuberculosis services is the elimination of tuberculosis; this identifies the strategy to be employed and the methods of evaluation to be undertaken. Is there good evidence that the application of the strategy has reduced the problem of tuberculosis in low-income countries?
Tuberculosis Control in Low-Income Countries
69
To date there is no incontrovertible evidence that the strategy has dramatically reduced transmission of M. tuberculosis infection in a low-income country. Indirect evidence of the effectiveness of the strategy comes from the experience previously noted in Beijing Municipality, where periodic surveys have shown that the prevalence of cases of tuberculosis has declined rapidly; one can only assume that this must be associated with a decrease in transmission of infection. As expected, the prevalence has declined more rapidly than the rate of newly diagnosed cases. Other indirect evidence comes from Nicaragua (51), where the case-notification rate has declined steadily over the past decade. What is the situation in sub-Saharan Africa? In the countries that have been involved in the IUATLD collaborative programs, case notification has not declined. Indeed, in a number of countries, case rates have risen alarmingly. This is due in large part to the epidemic of acquired immunodeficiency syndrome (AIDS) in these countries (see Chap. 20) (52). The dire predictions of a mathematical model of the impact of the AIDS epidemic on tuberculosis rates in countries of sub-Saharan Africa (53) have been shown to be disturbingly accurate. The impact of AIDS on the global situation of tuberculosis will be substantial as the epidemic spreads in the countries of the Indian subcontinent and Southeast Asia. The only bright spot is that, in spite of the rapid rise in the numbers of tuberculosis cases, it has been possible to maintain a high rate of success of treatment in smear-positive cases. B. Economic Sustainability
While tuberculosis services have been clearly shown to be cost-effective, the increasing economic crisis in many low-income countries has seriously jeopardized the possibility that these services can be routinely provided and sustained over the long term. This situation is leading to increasing donor dependence at a time of “donor fatigue.” If the strategy is donor-dependant, it will not be sustainable in the long term because it calls for efficient application for the duration of a full generation if it is to be effective. Moreover, the increasing reliance on bank loans will only compound the economic crisis as inflation and currency devaluation follow the decline in productivity over the short term. C. Maintenance of the Health Services
The economic crisis affecting many low-income countries and accompanying health sector reform (see Chap. 33) has reduced the number of health care workers, peripheralized decision making, and encouraged privatization of health services. The usual structure of tuberculosis services in the successful models may require revision. This is particularly true where the numbers of cases of tuberculosis are rapidly rising and accessibility to services is already compromised in consequence. Whether cost-effective tuberculosis services can be provided by the
70
Enarson
private sector in low-income countries is not clear. Moreover, the support required from central and regional levels for quality assurance of services in peripheral health facilities may be increasingly difficult to provide as the health sector reform process proceeds. D. Drug Resistance
The wide distribution of resistance, first to isoniazid (54) and then to both isoniazid and rifampicin (55), in low-income countries will be a threat to continued success of the tuberculosis services because cost-effective alternative treatment strategies are simply not available, nor are they expected in the near future. The importance of rapidly implementing the present strategy as a means of preventing further development and spread of drug resistance cannot be overemphasized (56). The ability of the strategy, and particularly the rigorous observation of administration of medications, to prevent the appearance of multidrug resistance has been shown where the strategy has been followed (57). The strategy incorporates specific measures to protect rifampicin, including never using it alone with isoniazid (unnecessary where thioacetazone is used in the continuation phase) (Fig. 3), always using it combined with isoniazid in preparations of proven bioavailability, and observing the swallowing of every dose of medication where rifampicin is given. This is in contrast with the situation where the strategy has not been followed (58). Where case rates can be expected to rise rather than decline, the least that can be done is to ensure that the development of multidrug resistance is minimized. It is highly unlikely that new medications will become available for use in low-income countries in the near future.
Figure 3. Balance of recommended regimens for treatment of new and retreatment cases of tuberculosis, outlining the medications in retreatment not previously used for new cases. Principles are as follows: Assume H resistance, always a companion to R never previously used alone with H. Assume that the patient is incurable when resistant to both H and R.
Tuberculosis Control in Low-Income Countries
71
References 1. World Development Report 1993: Investing in Health. Oxford: Oxford University Press, 1993. 2. Enarson DA. Why not the elimination of tuberculosis? Mayo Clin Proc 1994; 69: 85–86. 3. Brudney K, Dobkin J. A tale of two cities: tuberculosis control in Nicaragua and New York City. Sem Respir Inf 1991; 6:261–272. 4. Enarson DA, Rouillon A. The epidemiological basis of tuberculosis control. In: Davies PDO, ed. Clinical Tuberculosis London: Chapman Hall Medical, 1993:19–32. 5. Grzybowski S, Barnett GD, Styblo K. Contacts of cases of active pulmonary tuberculosis. Bull Int Un Tuberc 1975; 50:90–106. 6. Calmette A, Negre L, Boquet A. Essai de vaccination du lapin et du cobaye contre l’infection tuberculeuse. Ann Inst Pasteur 1922; 36:625–635. 7. Sutherland I, Lindgren I. The protective effect of BCG vaccination as indicated by autopsy studies. Tubercle 1979; 60:225–231. 8. Styblo K, Meijer J. Impact of BCG vaccination programmes in children and young adults on the tuberculosis problem. Tubercle 1976; 57:17–43. 9. Ferebee SH, Mount FW. Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. Am Rev Respir Dis 1962; 85: 490–510. 10. Crofton J. The contribution of treatment to the prevention of tuberculosis. Bull Int Union Tuberc 1962; 32:643–653. 11. Kamat SR, Dawson JJY, Devadatta S, Fox W, Janardhanam B, Radhakrishna S, Ramakrishnan CV, Somasundaram PR, Stott H, Velu S. A controlled study of the influence of segregation of tuberculous patients for one year on the attack rate of tuberculosis in a 5-year period in close family contacts in South India. Bull WHO 1966; 34: 517–532. 12. Rouillon A, Perdrizet S, Parrot R. Transmission of tubercle bacilli: the effects of chemotherapy. Tubercle 1976; 57:275–299. 13. Bleiker MA, Griep WA, Beunders BJW. The decreasing tuberculin index in Dutch recruits. KNCV Selected Papers 1964; 8:38–49. 14. Grzybowski S, Styblo K, Dorken E. Tuberculosis in Eskimos. Tubercle 1976; 57 (suppl. 4):S1–S58. 15. Nakielna EM, Cragg R, Grzybowski S. Lifelong follow up of inactive tuberculosis: its value and limitations. Am Rev Respir Dis 1975; 112:765–772. 16. Styblo K, Dankova D, Drapela J, et al. Epidemiological and clinical study of tuberculosis in the district of Kolin, Czechoslovakia. Bull WHO 1967; 37:819–874. 17. Nsanzumuhire H, Lukwago EW, Edwards EA, Stott H, Fox W, Sutherland I. A study of the use of community leaders in case-finding for pulmonary tuberculosis in the Machakos district of Kenya. Tubercle 1977; 58:117–128. 18. Lotte A (rapporteur). Results of the multiple radiophotography reading trial performed in 1963. Bull Int Union Tuberc 1965; 38:61–72.
72
Enarson
19. National Tuberculosis Association. Recommendations of the Arden House Conference on tuberculosis. Am Rev Respir Dis 1960; 81:482–484. 20. International work in tuberculosis 1949–1964. Geneva: World Health Organization, 1965. 21. United States Public Health Service Tuberculosis Therapy Trials. Long-term consequences of isoniazid alone as initial therapy. Am Rev Respir Dis 1960; 81:824–830. 22. Halfdan Mahler. “Posthumous” letter to Dr. Holm. Bull Int Union Tuberc 1990; 65 (4):82. 23. Waaler H, Geser A, Andersen S. The use of mathematical models in the study of the epidemiology of tuberculosis. Am J Public Health 1962; 6:1002–1013. 24. World Health Organization. WHO Expert Committee on Tuberculosis, Eighth Report. Geneva: WHO Technical Report Series 290, 1964. 25. World Health Organization. WHO Expert Committee on Tuberculosis, Ninth Report. Geneva: WHO Technical Report Series 552, 1974. 26. Bulla A. World health statistics report: tuberculosis patients—how many now? WHO Chron 1977; 31:35–40. 27. Styblo K, Rouillon A. Estimated global incidence of smear-positive pulmonary tuberculosis. Unreliability of officially reported figures on tuberculosis. Bull Int Union Tuberc 1981; 56:118–126. 28. Grzybowski S, Enarson DA. The fate of cases of pulmonary tuberculosis under various treatment programmes. Bull Int Union Tuberc 1978; 53:70–75. 29. Report on the Third Tuberculosis Prevalence Survey in Korea. Seoul: Korean National Tuberculosis Association, 1975. 30. Nationwide random survey for the epidemiology of pulmonary tuberculosis conducted in 1979. Chin J Respir Dis 1981; 5:67–71. 31. Frimodt-Moller J. Changes in tuberculosis prevalence in a south Indian rural community following a tuberculosis control programme over a seven years’ period. Ind J Tuberc 1962; 9:187–191. 32. International Union Against Tuberculosis/World Health Organization. Tuberculosis Control. Geneva: World Health Organization Technical Report Series 671, 1982. 33. Zhang L-X, Kan G-Q. Tuberculosis control programme in Beijing. Tuber Lung Dis 1992; 73:162–166. 34. L Stirling. Address to the National TB Workshop, Arusha, Tanzania, February 24, 1977. 35. International Union Against Tuberculosis. Tanzania National Tuberculosis Programme. Bull Int Union Tuberc 1977; 52:53–64. 36. Enarson DA, Hopewell PC. Treatment of tuberculosis in low income countries. In: Gangadharam PRJ, Jenkins PA, eds. Mycobacteria II: Chemotherapy. New York: Chapman and Hall, 1997:161–182. 37. Chonde TM. The role of bacteriological services in the National Tuberculosis and Leprosy Programme in Tanzania. Bull Int Union Tuberc 1989; 64:37–39. 38. Nuyangulu DS, Nkhoma WN, Salaniponi FML. Factors contributing to a successful tuberculosis control programme in Malawi. Bull Int Union Tuberc Lung Dis 1990/1991(suppl); 66:45–46. 39. Salomao MA, Parkkali LM. Case-finding and treatment results of pulmonary tuberculosis in Mozambique, 1985–1988. Bull Int Union Tuberc Lung Dis 1990 /1991 (suppl); 66:47–49.
Tuberculosis Control in Low-Income Countries
73
40. Idukitta GO, Bosman MCJ. The tuberculosis Manyatta Project for Kenyan nomads. Bull Int Union Tuberc Lung Dis 1990/1991(suppl); 66:44–47. 41. Gninafon M. The antituberculosis programme of Benin. Bull Int Union Tuber Lung Dis 1990/1991(suppl); 66:57–58. 42. Arguello L. Results of the tuberculosis control programme in Nicaragua in 19841989. Bull Int Union Tuberc Lung Dis 1990 /1991(suppl); 66:51–52. 43. Murray CJL, Styblo K, Rouillon A. Tuberculosis in developing countries: burden, intervention and cost. Bull Int Union Tuberc Lung Dis 1990; 65:2–20. 44. Murray CJ, DeJonghe E, Chum HJ, Nyangulu DS, Salomao A, Styblo K. Cost-effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries. Lancet 1991; 338:1305–1308. 45. Enarson DA. Principles of IUATLD Collaborative National Tuberculosis Programmes. Bull Int Union Tuberc Lung Dis 1991; 66:195–200. 46. Enarson DA. The International Union Against Tuberculosis and Lung Disease model National Tuberculosis Programmes. Tuber Lung Dis 1995; 76:95–99. 47. Reichman LB. The U-shaped curve of concern. Am Rev Respir Dis 1991; 144:741– 742. 48. China Tuberculosis Control Collaboration. Results of directly observed short-course chemotherapy in 112,842 Chinese patients with smear-positive tuberculosis. Lancet 1996; 347:358–362. 49. Styblo K. The epidemiological situation of tuberculosis and the impact of control measures. Bull Int Union Tuberc 1983; 58:179–186. 50. World Health Organization. Framework for effective tuberculosis control. Geneva: WHO / TB/CARG(4)/94.3, 1994. 51. Cruz JR, Heldal E, Amadottir T, Juarez I, Enarson DA. Tuberculosis case finding in Nicaragua: evaluation of routine activities in the control programme. Tuber Lung Dis 1995; 75:417–422. 52. Chum HJ, O’Brien RJ, Chonde TM, Graf P, Rieder HL. An epidemiological study of tuberculosis and HIV infection in Tanzania, 1991–1993. AIDS 1996; 10:299–309. 53. Schulzer M, Fitzgerald JM, Enarson DA, Grzybowski S. An estimate of the future size of the tuberculosis problem in sub-Saharan Africa resulting from HIV infection. Tuber Lung Dis 1992; 73:52–58. 54. Kleeberg HH, Olivier MS. A World Atlas of Initial Drug Resistance. 2d ed. Pretoria: Tuberculosis Research Institute of South African Medical Research Council, 1984. 55. World Health Organization. Anti-tuberculosis drug resistance in the world. Geneva: WHO / TB/97.229, 1997. 56. Chonde TM. The role of bacteriological services in the National Tuberculosis and Leprosy Programme in Tanzania. Bull Int Union Tuberc 1989; 64:37–39. 57. Anagonou SY, Gninafon M, Kinde-Gazard D, Tawo L, Trebucq A, Boulahbal F. Etude de resistance primaire des mycobacteries tuberculeuses aux antibacillaires: une enquete nationale au Benin 1995–1997. Int J Tuber Lung Dis 1997; 5(suppl.):S28. 58. Rodier G, Gravier P, Sevre J-P, Binson G, Omar CS. Multidrug-resistant tuberculosis in the horn of Africa. J Infect Dis 1993; 168:523–524. 59. Bjartveit K. The tuberculosis situation in Norway. Scand J Respir Dis 1978, 102:28–35.
3 Tuberculosis Control in Low-Prevalence Countries
JAAP F. BROEKMANS Royal Netherlands Tuberculosis Association (KNCV) The Hague, The Netherlands
I. The Prospect of Elimination A. Elimination in the Indigenous Population
Tuberculosis remains one of the world’s major public health challenges, causing more than 2 million (mostly young) adult deaths per year. The scale of the problem is such that in 1993 the World Health Organization (WHO) was forced to declare tuberculosis a “global emergency.” This somber picture hides the overall success of tuberculosis-control efforts in most of the industrialized countries. After the Second World War, most industrialized countries successfully moved from high to low tuberculosis prevalence in little more than a generation by effectively treating infectious cases in well-established tuberculosis networks. For example, in the Netherlands the decline in the risk of infection was 4–5% per year between the two world wars, and with the introduction of modern chemotherapy this decline further increased to 13% per year after World War II (Fig. 1) (1). Case rates followed suit (Fig. 2) (1b,2). The tremendous impact of these measures on the tuberculosis situation in the Netherlands is best understood by observing the estimated prevalence of Mycobacterium tuberculosis by age in the indigenous population of the Netherlands in 1940, 1970, 2000, and 2030. In 2030 the prevalence of infection in the Dutch 75
Figure 1 1a.)
Annual risk of tuberculous infection: the Netherlands, 1910–1979. (From Ref.
Figure 2 Annual risks of tuberculous infection and incidence of new active tuberculosis in subjects aged 0–14, 15–19, 20–24, and 25–29 years, the Netherlands, 1952–1970. (From Refs. 1b,2.)
Tuberculosis Control in Low-Prevalence Countries
77
Figure 3 Estimated prevalence of tuberculous infection prevalence by age, the Netherlands, 1940, 1970, 2000, 2030. (From Ref. 3.)
population will be less than 1% and the incidence of smear-positive tuberculosis is expected to be below 1 per million, the conventional limit of elimination (Fig. 3) (3). Further evidence as to the prospect of elimination can be derived from the decline in the incidence of new bacillary pulmonary cases in the Netherlands. The rates of such cases (foreigners excluded) from 1973–1976 to 1993–1995 declined from 3.7 per 100,000 to 2.4 per 100,000 (Table 1). Moreover, age-specific rates show a marked shift to higher age group, consistent with the underlying shift to higher age groups of the prevalence of infection (Fig. 4). An emerging international consensus defines a low-prevalence country as a country with a reliable case rate (all cases) of 20 per 100,000 and declining. Most industrialized countries fit in this category, although some countries like Spain and Portugal still have rates higher than 40 per 100,000 (Fig. 5). Thus, countries with case rates of 20 per 100,000 and declining can be considered to be in the elimination phase of the disease. However, elimination in low-
78
Broekmans
Table 1 Average Annual Notification Rates of Bacteriologically Confirmed Pulmonary Tuberculosis (New Cases Only, Foreigners Excluded) per 100,000 Population, The Netherlands, 1973–1996
Male Female All a b
1973–1976a (P/100,000)
1977–1980a (P/100,000)
1981–1984a (P/100,000)
1993–1996b (P/100,000)
4.9 2.6 3.7
3.9 2.4 3.2
3.5 2.0 2.7
2.6 1.6 2.1
Source: Ref. 3a. Source: Ref. 4.
prevalence countries, given the extent of the underlying high prevalence of infection in older age groups, will take at least another 30–50 years, for which period tuberculosis-control activities, preferably in the context of a national program, must be maintained. B. The Impact of Migration on Low-Prevalence Countries
Since 1992 more than half of all tuberculosis cases in the Netherlands have been among foreigners (Fig. 6). DNA fingerprint technology made it possible to study the impact of migration on the native Dutch tuberculosis situation. From a study
Figure 4 Age-specific rates of infectious cases (Dutch), by age, the Netherlands, 1973–1984 and 1993–1996. (From Ref. 4.)
Figure 5
Incidence rate of notified tuberculosis, 1995, WHO European region. (From Ref. 11.)
Tuberculosis Control in Low-Prevalence Countries 79
80
Figure 6 Ref. 4.)
Broekmans
Notified tuberculosis cases (all forms), the Netherlands, 1974–1996. (From
in 1993–1995 involving all infectious pulmonary cases, it has been concluded that (1) 17% of native Dutch cases can be attributed to recent transmission from a foreign source, (2) 15% of native Dutch cases can be attributed to recent transmission from a native Dutch source, and (3) 68% of cases had a unique DNA fingerprint (or were assigned as the source case of a cluster) and could be attributed to exacerbation of latent infection and not from recent transmission (Fig. 7).
Figure 7
Dutch tuberculosis cases by transmission category.
Tuberculosis Control in Low-Prevalence Countries
81
In addition to the excess transmission from foreign sources, native cases in low-prevalence countries occur due to infection acquired during travel in highprevalence countries. For example, it is reported that 61 (2%) of 3070 Dutch cases reported in 1993–1996 most likely were due to infection acquired outside the Netherlands (4). An extremely rare situation occurred in 1993–1997 in the Netherlands, when a single infectious source from outside the country caused at least 400 infections and more than 50 bacteriologically confirmed secondary cases. This ongoing cluster epidemic, which could only be studied with DNA fingerprint technology, is characterized by an unusually long patient’s and doctor’s delay in diagnosing the source case, which was a rather asymptomatic illness (5). The initial patient’s social life was extremely active. From the above it can be concluded that migration from countries with a high disease prevalence influences cases rates in low-prevalence countries and even has a distinct effect on transmission. Given the underlying trend in the prevalence of infection in the indigenous population, however, such migration at current rates is unlikely to delay elimination more than a few years. C. Impact of HIV Transmission
The effect of HIV transmission on the elimination of tuberculosis in low-prevalence countries will depend on the “overlap” between the prevalence of tuberculous and that of HIV infection in the population studied. In the Netherlands, the general population younger than 50 years of age is virtually free of tuberculous infection. The prevalence of tuberculous infection for those aged 15–54 years—the age group most vulnerable for HIV transmission—was only 7.1% in 1985 and 2.7% in 1995 (Fig. 3). Although excess cases of tuberculosis will occur due to HIV transmission, this will not result in a subsequent distinct deterioration of the tuberculosis situation in the Netherlands as a whole. In 1993–1996 116 (4.1%) of 2885 Dutch and 146 (4.3%) of 3411 foreign tuberculosis patients were reported to be HIV positive (4). However, because HIV testing is not encouraged, these data are not representative, and the precise interaction between the HIV epidemic and the tuberculosis situation in the Netherlands is not well documented. II. Framework for Tuberculosis Control in LowPrevalence Countries In 1993 WHO published the “Framework for Effective Tuberculosis Control,” which essentially encapsulates the DOTS (directly observed therapy, short course) strategy for high-prevalence countries. No such framework document exists for low-prevalence countries. The decline in disease incidence, the health sec-
82
Broekmans
tor reforms, and the shift towards outbreak management of tuberculosis control have major consequences for network maintenance and control activities. A. Consequences of the Decline in Disease Incidence
In a low-prevalence country tuberculosis essentially becomes a rare disease. At the level of the health care provider, a decline in practical experience will result in a decline of expertise in both the clinical and public health management of the disease. At programmatic level a categorical tuberculosis network becomes unsustainable and for this reason needs to be integrated with other public health programs (e.g., other infectious disease programs). A multifunctional approach after such an integration has a diluting effect on the expertise, especially in the public health management of the disease (Fig. 8). In the Netherlands 400 chest physicians and 40 tuberculosis control officers take care of 800 infectious cases annually. After integration in the infectious disease departments of the Municipal Health Services in the early 1990s, 80 multifunctional public health nurses (instead of 40 previously assigned to tuberculosis cases only) became responsible for approximately the same number of tuberculosis patients. B. Consequences of the Health Sector Reform
Most industrialized countries experienced health sector reforms resulting in a decentralization of responsibilities and funding of the management of public health programs. Such developments fragment national tuberculosis networks (Fig. 9). In the Netherlands health sector reform carried out in the early 1990s decentralized funding (from an earmarked national subsidy to a nonearmarked, multipurpose municipal grant) and responsibilities for the tuberculosis program management to 45 administratively autonomous Municipal Health Services.
Figure 8
Consequences of the decline of disease incidence.
Tuberculosis Control in Low-Prevalence Countries
Figure 9
83
Consequences of health sector reform.
C. Consequences of the Shift Toward Outbreak Management
Three distinct but very much interrelated developments elucidate a marked shift towards a more focused public health response during the elimination phase of the disease, best described as shifting away from passive case finding and toward outbreak management (Fig. 10). Occurrence of Microepidemics
In the elimination phase, in which the great majority of the younger population is virtually free of tuberculosis infection, the occurrence of microepidemics becomes a discernible epidemiological event. Microepidemics require a highly specialized public health response, based on the “stone in the pond principle.” Such outbreaks are often characterized by a single source of infection with a marked patient and/or doctor’s delay. A specific institutional environment (e.g., discotheque, school, or prison) may facilitate transmission to a multitude of contacts (see Chap. 15).
Figure 10 Consequences of shift towards outbreak management.
84
Broekmans Emergence of High-Risk Groups
During the elimination phase, in which the great majority of the young population is virtually free of infection, specific high-risk groups tend to be characterized by a higher prevalence of infection and/or disease than the general population. Such high-risk groups are often characterized by socially marginalized conditions. In the Netherlands, drug abusers, homeless persons, prisoners, and the foreign-born from high-prevalence countries have been found to have higher rates of tuberculosis. Identifiable high-risk groups thus become accessible for active case finding. In the Netherlands a high-risk group is characterized by a registered tuberculosis incidence (all cases) of 50 per 100,000 or more (6). Active case finding in such groups becomes the policy of choice where the following conditions are met: Passive case finding well organized Favorable treatment results (80%) in patients diagnosed by passive case finding Built-in evaluation of coverage and yield of the target population Treatment outcome monitoring Activities in accordance with ethical and legal regulations The importance of active case finding in high-risk groups is illustrated by the coverage and yield of screening asylum seekers on entry in the Netherlands in 1993–1996 (Table 2) (7). Introduction of DNA Fingerprint Technology
DNA fingerprint technology may revolutionize tuberculosis control in low-prevalence countries because of its ability to detect recent transmission (see Chap. 11). The application of this technology in a control program clarified and elucidated the epidemiological situation in the country as a whole, as well as the emergence Table 2 Tuberculosis Among Asylum Seekers Screened on Entry, The Netherlands, 1993–1996 Asylum seekers Examined Year 1993 1994 1995 1996
N
%
31,578 (90%) 42,939 (95%) 24,424 (97%) 17,919 (90%)
Source: Ref. 7.
Tuberculosis cases on entry
Total
All cases
Infectious PTB
N
N
p/100,000
N
p/100,000
35,000 45,202 25,089 19,868
137 149 94 52
434 347 385 290
46 61 40 26
146 142 164 145
Tuberculosis Control in Low-Prevalence Countries
85
of high-risk groups and so-called cluster epidemics in particular. The specific “added value” of the application of this technology in routine program management is still limited, but its potential in identifying outbreaks in special settings, only suspected to occur in earlier decades, makes it potentially an extremely powerful new tool in tuberculosis control in low-prevalence countries. The great challenge to program management will be to demonstrate the specific role of this technology in the actual control of cluster epidemics. The occurrence of microepidemics, the emergence of high-risk groups, and the ability to substantiate recent transmission by DNA fingerprint technology are characteristic for the shift towards outbreak management that is due to occur in the elimination phase of tuberculosis. Away from but definitively not excluding the emphasis on passive case finding, this shift toward outbreak management constitutes a paradigm shift in control technology. D. Program Support and Coordination
Declining expertise due to declining incidence and integration of services, the danger of fragmentation of the tuberculosis network, and, moreover, the unmistakable shift toward outbreak management require urgent reassessment as to maintain an adequate tuberculosis network during the elimination phase of the disease (Fig. 11). In the Netherlands the national support and coordination functions were reexamined against that background. Key (government) functions and supportive (nongovernmental) functions were delineated (Table 3). Key functions are vital for the support and coordination of the tuberculosis network. Supportive functions add value to the activities of the tuberculosis network. Within the network itself it is of major importance to continue to have identifiable and accountable staff (e.g., tuberculosis control officers, public health nurses) to guide and execute program implementation.
Figure 11 Key issues within the tuberculosis network in the elimination phase.
86
Broekmans Table 3
Key and Supportive Functions for Program Maintenance
Key functions for program maintenance: Consensus-based technical and policy guidelines Consensus-based system of quality assurance Surveillance Program monitoring Technical support by national consultants Supportive functions for program maintenance: Graduate/Postgraduate training Development of health-education material Research Documentation center International collaboration
E. Legal Framework
There exists a growing awareness of the importance of a legal framework to guide program policies. In most industrialized countries such a legal framework underlies most tuberculosis control activities. Surveillance, specific interventions such as screening of foreigners on entry, prisoners, sailors etc., mandatory isolation of noncompliant infectious patients, and even the specific functions of a tuberculosis clinic are often written in special laws or other official government documents. The distinct importance of a transparent and, from the public health point of view, up-to-date legal framework is not very well known. Research in this area is urgently needed for this reason as well as for the benefit of the implementation of WHO DOTS strategy in high-prevalence countries.
III. Surveillance A. Surveillance of Infection
The annual tuberculosis infection rate is the best single indicator for evaluating the tuberculosis problem and its trend in developed and developing countries. It is an index that expresses the attacking force of tuberculosis within a given population and, unlike disease notification rates, is not linked directly to the case-finding and treatment measures of the tuberculosis program. In the Netherlands the decline of the risk of infection was 13% annually in 1956–1965, 10.4% in 1966–1979, and 8.3% in 1979–1991 (Fig. 12). It is estimated that the annual rate of infection in the Netherlands was less than 10 per 100,000 in the mid-1990s.
Tuberculosis Control in Low-Prevalence Countries
87
Figure 12 Prevalence of tuberculous infection and annual risk of tuberculous infection, the Netherlands, 1956–1991. (From ITSC/TSRU, unpublished.) B. Surveillance of Recent Transmission
Introduction of DNA fingerprint technology in control programs in low-prevalence countries enables the identification of cluster epidemics and may open the way to control the size of these clusters (Table 4). The use of DNA fingerprint Table 4
The Four Largest Cluster Outbreaks, The Netherlands, 1991–1997
Number of cases with identical DNA fingerprint from January 1, 1991 66 55 50 41 Source: Ref. 8.
Notification of first source case
Cluster growth in 1997
July 1991 March 1993 July 1993 December 1992
11 10 6 13
Nature of cluster (proportion attributed) Homeless/Drug abusers (77%) Related to foreign source (92%) Homeless/Drug abusers (60%) Asylum seekers (Ethiopia/ Somalia) (95%)
88
Broekmans
technology often validates routine contact examinations and contributes to the identification of epidemiological links previously unsuspected (8). C. Surveillance of Disease
Notification of New and Relapse Cases
The notification rates of new and relapse cases in low-prevalence countries are of greatest value in evaluating the overall epidemological situation. In general, significant intracountry differences exist in the trend and level of notification. Resurgent tuberculosis in central Harlem in New York City was attributed to the effects of HIV transmission, homelessness, and the premature disintegration of the tuberculosis program. Implementation, at great cost, of standard control measures redressed the situation effectively. Even in a small country like the Netherlands, notification rates may differ from 25–35 (all cases) per 100,000 in major metropolitan areas to 5–10 (all cases) per 100,000 in more rural areas. Notification Rates for Infectious Pulmonary Tuberculosis
Notification rates of infectious pulmonary tuberculosis provide a sensitive measure for the occurrence of sources of infections in the population and its trend towards elimination (Table 1 and Fig. 4). Surveillance of Drug Resistance
Systematic surveillance of initial drug resistance in new cases and acquired resistance in retreatment cases may be of importance for both epidemiological surveillance as well as a measure of program performance. A special study concluded that in the Netherlands three quarters of all drugresistant cases occur in foreign-born persons (9). The great majority of these patients were infected or poorly treated in their country of origin. Thus, the rates of drug resistance in tuberculosis cases in the foreign-born in the Netherlands do not reflect the actual program performance in the Netherlands (Table 5). In the same Table 5
Drug-Resistant Pulmonary Tuberculosis, The Netherlands, 1993–1995
Isoniazid Streptomycin Rifampicin Other anti-TB drugs Any drug resistance Source: Ref. 4.
Asylum seekers, N 351 (%)
Other foreigners, N 786 (%)
Dutch N 1089 (%)
14 14 3 4 22
8 9 2 1 15
3 3 1 1 6
Tuberculosis Control in Low-Prevalence Countries
89
study it was observed that in Dutch patients both acquired and primary drug resistance were rare. The high mean age of Dutch patients with drug-resistant tuberculosis suggests that this level of drug resistance mostly reflects program performance of a more distant past (9). D. Surveillance of Mortality
In low-prevalence countries, mortality rates are of only historical value in indicating the extent of the tuberculosis problem and its trend. With the introduction of effective chemotherapy after World War II, mortality rates have been reduced to very low levels. IV. Program Monitoring A. Surveillance of Diagnostic Measures
Patient and Doctor Delay
Patient and doctor delays in the diagnosis of sources of infection, an inevitable phenomenon of a case-finding and treatment program, is of importance because it contributes to transmission and microepidemics. Routine surveillance data from the Netherlands, compared with earlier studies, suggest an increased patient and doctor delay for Dutch patients. This observation may be consistent with the fact that tuberculosis is becoming a rare disease for Dutch patients and Dutch physicians. The comparatively shorter delays for foreign-born patients could be consistent with active case finding among foreigners and/or greater awareness among physicians that tuberculosis is still a problem among foreign-born persons (Table 6). Further studies are necessary to validate these findings. Table 6 Patient and Doctor Delay Bacteriologically Confirmed Pulmonary Tuberculosis Patients, The Netherlands, 1973–1996 1973–1976a Months
N
1–2 1346 3–4 713 5 or more 468 Total 2527 No 78 information a b
Source: Ref. 3a. Source: Ref. 4.
1977–1980a
1981–1984a
1993–1996b Dutch
1993–1996b Foreigners
%
N
%
N
%
N
%
N
%
53 28 19 100 3
1136 601 450 2187 52
52 27 21 100 2
996 469 374 1839 77
54 26 20 100 4
326 203 217 746 142
44 27 29 100 16
455 187 165 807 156
56 23 20 100 16
90
Broekmans Table 7
Mode of Detection, The Netherlands, 1993–1996 1993–1996
Case finding Active case finding (screening) Passive case finding (complaints) Other/Unknown Total
N
%
1671 4482 492 6645
25 67 7 100
Source: Ref. 4.
Mode of Detection
In low-prevalence countries, in addition to passive case finding among self-reporting suspects, active case finding by screening of risk groups and the containment of microepidemics and cluster epidemics has become progressively more important. For example, in the Netherlands in 1993–1996, 25% of cases were detected by active case finding (Table 7). In the Netherlands in 1993–1996, 50% of patients were diagnosed by chest physicians, 21% by other clinical specialists, and 29% by tuberculosis control officers of a Municipal Health Service (Table 8) (4). B. Surveillance of Treatment Measures
Treatment-Outcome Monitoring of Infectious Pulmonary Cases
The first aim of a tuberculosis program is to cure all (or nearly all) sources of infection. To what extent the treatment results achieved in a tuberculosis program approximate the results obtained in controlled clinical trials is the most important issue in the surveillance of treatment measures.
Table 8 Mode of Detection, The Netherlands, 1993–1996 1993–1996 Diagnosing physician Chest physician Other specialist TB control officer Total Source: Ref. 4.
N
%
3294 1448 1903 6645
50 21 29 100
Tuberculosis Control in Low-Prevalence Countries
91
Table 9 Treatment Outcome Monitoring of Infectious Dutch Cases, The Netherlands, 1993–1996
Treatment result Total (N) Cured/Completed Interrupted Died (TB) Died (non-TB) Transferred out
1993 (%)
1994 (%)
1995 (%)
1996 (%)
(329) 74.5 7.9 3.3 12.5 1.2
(410) 81.2 5.9 1.7 11.2
(368) 80.4 4.3 3.0 11.7 0.5
(410) 84.4 2.0 3.7 10.0
Total N
%
1517 1224 74 44 171 4
100 80.3 4.9 2.9 11.2 0.4
Source: Ref. 4.
In the Netherlands the treatment success rate in Dutch infectious pulmonary cases was 80% for the period 1993–1996 (Table 9). The treatment success rate would be substantially higher if it was corrected for the relatively high case fatality due to other diseases than tuberculosis. The treatment success rate in nonDutch infectious pulmonary cases (Table 10) was 83% in the same period, with a markedly higher interrupted rate of 9.1% than in the Dutch cohort 4.9%. The importance of treatment outcome monitoring in specific subgroups is demonstrated by the fact that among asylum seekers 10% interrupted treatment in 1993–1996 (Table 11) (4). Directly Observed Treatment
The great majority of patients in low-prevalence countries are treated by medication self-administration. With an increasing proportion of patients coming from Table 10 Treatment Outcome Monitoring of Infectious Non-Dutch Cases, The Netherlands, 1993–1996 Total
Treatment result
1993 (%)
1994 (%)
1995 (%)
1996 (%)
N
Total (N) Cured/Completed Interrupted Died (TB) Died (non-TB) Transferred out
(429) 79.7 11.2 1.2 3.3 4.4
(453) 78.4 12.4 0.7 2.2 6.4
(401) 85.8 6.5 0.5 1.5 5.7
(420) 86.9 6.0 0.7 1.4 5.0
1703 1411 155 13 36 88
Source: Ref. 4.
% 100 82.6 9.1 0.8 2.1 5.4
92
Broekmans
Table 11 Treatment Outcome Monitoring of Infectious Asylum Seekers Only, The Netherlands, 1993–1996
Treatment result Cured/Completed Interrupted Died (TB) Died (non-TB) Transferred out Total
1993 (N)
1994 (N)
1995 (N)
1996 (N)
90 11 1
116 18 1
128 13
112 10
7 109
6 141
1 2 144
3 125
Total N
%
446 52 2 1 18 519
85.9 10.0 0.4 0.2 3.5 100
Source: Ref. 4.
specific risk groups and proportionally more patients detected by active case finding, direct observed treatment becomes an increasingly important intervention (see Chap. 16). Based on a special survey, it was observed that in 1996 at least 78 (4.6%) of 1678 cases reported in the Netherlands were put on direct observed treatment (10). References 1. Styblo K, Meijer J, Sutherland I. The transmission of tubercle bacilli. Its trend in a human population. Tuberculosis Surveillance Research Unit Report No. 1. Bull Int Un Tuberc 1969; 42:5–104. 1a. Sutherland I, Bleiker MA, Meijer J, Styblo K. The risk of tuberculous infection in The Netherlands from 1967 to 1979. Tubercle 1983; 64:241–253. 1b. Styblo K. Epidemiology of Tuberculosis. In: Selected papers, Vol. 24, KNCV, The Hague, The Netherlands. 2. Styblo K, Meijer J. Impact of BCG vaccination programmes in children and young adults on the tuberculosis problem. Tubercle 1976; 57:17–43. 3. Styblo K. The elimination of tuberculosis in the Netherlands. Bull Int Un Tuberc 1990; 65:49–55. 3a. van Geuns HA, Hellinga HS, Bleiker MA, Styblo K. Surveillance of diagnostic and treatment measures in The Netherlands. Comparison between the periods 1971–1976, 1977–1980, and 1981–1985. Tuberculosis Surveillance Research Unit of the International Union Against Tuberculosis. Progress Report 1987; 1:60–81. 4. Index Tuberculosis 1993–1996. Netherlands Tuberculosis Register (NTR/KNCV). The Hague, The Netherlands, 16 Feb 1998. 5. Kiers A, Drost AP, Soolingen D van, Veen J. Use of DNA fingerprinting in international source case finding during a large outbreak of tuberculosis in the Netherlands. Int J Tuberc Lung Dis 1997; 1:239–245. 6. Tuberculosis Control in High Risk Groups in The Netherlands. Netherlands Tuberculosis Policy Committee/KNCV, The Hague, The Netherlands, 1997.
Tuberculosis Control in Low-Prevalence Countries
93
7. Annual Reports 1993–1996 Tuberculose-screening asielzoekers in opvangcentra. Regio Noord en Zuid Nederland, Municipal Health Service Tilburg and Municipal Health Service Lelystad. 8. Data from KNCV/RIVM Surveillance Project, The Hague/Bilthoven, The Netherlands. 9. Lambregts-van Weezenbeek CSB. Drug-resistant tuberculosis in the Netherlands: trifle or threat? Thesis, University of Amsterdam, 1998. 10. Verhagen M. DOT in Nederland. Ervaringen met en meningen over directly observed therapy bij door Nederlandse GGD’en georganiseerde tuberculosebestrijding. Venlo, The Netherlands, 1998. 11. Euro TB Surveillance of Tuberculosis in Europe. Report on the feasibility study (1996–1997). Tuberculosis cases notified in 1995. European Centre for the Epidemiological Monitoring of AIDS (CESES) and Royal Netherlands Tuberculosis Association (KNCV), Saint Maurice, 1997.
4 Tuberculosis Laboratories The Centerpiece of National Tuberculosis Control Programs
ADALBERT LASZLO Health Canada, Ottawa, and International Union Against Tuberculosis and Lung Disease Nepean, Ontario, Canada
I. Introduction By March 1882, when Robert Koch reported his momentous discovery to the monthly meeting of the Berlin Physiological Society, tuberculosis in Europe had already been in decline for over a generation. In spite of wars and economic depressions, this decline was further accentuated during the first half of the twentieth century, probably fueled by improving socioeconomic conditions and the isolation of infectious cases in sanatoria. The end of World War II marked a turning point in tuberculosis prevention and control programs. In the late 1940s and early 1950s, mass radiography campaigns and bacille Calmette-Guérin (BCG) vaccination programs were introduced almost concurrently with the beginning of the chemotherapy era in industrialized countries as well as in some developing countries. Because the majority of tuberculosis cases are pulmonary, chest x-rays have, from the beginning, played an important role in tuberculosis case finding and in the assessment of the severity of disease. Despite the fact that no chest radiographic pattern is characteristic of tuberculosis and that a scar is not indicative of active disease, certain configurations are still considered by some as highly suggestive of tuberculosis. These assumptions did not apply to as many as one third of patients diagnosed with pulmonary tuberculosis who, even before the HIV/AIDS 95
96
Laszlo
era, were found to have “atypical” chest x-ray patterns. Furthermore, observer error of interpretation of chest radiography films, extensively studied in the late 1940s and early 1950s, was found to be invariably and unacceptably high, with rates of underreading of up to 43% (1). By the early 1970s, periodic radiographic screening campaigns of entire populations were shown to be an inefficient tool of tuberculosis control because of low yields (only 20% of new cases were being discovered) (2). This was explained by the fact that infectious cases develop faster than repeated screening can logistically and economically follow up (3). Case finding by the detection of acid-fast bacilli in sputum, on the other hand, was less prone to misinterpretation and much less expensive than chest radiography. Although Ziehl-Neelsen (ZN) sputum smear microscopy can detect only about 60% of all adults with pulmonary tuberculosis, its specificity is at least 90%, especially in developing countries. Due to the fact that it provides actual proof of the presence of bacilli, that it can give a measure of the extent of disease, and provide an indication of the progress of chemotherapy, sputum smear microscopy is an important diagnostic tool in developed countries (4) and the diagnostic cornerstone of national tuberculosis programs (NTPs) in developing countries (5). Disparity in the results obtained in BCG controlled trials during the 1950s prompted organization by the Indian Council of Medical Research in cooperation with the World Health Organization (WHO) and the Centers for Disease Control, U.S. Public Health Service, of a large-scale controlled BCG trial in south India. Starting in 1968, it included 260,000 participants, but the first results in 1979 (6) showed that there had been no protective effects. Indiscriminate mass BCG vaccination campaigns had been superseded by mass vaccination of newborns and young children, but by the mid-1970s it became evident that this tuberculosis-prevention measure would not substantially improve the overall epidemiological situation (7). The main reason for this was that more than 95% of reported tuberculosis cases among children are smear negative, and it has been shown that smear-negative patients are much less infectious than smear-positive ones. Furthermore, the protection afforded by BCG vaccination was found to be transient at best. In the late 1950s, in spite of early scepticism, it became evident that adequate chemotherapy was the best available tool to achieve high cure rates (8) and to control tuberculosis in the community. Adequate chemotherapy accelerated the decline in the risk of infection by 10–14% in developed countries, whereas in developing countries, which today carry 95% of the world’s burden of tuberculosis, the annual decrease rates were very low during the last four decades—as low as 1 or 2% in certain African countries such as Tanzania (9). This could be ascribed mainly to poor chemotherapeutic services in these countries. Therefore, the picture emerging in 1964 when the rationale for the WHO national tuberculosis program was being formulated and in 1974 when it was further refined by a WHO expert committee (10) was that tuberculosis control as well as
Tuberculosis Laboratories
97
prevention could be achieved by adequate chemotherapy and that the detection of contagious sources of tuberculosis in the community could best be attained by inexpensive bacteriological means. By that time, tuberculosis in developed countries was perceived as virtually eradicated, and it was only in some developing countries that the principles of tuberculosis control and prevention described in the 1974 WHO document were formally adopted and implemented, with varying degrees of success. Since the late 1970s, the focus of the International Union Against Tuberculosis and Lung Disease’s (IUATLD) activities with respect to tuberculosis has been the development of an appropriate model for the NTPs of developing countries (11). This model was developed in Tanzania and subsequently applied to six other countries in Africa as well as to Nicaragua and Vietnam. In 1989, this model was evaluated by the Health Sector Priority Review of the World Bank and assessed as being among the most cost-effective of any health intervention strategy in developing countries. II. National Tuberculosis Programs The major sources of infection in the community are smear-positive pulmonary tuberculosis patients (2,12); smear-negative, culture-positive patients are much less infectious. The rapid discovery of infectious cases is a high priority, because it usually leads to the cure of the individual and the elimination of a source of infection in the community. Where resources are scarce, case-finding methods are limited to activities that have been shown to bring the highest rewards at the lowest possible cost. In most low-income countries, passive case finding for smear-positive cases, active case finding for contacts, and the simultaneous raising of community and medical profession awareness have become the method of choice for their tuberculosis control programs (13). Experience from recent decades indicates no improvement of tuberculosis rates in developing countries without a well-run NTP. The rationale for a NTP is based on the following facts (14): 1. Tuberculosis can be controlled with available tools under any socioeconomic circumstances because the infectious agent has only one major reservoir—the diseased patient—who can quickly be rendered noninfectious. This is particularly true for epidemiologically significant M. tuberculosis infections, which are almost exclusively confined to humans and captive primates (15,16). 2. Since there is a natural balance between the tubercle bacillus and the human host, any reduction of sources of infection will inevitably improve the epidemiological situation. A sputum smear–positive patient, if left untreated, will infect on average 10–15 close contacts per year; if
98
Laszlo this patient is properly treated one case will be eliminated and up to 15 cases of tuberculosis will be prevented. 3. Smear microscopy detects almost all sources of infection, and highly efficient chemotherapy regimens can cure almost all discovered cases. Experience in IUATLD field programs has shown that maintaining a detection rate of 70% of smear-positive cases and a cure rate of 85%, the tuberculosis endemic would, in time, come under control.
The principles for the NTPs reviewed and expanded in the Ninth Report of the Expert Committee on Tuberculosis (10) are the following: 1. The distribution of tuberculosis cases is fairly even, and since populations in developing countries, in spite of rapid urbanization, are still predominantly rural, the program has to be delivered countrywide. Due to the disease’s transmissibility and the high mobility of populations, solutions must be found for the entire community; failing this, the part of the population without coverage will keep transmitting the disease to the part of the population receiving coverage. This is one condition that is often difficult to fulfill because of inadequate primary health service coverage in most developing countries. Fragmentation of tuberculosis control efforts in many countries between different governmental agencies and nongovernmental organizations poses a severe problem because of lack of uniformity in diagnostic and treatment guidelines. This lack of uniformity inevitably leads to poor treatment practices and to less than ideal program performance. 2. Most of the population in developing countries has been infected with tubercle bacilli and the risk of infection remains high, therefore the program must be permanent. Tuberculosis infection is chronic in character